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Ch. 1 GENERAL INTRODUCTION 
REVIEW OF THE LITERATURE 
Respiratory disease in pigs is one of the most important disease conditions in intensive 
pig production systems worldwide. Mycoplasma hyopneumoniae is the primary agent of 
enzootic pneumonia, a chronic respiratory disease in pigs resulting from mixed respiratory 
infections with M. hyopneumoniae and one or more secondary bacterial pathogens (Maes et 
al., 2008a). M. hyopneumoniae is present in most of the countries with intensive swine 
production and is also considered as one of the main pathogens involved in the porcine 
respiratory disease complex (PRDC). The multifactorial aetiology of the PRDC includes both 
viral and bacterial pathogens, and is also influenced by management and environmental 
conditions (Opriessnig et al., 2011). Both EP and PRDC lead to major economic losses due to 
the reduced growth, increased mortality and feed conversion, costs for antimicrobials and 
immunoprophylaxis and increased time to market (Maes et al., 2008a). 
M. hyopneumoniae lacks a cell wall and has a small genome encoding only a few 
biosynthetic pathways. The pathogenesis of M. hyopneumoniae infections includes various 
steps: adhesion of the respiratory tract, modulation of the immune system leading to damage 
of pulmonary tissue and persistence in the respiratory tract, as well as interaction with other 
infectious agents. 
Non-productive coughing is the most obvious clinical sign. Macroscopic lesions are 
characterized by catarrhal bronchopneumonia. They consist of red to purplish consolidated 
areas on the cranial-ventral parts of the apical, cardiac, accessory and diaphragmatic lobes. 
The diagnosis of enzootic pneumonia is generally made at herd level rather than at individual 
level (Thacker and Minion, 2012; Taylor, 2013). 
Since eradication of M. hyopneumoniae from infected herds is complicated and difficult 
to achieve, control of the infections is considered the best strategy. Control measures include 
optimization of housing and management practices, antimicrobial treatment and vaccination. 
This review aims to summarize the current knowledge on M. hyopneumoniae infections and 
enzootic pneumonia, with emphasis on antimicrobial agents used for treatment and vaccines 
used for control this disease.  
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Ch. 1 GENERAL INTRODUCTION 
1.1. CHARACTERISTICS OF MYCOPLASMA HYOPNEUMONIAE 
Mycoplasmas are taxonomically classified as members of the class Mollicutes, a group 
of bacteria characterized by the lack of a cell wall. Mycoplasma cells are mostly spherical 
and range from 0.3 to 0.8 µm in size (Razin, 2006). They have a small genome (893-920 
kilobase pairs) (Dybvig and Voelker, 1996), which encodes a limited number of genes, 
resulting in a few biosynthetic pathways (Razin et al., 1998). Because of this limited 
metabolism, mycoplasmas need to obtain essential metabolites from the host or growth 
environment (Thacker and Minion, 2012). 
The first isolation of M. hyopneumoniae was performed in 1965 in the U.S. (Mare and 
Switzer, 1965) and the U.K. (Goodwin et al., 1965). In the 70‟s of the previous century, 
important research was carried out to determine the main characteristics of this organism. M. 
hyopneumoniae is very sensitive to environmental conditions due to the absence of a cellular 
wall (Goodwin, 1972). In 1973, the J-strain was isolated (Whittlestone, 1973), which is still 
considered as the reference strain. Due to its slow and fastidious growth in vitro (Friis, 1974), 
a special culture medium supplemented with serum, Friis medium, is necessary for isolation 
(Friis, 1975). Using electron microscopy, M. hyopneumoniae appears as round or oval cells 
with a mean diameter ranging from 0.5 to 0.8 µm (Tajima and Yagihashi, 1982; Blanchard et 
al., 1992). 
The whole genome sequence of several M. hyopneumoniae strains has been published 
(strains J, 232, 7448 and 168) (Liu et al., 2011; Minion et al., 2004; Vasconcelos et al., 
2005). Recent studies using molecular techniques have revealed a large diversity of M. 
hyopneumoniae isolates at genomic (Stakenborg et al., 2006b; Strait et al., 2008; Nathues et 
al., 2011), and proteomic (Vicca et al., 2003; Calus et al., 2007; Pinto et al., 2007) level. 
Different M. hyopneumoniae isolates also have different virulence characteristics, as assessed 
by experimental infections in pigs (Vicca et al., 2003; Villarreal et al., 2009). 
 
 13 
 
Ch. 1 GENERAL INTRODUCTION 
1.2. PATHOGENESIS OF MYCOPLASMA HYOPNEUMONIAE 
INFECTIONS 
M. hyopneumoniae is a host specific organism that only infects pigs. The pathogenesis 
of M. hyopneumoniae infections includes various steps: colonization of the respiratory tract, 
modulation of the immune system leading to damage of pulmonary tissue and persistence in 
the respiratory tract. This complex pathogenesis may also be affected, mainly under field 
conditions, by the interaction with other infectious agents. 
Colonization of the respiratory tract begins with the adherence of M. hyopneumoniae 
to the ciliated epithelial cells of the trachea, bronchi and bronchioles (Blanchard et al., 1992). 
This attachment to the mucosal surface of the ciliated epithelium is a pre-requisite for 
initiation of disease (Tajima and Yagihashi, 1982) and is mainly enabled by various proteins 
(e.g. P97, P102, P116, P135, P159, P216) and other cell surface structures. A complete 
description of these multifunctional adhesins and their binding abilities can be found in 
Simionatto et al. (2013). The binding of M. hyopneumoniae to the cilia provokes ciliostasis, 
clumping and finally loss of cilia (DeBey and Ross, 1994). The impaired ciliary activity leads 
to a reduction of the mucosal clearance of the respiratory tract. Once the first non-specific 
defense barrier of the lung is damaged, further multiplication of the M. hyopneumoniae and 
colonization of the airways occur. The loss of the cilia is predominantly limited to the 
airways from cranio-ventral lobes of the lungs (apical and cardiac) and this distribution is 
associated also with the main location of macroscopic lesions of pneumonia (Mebus and 
Underdahl, 1977). 
It has been shown that M. hyopneumoniae is able to modulate both innate and 
adaptive immune responses (Thacker, 2001), leading to evasion of host defenses and 
establishment of a chronic and persistent infection (Razin et al., 1998). The exact mechanism 
of modulation of the immune response is not yet fully elucidated (Simecka, 2005), but it is 
generally accepted that the immune response plays a role in the development of lesions. 
Immediately after colonization, there is a massive infiltration of peribronchiolar and 
perivascular lymphohistiocytic cells (Morris et al., 1995). Alveolar macrophages and 
lymphocytes are the predominant cells. M. hyopneumoniae has the ability to alter the function 
of these cells. The phagocytic capacity of the macrophages is impaired, resulting in a reduced 
clearance, and consequently, in a chronic colonization of the respiratory tract by M. 
hyopneumoniae (Caruso and Ross, 1990). In addition, M. hyopneumoniae stimulates 
macrophages to produce proinflammatory cytokines, which leads to an inflammatory 
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response and lung damage (Thacker and Minion, 2012). A general immunosuppression has 
been suggested since M. hyopneumoniae may also alter the function of lymphocytes 
(Kishima and Ross, 1985). 
M. hyopneumoniae usually persists for a long time in the animal. Sorensen et al. (1997) 
demonstrated the presence of M. hyopneumoniae in the respiratory tract by means of 
Polymerase Chain Reaction (PCR) up to 85 days post-infection. Using nested PCR (nPCR), 
Fano et al. (2005) detected M. hyopneumoniae in nasal swabs up to 185 days post-infection. 
More recently, Pieters et al. (2009) showed that M. hyopneumoniae can be isolated from the 
respiratory tract of potential infectious carriers up to 200 days post-infection, it can persist up 
to 214 days post-infection, and total clearance is only complete by 254 days post-infection. 
The complete pathogenesis of M. hyopneumoniae infections is not yet fully understood, 
since not all respiratory tract infections with M. hyopneumoniae lead to pneumonia. Other 
factors, such as virulence of the strain involved (Zielinski and Ross, 1990; Vicca et al., 2003; 
Meyns et al., 2007; Villarreal et al., 2009) and interactions with other respiratory pathogens 
(Ciprián et al., 1994; Opriessnig et al., 2011), may play a decisive role in the development of 
the disease. 
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1.3. EPIDEMIOLOGY OF MYCOPLASMA HYOPNEUMONIAE 
1.3.1. Occurrence of M. hyopneumoniae infections 
M. hyopneumonie is present in almost all countries with an intensive swine production 
(Sibila et al., 2004a; Fano et al., 2007; Maes et al., 2008a; Martínez et al., 2009; Fraile et al., 
2010; Meyns et al., 2011; Fablet et al., 2012b; Nathues et al., 2012b), and within herds, 
infections may occur in all the production phases, namely breeding animals, suckling and 
weaned piglets, as well as fattening pigs. 
The prevalence of M. hyopneumoniae in suckling pigs assessed by nPCR on nasal 
swabs ranges from 0.5 to 10 per cent (Sibila et al., 2007a; Sibila et al., 2007b; Villarreal et 
al., 2010). The prevalence is higher in weaned piglets, namely from 0 to 51 per cent (Sibila 
et al., 2004a; Fano et al., 2007; Sibila et al., 2007b). Even though infections may already 
occur during suckling period, in most pig herds, the highest infection levels of M. 
hyopneumoniae occur during the grow-finishing period (Sibila et al., 2004a). The dynamics 
of infection vary largely between herds, and are influenced by different environmental 
conditions, such as management and housing conditions and the production system of the 
herd. The potential of the sows to shed M. hyopneumoniae is one of the key points on the 
epidemiology of this agent, not only because of the transmission to their offspring 
(Calsamiglia and Pijoan, 2000), but also in the maintaining of the infection within the herd. 
There is however not much information available on occurrence of M. hyopneumoniae in 
breeding animals (Sibila et al., 2009). The prevalence of M. hyopneumoniae in sows 
assessed by antibodies in sera ranges from 27 to 65 per cent (Sibila et al., 2007a; Grosse 
Beilage et al., 2009). 
1.3.2. Transmission of M. hyopneumoniae 
The transmission of M. hyopneumoniae can take place by different routes. 
Transmission between herds occurs mainly by the introduction of infected animals or 
airborne. Regarding the transmission within herds, distinction can be made between vertical 
(from the sow to the offspring) and horizontal transmission (between pigs of the same or 
different pens). 
Vertical transmission 
Vertical transmission occurs predominantly via nose-to-nose contact (Calsamiglia and 
Pijoan, 2000). To date, in-utero or lactogenic transmission has not been reported (Maes et al., 
 16 
 
Ch. 1 GENERAL INTRODUCTION 
2008b). Moore et al. (2001) suggested a reduction of the severity of pneumonia lesions in 
slaughter pigs born from parity 2 sows when compared with pigs born from parity 1 sows. 
Recent epidemiological studies confirmed these observations and have demonstrated that the 
piglets from younger sows (gilts and parity 1-2) have more risk of being infected with M. 
hyopneumoniae compared to piglets from older sows (Fano et al., 2007). Although the risk is 
lower than in younger sows, older sows may still transmit M. hyopneumoniae to their 
offspring (Calsamiglia and Pijoan, 2000; Grosse Beilage et al., 2009). 
Horizontal transmission 
a. Direct contact: 
Nose-to-nose contact between penmates or even between pigs of different pens may 
result in spread of M. hyopneumoniae from infected to susceptible animals (Thacker and 
Minion, 2012). Using transmission experiments under experimental conditions, Meyns et al., 
(2004) showed that one infected pig may be able to infect one littermate during a nursery 
period of six weeks. Similar results were obtained by Villarreal et al,. (2011) in transmission 
experiments under field conditions. 
b. Indirect contact: 
Airborne transmission has been shown to be important for M. hyopneumoniae. 
Goodwin (1985) stated that M. hyopneumoniae-free herds may become infected with M. 
hyopneumoniae if infected herds are located within a distance of 3.2 km. Cardona et al. 
(2005) showed under experimental conditions using aerosols that transmission of M. 
hyopneumoniae is possible over 150 m. More recent studies have demonstrated that M. 
hyopneumoniae may be transmitted over much larger distances namely 4.7 km (Dee et al., 
2009) and 9.2 km (Otake et al., 2010). 
The implementation of standard hygiene measures of the personnel when entering the 
herd may reduce the risk of transmission of M. hyopneumoniae between herds (Batista et al., 
2004). More recently, an observational study performed during four years illustrated that one-
night downtime period prevents the entry of M. hyopneumoniae in a herd not only by 
personnel, but also by fomites (Pitkin et al., 2011). In general, mechanical vectors, such 
fomites and personnel, are considered to be of limited importance in the transmission of M. 
hyopneumoniae.  
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1.4. CLINICAL SIGNS, LESIONS AND PORCINE RESPIRATORY 
DISEASE COMPLEX 
1.4.1. Clinical signs 
In general, two distinct forms of clinical disease can be observed, namely endemic and 
epidemic disease (Thacker and Minion, 2012; Taylor, 2013). 
Endemic mycoplasmosis, commonly known as enzootic pneumonia, is the form most 
frequently observed. In many cases, infections are subclinical (Clark et al., 1991). In case of 
clinical disease, a non-productive coughing is the most obvious clinical sign. Coughing may 
be present in nursery, grower and finisher pigs and usually a considerable percentage of the 
pigs are affected. Coughing may disappear after 2-3 weeks, but it can also persist throughout 
the whole fattening period. 
Under experimental infections, clinical signs are mainly characterized by slight fever, 
followed by dry coughing. Coughing appears from 10 to 14 days post-infection, reaches a 
maximum peak at about 4-5 weeks, after which it disappears gradually (Whittlestone 1972; 
Kobisch et al., 1993). 
Under field conditions, herds that are only infected with M. hyopneumoniae are rarely 
seen. Mostly, mixed infections occur. In case of secondary bacterial infections, the severity of 
the clinical signs increases, namely a severe respiratory distress including fever, labored 
breathing and prostration, and reduced appetite. This leads to an increase of the feed 
conversion ratio, lower average daily weight gain, and more weight variation between the 
pigs. 
Epizootic mycoplasmosis is uncommon. It occasionally occurs when M. 
hyopneumoniae enters into a negative, immunologically naive herd. The spread of the disease 
occurs rapidly and all age groups may be affected. Coughing, acute respiratory distress, fever 
and deaths may be present (Thacker and Minion, 2012). 
1.4.2. Lesions 
M. hyopneumoniae infection can lead to different gross lesions depending on the course 
of the disease. The most common macroscopic lesion in chronic M. hyopneumoniae 
infections is characterized by red to purplish consolidated areas on the cranial-ventral parts of 
the apical, cardiac, accessory and diaphragmatic lobes. These lesions are commonly called 
Mycoplasma-like pneumonia lesions (active lesions) (Figure 1) (Whittlestone, 1972; Kobisch 
et al., 1993). They may appear from 7 days after experimental infection onwards and reach a 
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maximum size at about 4 weeks post-infection (Whittlestone, 1972; Kobisch et al., 1993). 
These uncomplicated lesions are characterized by the presence of a catarrhal exudate in the 
airways, a uniform colour of the parenchyma of the lung and a “meaty” consistency. The 
pneumonia lesions may be recovered after 7-10 weeks, and by that time, red to purplish 
interlobular scar retractions of connective tissue, called fissures, are present (old lesions) 
(Whittlestone, 1972; Kobisch et al., 1993). 
Under field conditions, when M. hyopneumoniae infections are complicated by 
secondary bacterial pathogens, the pneumonia lesions occupy a large surface of the lung, and 
are characterized by the presence of mucopurulent exudate in the airways, a more firm 
consistency and an inconsistent greyish colour of the parenchyma (Osborne et al., 1981). 
However, Mycoplasma-like pneumonia lesions at slaughter are not pathognomonic for 
infections with M. hyopneumoniae. Apart from M. hyopneumoniae, it is well known that 
infections e.g. with viruses and in particular swine influenza virus, may cause similar 
pneumonia lesions (Thacker et al., 2001, Sibila et al., 2009). 
Adhesive pleurisy is a common finding in slaughter pigs reared under field conditions 
and has been associated with respiratory disease (Fraile et al., 2010; Meyns et al., 2011; 
Fablet et al., 2012b; Merialdi et al., 2012). It is defined as fibrotic adherence between the 
visceral and parietal membranes of the pleural sac. Although adhesive pleurisy is not a 
characteristic lesion of M. hyopneumoniae infections, Meyns et al. (2011) found a positive 
association between higher prevalence of pneumonia and the presence of pleurisy at 
slaughter. 
Histopathological examination of the pneumonia lesions infected with M. 
hyopneumoniae revealed neutrophil and lymphocyte infiltration around the airways and 
alveoli (Whittlestone, 1972). As the infection progresses, broncho-interstitial pneumonia 
develops. The accumulation of mononuclear cells, mainly lymphocytes and macrophages, is 
more evident and results in the formation of lymphocytic cuffs around the airways, which is 
commonly known as perivascular and peribronchiolar lymphohistiocytic infiltration and 
nodule formation (Blanchard et al., 1992; Morris et al., 1995). In cases of enzootic 
pneumonia, a neutrophilic exudate may be present in the lumen of airways and alveoli. 
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Figure 1. Red to purplish consolidated areas on the cranial-ventral parts of the apical, 
cardiac, accessory and diaphragmatic lobes, called Mycoplasma-like pneumonia lesions. 
1.4.3. Porcine respiratory disease complex 
During the past 40 years, swine production has experienced an important 
intensification, mainly based on larger pig herds operating under conditions of confinement, 
which leads to an increase of respiratory disease. Respiratory disease in swine is most often 
due to the interaction and synergy of primary and opportunistic infectious agents, both viral 
and bacterial pathogens. The severity of this respiratory disease may be exacerbated when 
adverse environmental and management conditions are present. This multifactorial nature of 
respiratory disease in pigs is called the Porcine Respiratory Disease Complex (PRDC) 
(Brockmeier et al., 2002). 
The term PRDC was coined during the 90‟s in U.S. to describe pneumonia of multiple 
etiology causing clinical respiratory disease and poor performance later in the finishing 
period (15 to 20 weeks) (Halbur and Andrews, 1993; Dee, 1996). Shortly afterwards, it was 
observed that it most often occurred 8 to 10 weeks following placement into the finishing 
facilities and PRDC was commonly referred to as the "18 to 20 week wall" (Dee, 1997). 
Nowadays, this term may also refer to pneumonia of mixed etiology at other production 
stages, such as in weaned, nursery or grower pigs, and not only during the finishing period. 
However, in these cases the correct terminology may be mixed respiratory disease. Currently, 
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it is generally accepted that when M. hyopneumoniae is the primary agent of respiratory 
disease and other secondary bacteria take advantage of this situation, the resulting disease is 
called enzootic pneumonia. On the other hand, in case of PRDC, M. hyopneumoniae plays a 
central role together with viral pathogens such as Porcine Reproductive and Respiratory 
Syndrome Virus (PRRSV), Porcine Circovirus type 2 (PCV-2) and Swine Influenza Virus 
(SIV), whereas other viruses and opportunistic bacteria are considered as secondary actors 
(Opriessnig et al., 2011). 
1.4.3.1. Polymicrobial nature 
Numerous studies have illustrated during the past years the polymicrobial nature of 
PRDC (Morrison et al., 1985a; Loeffen et al., 1999; Bochev, 2007; Moorkamp et al., 2008; 
Hansen et al., 2010; Opriessnig et al., 2011; Fablet et al., 2012a; Ticó et al., 2013). There is 
an enormous variety of microorganisms associated with PRDC and they can be categorized 
as commensal microflora vs potentially pathogenic agents; primary vs secondary or 
opportunistic pathogens. There is no clear distinction between commensal and potential 
pathogenic agents, since different studies categorized the same agent as either commensal or 
pathogenic (VanAlstine, 2012). Primary pathogens are capable of evading respiratory defense 
mechanisms from the host and establishing infection and disease on their own, whereas 
secondary pathogens take advantages of the damage caused by primary pathogens to establish 
infections and exacerbate respiratory disease (Brockmeier et al., 2002). In general, primary 
pathogens, such as viral agents and M. hyopneumoniae, may damage the epithelium of the 
respiratory tract and decrease the local and systemic defense mechanisms, favoring invasion, 
colonization and establishment of the infection by secondary agents, mainly bacteria. Primary 
pathogens involved in PRDC include PRRSV, PCV-2, SIV, Aujeszky‟s Disease Virus, M. 
hyopneumoniae, Actinobacillus pleuropneumoniae and Bordetella bronchiseptica. Other 
pathogens include Paramyxovirus, Porcine Cytomegalovirus, Porcine Respiratory 
Coronavirus, Torque teno sus virus, Actinobacillus suis, Haemophilus parasuis, M. hyorhinis, 
Pasteurella multocida, Streptococcus suis and Trueperella pyogenes (Opriessnig et al., 
2011). Major efforts have been done to study and understand the interaction between 
different respiratory pathogens under experimental conditions. Although the reproduction of 
disease has been easily achieved by the use of single challenge infection models, it is not 
always possible to reproduce disease in dual infections or co-infection experiments. A review 
was published by Opriessnig et al. (2011) where a wide variety of interactions between 
different viral and bacterial pathogens is discussed. 
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Under field conditions, it is very rare to observe a clinical case of respiratory disease in 
which only one primary pathogen is involved. Frequently, one or more primary agents are 
present and cause primary infections which become complicated with opportunistic bacteria 
that aggravate the respiratory disease (VanAlstine, 2012). A study published in the U.S. 
including three case reports of PRDC (Harms et al., 2002) illustrated a low morbidity and 
mortality. Postmortem examinations revealed a high extent of pneumonia lesions and 
bronchopneumonia as major gross and microscopic findings, respectively. Concurrent 
infections of PCV-2 combined with PRRSV, SIV and M. hyopneumoniae were described. 
1.4.3.2. Non-infectious factors 
Apart from its polymicrobial nature, PRDC also depends largely on many non-
infectious factors. Identifying and reducing risk factors may lead to a reduction of the 
transmission of pathogens, less stress provoked to the animal by hostile environments 
(physical, climate and air quality factors) and less direct impairment of the respiratory tract 
(Opriessnig et al., 2011). A short description of non-infectious factors is presented in section 
1.6 of this thesis. Details on the influence of management and environmental factors on 
respiratory disease are also well described in the review papers by Stärk (2000) and Maes et 
al. (2008a). 
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1.5. DIAGNOSIS 
Diagnosis of enzootic pneumonia is generally established at group level rather than at 
individual level (Thacker and Minion, 2012; Taylor, 2013). The presence of coughing in 
fattening pigs combined with chronic bronchopneumonia lesions at slaughter, as well as poor 
performance and feed efficiency during the fattening period may lead to a presumptive 
diagnosis of enzootic pneumonia. However, definitive diagnosis is based on detection of 
(parts of) M. hyopneumoniae. Differential diagnosis should consider other possible causes of 
coughing, as well as bacteria and viruses causing Mycoplasma-like pneumonia lesions (Sibila 
et al., 2009). 
1.5.1. Clinical signs 
Non-productive coughing, especially in fattening pigs, being more evident after 
boosting and characterized by persistence in the population is a typical sign of enzootic 
pneumonia. 
Several methods have been described to assess the severity of coughing under 
experimental and field conditions. Halbur et al. (1996) described a Respiratory Disease Score 
(RDS) to quantify the severity of coughing under experimental conditions. The RDS could 
range from 0 to 6: 0 (no coughing), 1 (mild coughing after encouraged move), 2 (mild 
coughing in rest), 3 (moderate coughing after encouraged move), 4 (moderate coughing at 
rest), 5 (severe coughing after encouraged move), 6 (severe coughing at rest). This method 
has been used in recent transmission and pathogenesis studies, as well as in the assessment of 
efficacy of vaccines and antimicrobial treatments (Vicca et al., 2003; Meyns et al., 2004; 
Vicca et al., 2005; Meyns et al., 2006; Meyns et al., 2007). Under field conditions, a method 
that quantifies the number of pigs coughing in a given period of time has also been described 
(Maes et al., 1999; Mateusen et al., 2001). The pigs were moved up and the number of pigs 
coughing per pen during 10 minutes was counted. A RDS was calculated by dividing the 
number of pigs per pen that coughed during 10 min, by the total number of pigs in that pen, 
multiplied by 100. A similar method has been used by Nathues et al. (2012a). These authors 
confirmed that a quantitative assessment of the onset of coughing is useful for the diagnosis 
of enzootic pneumonia and is correlated with the infection pattern of M. hyopneumoniae 
assessed by PCR.  
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1.5.2. Macroscopic lung lesions 
Examination of the lungs of slaughter pigs is an excellent method to monitor the 
respiratory health in a herd under field conditions. If possible, checks should include visual 
examination and palpation in a well-illuminated place, and the lesions should be sketched 
onto a diagram, which may be followed by image analysis (VanAlstine, 2012). The 
prevalence and extent of the lesions, not only pneumonia, but also adhesive pleurisy, nodules, 
abscesses, pericarditis, etc., may provide reliable information regarding the severity of the 
respiratory disease. 
However, slaughterhouse examinations also have limitations. Lesion assessement is 
subjective and the lesions are generally not pathognomic (Sibila et al., 2009). Subclinical 
infections may be not detected and lesions in young animals may be healed at the moment of 
slaughter (Regula et al., 2000). Also, the fast speed of slaughtering in modern slaughter 
facilities makes it more difficult to perform reliable slaughter checks. Although a mimimum 
of 30 randomly selected pigs from the same slaughter batch has been shown to provide 
reliable information at herd level (Straw et al., 1989), it is generally accepted that it is better 
to evaluate more pigs. In recent epidemiological studies performed in Europe, in which 
slaughter examinations were carried out in order to estimate the prevalence and severity of 
lung lesions, an average of 127 (Meyns et al., 2011), 106 (Fraile et al., 2010), 100 (Merialdi 
et al., 2012) and 30 (Fablet et al., 2012) pigs per batch were investigated. The low number of 
the last study may be due to the large amount of additional bacteriological investigations 
carried out on these lungs. 
Different scoring systems have been described in the past years to monitor enzootic 
pneumonia under experimental (Hanan et al., 1982), as well as field conditions (Madec et al., 
1982; Morrison et al., 1985b; Straw et al., 1986; Christensen et al., 1999). Only the methods 
used in this thesis will be described here. The scoring system described by Hannan et al. 
(1982) is appropriate to carefully quantify lung lesions caused by experimental infection with 
M. hyopneumoniae. The score ranges from 0 (no lesions) to 35 (all lung tissue affected). This 
method is especially designed for Mycoplasma-like pneumonia lesions, since they are mainly 
located in the cranial-ventral parts of the lungs, and this score gives the same significance to 
each of the 7 lobes, namely 5 points/lobe out of the total are of the lung (35 points). The lung 
lesion score from Morrison et al (1985b) is appropriate for field evaluation. It is based on the 
total percentage of affected lung tissue, with the different lung lobes representing the 
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following percentage of the total lung surface area: apical (10 per cent), cardiac (7 per cent), 
accessory (6 per cent) and diaphragmatic (30 per cent). 
1.5.3. Microscopic lung lesions 
Microscopic findings of peribronchiolar and perivascular lymphohistiocytic infiltration 
and nodule formation are not specific of M. hyopneumoniae infections, but they may be 
helpful for a final diagnosis. Two methods can be performed to measure the severity and the 
extent of the mycoplasmal lesions. 
The severity of peribronchiolar and perivascular lymphohistiocytic infiltration and 
nodule formation related to M. hyopneumoniae induced pneumonia lesions may be scored by 
using light microscopy according to the method described by Morris et al. (1995). The score 
ranges from 1 (limited cellular infiltrates around bronchioles) to 5 (severe infiltration of 
lymphocytic cells around bronchioles and interstitium, and inflammatory cell exudates into 
the airways) (Fig. 2). 
The extent of pneumonia can also be measured by calculating the percentage of tissue 
occupied by air. Using a camera software and light microscopy, a picture is taken from a 
microscopic field including a sample of lung lesion. By means of an automatic image 
analysis system, the percentage of air in each picture is calculated. This percentage is 
negatively correlated to the number of infiltrating cells, the amount of atelectasis, 
intrabronchiolar-intrabronchial exudates, intra-alveolar exudates and/or oedema and 
proliferation of type II cells. The advantage of this method is that the measurements are done 
in an objective way. 
1.5.4. Demonstration of M. hyopneumoniae infections 
Bacteriological culture from fresh lung tissue is considered as the gold standard for 
diagnosis of enzootic pneumonia. However, due to the fastidious growth of M. 
hyopneumoniae, the very time-consuming isolation procedure, the fact that special media are 
required and the low sensitivity of the procedure, bacteriological culture is not used for 
routine diagnosis of M. hyopneumoniae (Friis, 1975). 
The detection of M. hyopneumoniae antigen in lung tissue can be performed by 
immunofluorescence (IF) and by immunohistochemistry. Immunofluorescence is a semi-
quantitative assay to assess the amount of M. hyopneumoniae-organisms in the airways 
(Kobisch et al., 1978). Commonly used scores range from 0 to 3: 0 (no IF), 1 (limited IF), 2 
(moderate IF) and 3 (intense IF) (Vicca et al., 2003). The limitations of this technique include 
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the laborious and time-consuming procedure, the diagnosis can only be done post-mortem 
and the semi-quantitative outcome obtained, which does not allow to accurately quantify the 
load of M. hyopneumoniae organisms. 
The detection of M. hyopneumoniae DNA by PCR testing is currently widely used to 
investigate the potential role of this agent in respiratory disease. The accurate detection level 
of infection, as well as the relatively rapid and inexpensive characteristic of this method, have 
favored its establishment in routine diagnostic labs (Thacker and Minion, 2012). PCR assays 
are suitable for detection of M. hyopneumoniae in a wide range of samples, including lung 
tissue, nasal and trachea-bronchial swabs, as well as broncho-alveolar lavage fluid. Different 
PCR assays have been described. Nested PCR has an excellent sensitivity, even capable to 
detect as few as 4 or 5 DNA copies (Stärk et al., 1998a). Recently, a real-time (quantitative) 
PCR (qPCR) has been developed which allows to quantify the number of DNA copies per ml 
(Marois et al., 2010). Even the problem of identifying multiple mycoplasmas that grow in 
culture broth has been solved with the development of a multiplex PCR (Stakenborg et al., 
2006a). Although this increased accuracy allows detection of M. hyopneumoniae earlier than 
seroconversion, contamination of the samples should be avoided as this may result in false 
positive results (Thacker and Minion, 2012). 
Serology is commonly used to detect serum antibodies against M. hyopneumoniae 
(Calsamiglia et al., 1999; Thacker, 2004) at group or herd level. Commercial ELISAs 
generally have a good specificity. However, the sensitivity of these assays may be low, 
ranging from 37 to 49 per cent, which results in a high percentage of false negatives 
(Thacker, 2004). Consequently, the use of ELISAs is specially recommended for monitoring 
the M. hyopneumoniae status of a population, and, therefore, careful interpretation at 
individual level is required. 
1.5.5. Molecular typing 
Molecular typing techniques (e.g. pulsed-field gel electrophoresis, amplified fragment 
length polymorphism, randomly amplified polymorphic DNA, PCR-random fragment length 
polymorphism, multiple-locus variable number of tandem repeats analysis) have been 
developed recently and they are mainly used to investigate the diversity of M. 
hyopneumoniae strains (Stakenborg et al., 2005b; 2006b). 
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2a          2b    2c        2d              2e 
     
     
Figure 2. Microscopic scoring system to evaluate the severity of peribronchiolar and perivascular lymphohistiocytic infiltration and nodule 
formation related with M. hyopneumoniae induced pneumonia lesions (Morris et al., 1995). The following scores are represented in the picture: 
(2a) score 1 [limited cellular infiltrates (macrophages and lymphocytes) around bronchioles, with airways and alveolar spaces free of cellular 
exudates]; (2b) score 2 (light to moderate infiltrates with mild diffuse cellular exudates into airways); (2c) score 3, (2d) score 4 and (2e) score 5 
(mild, moderate and severe lesions characteristic of broncho-interstitial pneumonia, centered around bronchioles but extending to the 
interstitium, with lymphofollicular infiltration and mixed inflammatory cell exudates). Scores 1 and 2 are considered non M. hyopneumoniae-
related, whereas scores 3 to 5 are suggestive of M. hyopneumoniae infection. 
 27 
 
Ch. 1 GENERAL INTRODUCTION 
1.6. TREATMENT AND CONTROL OF MYCOPLASMA 
HYOPNEUMONIAE INFECTIONS 
The control of M. hyopneumoniae infections can be accomplished by optimization of 
management practices and housing conditions, antimicrobial treatment and vaccination (Maes 
et al., 2008a). 
1.6.1. Optimization of management practices and housing conditions 
Improvement of the management practices and the environment of the animals is of 
crucial importance in the control of M. hyopneumoniae infections. Most authors classify non-
infectious risk factors in three categories (management, environment and pig factors) (Stärk 
2000; Brockmeier et al., 2002; Opriessnig et al., 2011), but it is clear that in practice, many 
factors may interact with each other. A short description of the main control and preventive 
measures that reduce the occurrence and transmission of respiratory pathogens is presented in 
table 1.  
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Table 1. Control and preventive measures that reduce the occurrence and transmission of 
respiratory pathogens. 
Control and preventive measures References 
Herd characteristics reduction  increase  
Type of herd Multi-site systems vs Farrow-to-finish Clarck et al., 1991; Sibila et al., 
2004a; Maes et al., 2008a All-in/all-out vs Continous flow 
Nursery vs Growing-finishing 
farm 
Sibila et al., 2004a; 
Size of the herd Small vs Large Tuovinen et al., 1997; Stärk et 
al., 1998b 
Regional pig 
density 
Low vs High  Dee et al., 2009 
Purchase policy Closed herds vs High replacement 
rate of gilts 
Maes et al., 2000 
Single-source 
purchase 
vs Multi-source 
purchase 
Stärk et al., 2000 
Quarantaine  vs No quarantaine Amass and Baysinger, 2006 
Management practices 
All-in/all-out Avoid mixing animals of different sources and 
ages in the same airspace 
Clark et al., 1991 
Early weaning < 3 weeks of age Maes et al., 2008a; 
Parity segregation Gilts and their offspring separated from the sows 
until they reach their second gestation 
Hoy et al., 1986; Joo, 2003. 
McREBEL 
(Management 
Changes to Reduce 
Exposure to Bacteria to 
Eliminate Losses) 
Reduction of cross-fostering McCaw (2000) 
Strict hygiene and biosecurity: 
- cleaning, disinfection and empty period between batches 
- changing needles between litters 
- caretaking and isolation of sick animals, elimination of wasted animals 
- movement restriction of personnel and material within the herd 
- control of rodents and birds, and restriction of visits 
Prevention of: Other diseases by vaccination or medication 
Mycotoxin contamination of feed 
Maes et al., 2008a 
Antonissen et al., 2014 
Environmental and housing conditions 
Physical factors Appropriate stock density (m
2
/pig) Zulovich, 2012 
Sufficient air volume (m³/pig) Flesjå et al., 1982 
Type of floor, the manure system, the bedding 
material and the type of feed 
Honey and Mcquitty, 1979; 
Donham 1991 
Climate factors Control of fluctuations of temperature, specially 
during cold seasons 
Avoid high relative humidity 
Maes et al., 2000; Stärk et al., 
2000; Maes et al., 2001; Segalés 
et al., 2012 
Efficient ventilation pattern Gonyou et al., 2006 
Air quality factors Avoid exposure to aerial pollutants and 
excessive ammonia 
Done, 1991; Wathes et al., 2004 
Avoid high dust concentrations Robertson et al., 1990; Hamilton 
et al., 1999; Gonyou et al., 2006 
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1.6.2. Antimicrobial treatment 
This section summarizes the current knowledge on antimicrobial agents used for the 
treatment of M. hyopneumoniae infections, the route of administration of these antimicrobials, 
as well as the presence of antimicrobial resistance. Although antimicrobials are capable of 
controlling M. hyopneumoniae infections, complete elimination of the organism from the 
respiratory tract cannot be achieved by medication (Thacker and Minion, 2012). 
1.6.2.1. Antimicrobials 
Potentially active antimicrobials against M. hyopneumoniae include tetracyclines, 
macrolides, lincosamides, pleuromutilins, florfenicol, aminoglycosides, aminocyclitols and 
fluoroquinolones (Vicca, 2005; Maes et al., 2008a; AMCRA, 2013). Only the last two agents 
have mycoplasmacidal effects (Hannan et al., 1989). To control and treat respiratory disease, 
tetracyclines (doxycycline), potentiated sulfonamides (sulfadiazine-trimethoprim) and 
macrolides (tylosin and tilmicosin) are mostly used. Although sulfadiazine-trimethoprim is not 
effective against M. hyopneumoniae, it may be useful for treatment of secondary bacterial 
infections, often present during enzootic pneumonia. An overview of the main antimicrobials 
effective against M. hyopneumoniae is presented in this section, including pharmacokinetic and 
pharmacodynamic characteristics, as well as the mode of action and spectrum of activity (Table 
2). 
1. Tetracyclines 
Most of the tetracyclines can be administered per os, although intramuscular and 
intravenous formulations may also be used. Oral bioavailability may be lower when 
administered in feed, since bivalent cations (calcium, magnesium, iron) have a chelating effect 
on tetracyclines and, therefore, absorption and activity is reduced (Luthman and Jacobsson, 
1983). Oral bioavailability when administered via the drinking water may also be reduced by 
the water acidity and bivalent cations (iron) of the water pipes (Prescott, 2000b). Some 
tetracyclines are more lipophilic than other members, such as doxycycline, and therefore 
diffuse easily through most tissues, biological barriers and cell membranes. The degree of 
liposolubility largely varies between the different tetracyclines and determines their tissue 
distribution and elimination rate. Based on the duration of the effect, tetracyclines can be 
classified in three different groups: short acting (chlortetracycline, tetracycline, 
oxytetracycline), medium duration (demeclocycline, metacycline) and long acting 
(doxycycline, minocycline) (Lemos, 2002). Susceptibility testing has demonstrated that some 
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coliforms (Burch 2013), Mycoplasma hyopneumoniae (Inamoto et al., 1994), A. 
pleuropneumoniae (Vanni et al., 2012), S. suis (De Jong et al., 2014), H. parasuis (De la 
Fuente et al., 2007) and P. multocida (De Jong et al., 2014) have acquired resistance to 
tetracyclines. Generally, tetracyclines are widely used in the treatment of M. hyopneumoniae 
infections, as well as to treat and prevent atrophic rhinitis and other respiratory infections in 
pigs caused by A. pleuropneumoniae and P. multocida. 
2. Macrolides 
Most of the macrolides can be administered orally or parenterally. They are basic 
compounds very lipophilic, they are well absorbed from the intestine and have a good tissue 
distribution (Vicca, 2005). This high liposolubility enables macrolides to diffuse easily through 
biological barriers, and to reach therapeutic concentrations in most of the tissues, often many 
times higher than serum concentrations (Lemos, 2002). Once macrolides are distributed 
through the tissues, they accumulate intracellularly in the lysozomes of the phagocytes 
(Scorneaux and Shryock, 1998). Acquired resistance to macrolides has been described under 
field conditions in M. hyopneumoniae (Stakenborg et al., 2005a). 
Generally, macrolides are recommended to treat M. hyopneumoniae infections, as well as 
pneumonia and respiratory infections caused by other bacteria, such as A. pleuropneumoniae, 
B. bronchiseptica, H. parasuis, and P. multocida. 
3. Lincosamides 
Lincosamides are alkaline, lipophilic compounds, which favors absorption through the 
gastrointestinal tract and diffusion through biological barriers, leading to high tissue 
concentrations. Lincomycin is indicated in the treatment of M. hyopneumoniae infections. 
Acquired resistance to lincosamides has been described under field conditions in M. 
hyopneumoniae (Stakenborg et al., 2005a). 
4. Pleuromutilins 
Pleuromutilins present an excellent absorption after oral administration in monogastric 
mammals (Prescott, 2000c), a high bioavailability (around 90 per cent) and achieve high tissue 
concentrations in the lung (Burch, 2012). Pleuromutilins are often used to treat PRDC. 
Tiamulin and valnemulin may be used for the treatment of M. hyopneumoniae infections. 
However, it is better to restrict their use to control Brachyspira infections (AMCRA, 2013), 
since only a few effective antimicrobials are still available for the treatment of swine dysentery 
due to the increased antimicrobial resistance.  
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Table 2. Mode of action and spectrum of activity of the main antimicrobials effective against M. hyopneumoniae. 
Family of 
antimicrobials 
Mode of action Spectrum References 
Tetracyclines 
chlortetracycline 
doxycycline 
oxytetracycline 
Inhibition of protein synthesis 
by binding reversely to 30S ribosomal subunit, which 
interferes with association of aminoacyl-tRNA to 
mRNA-ribosomal complex 
Broad-spectrum; bacteriostatic 
Gram+, Gram-, chlamydiae, 
mycoplasmas, rickettsiae, protozoa 
Aronson, 1980; Riviere et 
al., 1991; Prescott, 2000b; 
Chopra and Roberts, 2001 
Macrolides 
erythromycin 
tildipirosin, tilmicosin 
tulathromycin 
tylosin, tylvalosin 
Inhibition of protein synthesis 
by binding reversely to 50S ribosomal subunit, which 
interferes with translocation of peptides, hence with 
growth of peptide chain and results in dissociation of 
peptydil-tRNA from ribosome 
Bacteriostatic 
Gram+, selected Gram- (Pasteurella, 
Mannheimia, Leptospira, 
Campylobacter, Actinobacillus), some 
anaerobes and Mycoplasma spp. 
Adams, 2001; Vester and 
Douthwaite, 2001; Vicca, 
2005 
Lincosamides 
lincomycin 
Inhibition of protein sysnthesis 
cfr. Macrolides 
Bacteriostatic. Gram+ and anaerobes, 
but less effective against Gram- and 
mycoplasmas than macrolides 
Prescott, 2000c 
Pleuromutilins 
tiamulin 
valnemulin 
Inhibition of protein sysnthesis 
cfr. Macrolides 
Bacteriostatic. Gram+, anaerobes and 
mycoplasmas, but less effective against 
Gram- than macrolides. Tiamulin: active 
against Gram- (Actinobacillus, 
Bordetella, Brachyspira, Haemophilus, 
Mycoplasma and Pasteurella).  
Weisblum, 1998; Aitken 
et al., 1999; Vester and 
Douthwaite, 2001; 
Lemos, 2002 
Amphenicols 
florfenicol 
Inhibition of protein sysnthesis 
cfr. Macrolides 
Broad-spectrum; bacteriostatic 
Gram+, Gram-, chlamydiae, 
mycoplasmas, rickettsiae and anaerobes 
Cannon et al., 1990; 
Sams, 1994; Priebe and 
Schwarz, 2003; Shin et 
al., 2005 
Aminoglycosides 
apramycin, gentamicin, 
neomycin, streptomycin 
Aminocyclitols 
spectinomycin 
Inhibition of protein sysnthesis 
by binding irreversibly 30S ribosomal subunit and 
blocking tRNA translation. Translation fidelity is 
decreased by disruption of translocation step of protein 
synthesis and by induction of translation errors 
Broad-spectrum; bactericidal 
Some Gram + (Mycobacteria, 
Staphylococcus spp.), many aerobic 
Gram- (Spirochetes) and mycoplasmas 
Calvert et al., 1985; 
Brown, 1988; Malik et 
al., 1994; Riviere and 
Spoo, 1995; Kotra et al., 
2000; Prescott, 2000a; 
Lemos, 2002;  
Fluoroquinolones 
danofloxacin 
enrofloxacin 
flumequine 
marbofloxacin 
Abolition DNA supercoiling and replication 
by inhibition of the topoisomerase II, DNA gyrase and 
topoisomerase IV 
Broad-spectrum; bactericidal 
Some Gram+, most Gram-, chlamydiae, 
mycobacteria and mycoplasmas 
Arai et al., 1992; Roberts, 
1992; Brown, 1996; 
Hannan et al., 1997; 
Papich and Riviere, 2001; 
Lees and Shojaee 
AliAbadi, 2002 
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5. Florfenicol 
Florfenicol can be administered orally or parenterally (Liu et al., 2003; Ciprián et al., 
2012). This lipophilic drug has a wide tissue distribution. Immediately after intramuscular 
administration, high initial blood levels are reached, leading to a quick initial response. 
Duration of therapeutic plasma level may last more than 53 h after intramuscular 
administration (Liu et al., 2003). 
The use of florfenicol is indicated for the treatment of bacterial pneumonia and 
associated respiratory infections caused by A. pleuropneumoniae, B. bronchiseptica, H. 
parasuis, M. hyopneumoniae, M. hyosynoviae, P. multocida, Salmonella enterica and S. suis 
(Burch, 2012). 
6. Aminoglycosides and aminocyclitols 
Aminoglycosides can be administered orally or parenterally. Due to their low lipophilic 
degree, diffusion through cell membranes is limited and distribution impaired (Giroux et al., 
1995). They are rapidly and well absorbed from intramuscular and subcutaneous routes of 
administration (Hammond, 1953; Brown and Riviere, 1991). When administered 
parenterally, aminoglycosides easily penetrate in lung parenchyma and bronchial secretions 
(Saux et al., 1986; Goldstein et al., 2002). Therefore, they are specially indicated in the 
treatment of M. hyopneumoniae infections. However, they are very poorly absorbed after oral 
administration (Brown and Riviere, 1991). Therefore, the oral route is mainly used to treat 
enteric infections, and parenteral treatment for other infections. 
7. Fluoroquinolones 
Fluroquinolones can be administered via oral, intramuscular or subcutaneous route. 
Fluoroquinolones are strongly lipophilic and therefore a high tissue distribution is reached 
with good penetration through biological barriers. In monogastric animals, orally 
administered fluoroquinolones are absorbed quickly and completely (80-100 per cent) (Inui et 
al., 1998) and maximum plasma concentrations are reached one hour after intake. Oral 
absorption is high, but it can be affected by divalent and trivalent cations. Absorption from 
parenteral administration is rapid and nearly complete (Cabanes et al., 1992; Gavrielli et al., 
1995; Kaartinen et al., 1995; Brown, 1996; Mengozzi et al., 1996; Nielsen and Gyrd-Hansen, 
1997; Richez et al., 1997; Bailey et al., 1998). They achieve concentrations that are at least as 
high as plasma in most tissues (Papich and Riviere, 2001) and are rapidly accumulated in 
macrophages and neutrophils. 
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Fluoroquinolones can be utilized for the treatment of M. hyopneumoniae, as well as 
other respiratory infections (P. multocida). 
1.6.2.2. Antimicrobial use and routes of administration 
The intensification of swine production in the past years has increased the use of 
antimicrobials to maintain pig health. Nowadays, the use of antimicrobial remains necessary 
to control respiratory disease (Mateu and Martin, 2001; Schwarz et al., 2001; McEwen and 
Fedorka-Cray, 2002; Timmerman et al., 2006; Maes et al., 2008a; Callens et al., 2012). 
Based on the objective of the therapeutic medication, antimicrobial use can be divided 
in three categories: treatment, metaphylactic, prophylactic. Metaphylaxis is defined as the 
mass medication of a group of animals when some of these animals are clinically diseased 
while others are subclinically infected (Vicca, 2005). Prophylaxis is defined as the mass 
medication of a group of animals to prevent a possible clinical outbreak during high-risk 
periods for disease (Vicca, 2005). The high-risk period of M. hyopneumoniae infections 
occurrence under European production conditions is known to be after transfer of animals to 
the finishing facilities (10 weeks of age) (Léon et al., 2001). A recent study in Belgian pig 
herds (Callens et al., 2012) demonstrated that antimicrobials are frequently utilized 
therapeutically but also metaphylactically or prophylactically. This study illustrated a 7 and 
93 per cent of metaphylactic and prophylactic use, respectively, in Belgian pig herds. 
However, when compared with a similar previous report (Timmerman et al., 2006) 
(metaphylactic: 44 per cent; prophylactic: 56 per cent), an increased number of prophylactic 
group treatments and a drastic decrease of the portion of metaphylactic group treatments to 
the total number of group treatments were observed along the time. These studies have also 
described an increased number of treatment incidents in 2010 when compared with 2006 in 
Belgium. Therefore, these results clearly show the need for a reduction of group level 
prophylactic antimicrobial use (Callens et al., 2012). It also further confirms previous 
observation which indicated that in modern pig production, animals are mostly treated as a 
group and not as single individuals (Vicca, 2005; Timmerman et al., 2006; Burch, 2012). 
Antimicrobial group treatments are predominantly applied via in-feed or in-water 
medication because oral administration is less laborious and stressful compared to parenteral 
administration. Oral administration is the most common method of administering 
antimicrobials at group level. It can be quantified as treatment incidences (TI) based on the 
animal daily dose pig (ADDpig: average maintenance dose per day per kg pig of a drug used 
for its main indication) and the used daily dose pig (UDDpig: administered dose per day per 
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kg pig of a drug) (Callens et al., 2012). Also parenteral treatment can be quantified in this 
way. It has been shown that oral administrations are mostly underdosed (Timmerman et al., 
2006). 
It is generally accepted that in-feed medication is the most common method of 
administering antimicrobials at group level. However, it presents various disadvantages, 
which may be common to both (in-feed and via drinking water) oral administrations (Table 
3). First, a proportion of the feed provided to the pigs is wasted and not consumed by them. 
Gonyou and Lou (1998) and Van Heugten and Van Kempen (1999) showed that wasted feed 
can range from 5 to 6 per cent. Therefore, to avoid underdosing, the dosage of antimicrobial 
should be calculated based on real feed intake, and not on total feed provided (Gottlob et al., 
2007). Second, the absorption and metabolism of some antimicrobials agents depend on the 
pH of the stomach and the solubility of the agent. Therefore, a perfect knowledge of the 
pharmacokinetic properties is required for the selection of the correct antimicrobial. Third, in-
feed medication is not recommended for the treatment of acute infections (e.g. A. 
pleuropneumoniae), where a quick administration is of crucial importance for the success of 
the therapy (Pijpers et al., 1990; Henry and Apley, 1999; Friendship, 2000). However, it is 
especially suited for endemic or chronic diseases, such as enzootic pneumonia. Fourth, it 
appears that a not depreciable amount of medication is wasted or not ideally administered, 
since not only sick animals, but also healthy pigs receive medication. This can be justified by 
the intention to treat also penmates that are at-risk to become infected, especially in herds 
with a high stocking density. 
Antimicrobial group treatment can also be implemented via drinking water. Currently, 
administration of antimicrobials given as soluble formulations in the drinking water is 
becoming more popular. The development of more reliable dosing/water-proportioner 
machines has favored this increased use. It is especially recommended for the treatment of 
acute diseases. Urgent group treatment can be done in a quick way and sick pigs often 
continue to drink, even when they refuse feed. An important limitation is the antimicrobial 
wastage due to water disappearance. Water disappearance is defined as the overall usage of 
water, including water intake and wastage. Water wastage is mainly caused by either the type 
of drinking system and/or playing with the drinking nipple both intentionally (out of 
boredom) or unintentionally (highly dense stocked pens) (Brumm and Heemstra, 2000). For 
example, nipple drinkers waste 50 per cent more than bowl drinkers and nipple drinkers that 
are activated from any angle waste more that the ones that are activated from a forward angle 
(Brumm and Heemstra, 2000; Gottlob et al., 2007). Water intake may also be largely 
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influenced by the season. Therefore, appropriate follow-up of water usage efficiency is a 
prerequisite for achieving correct therapeutic doses (Henry and Apley, 1999). 
Group treatment can also be applied by parenteral administration. Advantages and 
disadvantages of in-feed, drinking water and the parenteral route of administration are 
presented in table 3. Callens et al. (2012) have illustrated a change in the relative importance 
of the different routes of administration of group treatments in Belgian pig herds, when 
compared with 2003 (Timmerman et al., 2006). The oral group treatments appeared to have 
been replaced by long-acting injectable group treatments. Injectable group treatments are 
mainly used in suckling pigs, and according to Timmerman et al. (2006) and Callens et al. 
(2012), overdosing often takes place. 
Individual treatments are usually applied by parenteral administration. Data from 
Callens et al. (2012) revealed that in most of the Belgian herds antimicrobials at individual 
level were administered. Individual treatments are frequently practiced in pigs suffering from 
acute disease by parenteral injection during onset and first days of disease. It often results in a 
good response against the disease, especially when acute outbreaks of respiratory disease 
occur and appetite of sick animals is diminished (Pijpers, 1990; Henry and Apley, 1999). 
The control of the M. hyopneumoniae infections by group medication can be 
accomplished by strategic administration of antimicrobials. It is considered as a 
prophylactic practice in swine (Karriker et al., 2012). It is usually applied by oral 
administration. Strategic medication may reduce the consequences of the disease and the 
infection load, but it does not prevent pigs from becoming infected with M. hyopneumoniae 
(Thacker et al., 2006). In addition, the symptoms may reappear after cessation of the therapy. 
Strategic medication during extended periods of time is not recommended. The risk for 
antimicrobial residues in pig carcasses at slaughter and the development of antimicrobial 
resistance in pathogens and bacteria belonging to the normal microbiota are major concerns 
in Europe (Maes et al., 2008a). Currently, several countries of the EU (Denmark, Sweden, 
The Netherlands, Germany) are running different programs at national level to monitor and 
reduce the use of antimicrobials in livestock (Callens et al., 2012). 
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Table 3. Advantages, disadvantages and reasons of failure to consider when using in-feed, drinking water and parenteral medication (Burch, 
2013). 
 In-Feed Drinking water Parenteral 
Indication Enzootic/chronic Chronic/acute Acute 
Target population Mass medication Mass medication Individual treatment 
Dose accuracy Low Variable High 
Application to selective groups Difficult (healthy pigs treated) Intermediate Easy (only sick pigs treated) 
Implementation Slow Fast Fast 
Labor Low Low High 
Cost Relatively high Low High 
Risk of cross-contamination High Low/Intermediate Low 
Failure due to …    
Lack of appetite High in sick animals NA NA 
High seasonal temperatures Low consumption High consumption/ wastage Stress inflict 
Wastage High High Fail to inject 
Accuracy of dosification systems Intermediate Intermediate Low 
Stress during administration NA NA Possible 
Antimicrobial drug stability to gastric pH Variable absorption Variable absorption NA 
Gastric emptying and interaction with feed Variable absorption Variable absorption NA 
Reduction of oral bioavailability 
Variable (e.g. Tetracyclines: 
presence of bivalent cations) 
Variable (e.g. Tetracyclines: 
presence of bivalent cations and 
water acidity) 
NA 
Homogeneity of antimicrobial drug in 
vehicle 
Variable Higher compared to in-feed NA 
Stability of antimicrobial drug in vehicle Higher compared to in-water Variable NA 
NA: not applicable
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1.6.2.3. Efficacy of antimicrobials against M. hyopneumoniae infections under 
experimental and field conditions 
Various studies have been performed in the past years to assess the efficacy of 
commercial antimicrobials used for the control and treatment of M. hyopneumoniae 
infections. A summary of the principal results obtained from these studies published in peer-
reviewed journals is given in tables 4 and 5. Since these studies were conducted under 
different conditions and many variables were included, comparison of results is complicated. 
However, it can be concluded that for the majority of antimicrobials tested, performance 
losses, clinical signs and lung lesions were reduced in treated animals. Nevertheless, M. 
hyopnemumonia could still be isolated from treated animals. 
 38 
 
Ch. 1 GENERAL INTRODUCTION 
Table 4. The effect of different antibiotic regimens for treatment of experimental infections with Mycoplasma hyopneumoniae. 
References Antibiotic and dosage Scheme Effects* 
Hannan and Goodwin, 
1990 
6-chloro analogue of Norfloxacin 
400 or 200 ppm Norfloxacin 100 
ppm in-feed 
during 3 w starting 1 m after 
infection 
improvement of ADG and FCR 
improvement of LL by 6-chloro analogue at 400 ppm 
only 
Schuller et al.,  
1977 
Tiamulin 100 or 200 ppm 
in-feed 
during 10 d starting 2 d before 
infection 
improvement of ADG and FCR 
LL were not prevented 
Mh could still be isolated 
Goodwin,  
1979 
Tiamulin 50 mg/kg 
in-feed 
during 10 d starting 1 m after 
infection 
improvement of ADG, CS and LL 
Mh could still be isolated 
Kobisch and Sibelle, 
1982 
Tiamulin 240 ppm 
in-feed 
during 10 d starting 10 d after 
infection 
improvement of ADG, FCR, CS, MLL and mLL 
Hsu et al., 
1983 
Tiamulin 10, 20, 30 ppm 
in-feed 
during 28 d starting 14 d after 
infection 
improvement of ADG and FCR 
no beneficial effect on CS and LL 
Ross and Cox,  
1988 
Tiamulin 60, 120, 180 ppm 
in-water 
during 10 d starting 11 d after 
infection 
no beneficial effect on ADG, FCR, CS, MLL and mLL 
Hannan et al., 
1982 
Tylosin tartrate 50 mg/kg combined 
with Tiamulin 10 mg/kg in-water 
during 10 d starting 14 d after 
infection (with lung homogenate) 
improvement of MLL 
Mh could still be isolated 
less secondary bacteria 
Clarck et al., 
1998 
Tilmicosin 363 ppm 
in-feed 
during 21 d starting 7 d before 
infection 
improvement of CS 
no beneficial effect on ADG and LL 
Thacker et al.,  
2006 
Chlortetracycline 500 ppm 
in-feed 
during 14 d starting 3 d before or 
10 d after infection 
3 d before infection: improvement of CS, LL 
both regimens: reduction of Mh organisms, but it could 
still be isolated 
Vicca et al.,  
2005 
Tylosin tartrate 100 mg/kg 
in-feed 
during 21 d starting 12 d after 
infection 
no beneficial effect on ADG 
improvement of CS and MLL 
Mh could still be isolated 
Ciprián et al.,  
2012 
Florfenicol 20 ppm 
in-feed 
during 35 d starting the day of 
infection 
improvement of ADG and LL 
Mh could still be isolated 
McKelvie et al. 
2005 
Tulathromycin 2.5 mg/kg IM 
Enrofloxacin 5 mg/kg IM 
during 1 or 3 d starting 5 d after 
infection 
Tulathromycin: improvement weight gain, CS,LL 
Enrofloxacin: improvement of CS, LL 
Le Carrou et al.,  
2006 
Marbofloxacin 1 or 2 mg/kg 
IM 
during 3 d starting 27 and 4 d 
after infection 
no beneficial effect on ADG, MLL 
Mh could still be isolated 
* Adapted from Vicca (2005); IM: intramuscular; d: day(s); w: week(s); m: month(s); ADG: average daily gain; FCR: feed conversion ratio; LL: lung lesions; CS: clinical signs; MLL: 
macroscopic LL; mLL: microscopic LL; 
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Table 5. The effect of different antibiotic regimens for treatment of infections in herds clinically affected by enzootic pneumonia. 
References Antibiotic and dosage Scheme Effects* 
Frank, 
1989 
Enrofloxacin 5 mg/kg 
Per os + IM + IM 
Per os: during 3 w starting after birth 
IM: during 3 w every 3 d starting after 
weaning 
IM: during 1 w every 2 d starting 
immediately 
prevention of CS 
Ganter, 
1995 
Chlortetracycline 800 ppm 
in-feed 
during 3 w improvement of CS and oxygen saturation 
Lukert and Mulkey, 
1982 
Lincomycin 5 mg/kg 
IM 
at 1, 2, 3, 39, 40, 41 d improvement of ADG, FCR and CS 
Martineau et al., 
1980 
Tiamulin 200 ppm 
in-feed 
during 10 d in growing unit 
improvement of ADG, CS, MLL and 
mortality rate 
Burch, 
1984 
Tiamulin 30 ppm 
in-feed 
during 8 w in pigs from 30 to 70 kg 
improvement of ADG, FCR 
no beneficial effect on MLL 
Burch et al., 
1986 
Tiamulin 100 ppm + Chlortetracycline 
300 ppm 
or Chlortetracycline 300 ppm alone 
in-feed 
during 7 d 
Tiamulin + Chlortetracycline: improvement 
of ADG and FCR, but no beneficial effect 
on MLL 
Chlortetracycline: improvement of ADG 
Kunesh, 
1981 
Tylosin 4 mg/kg or  
Lincomycin 5 mg/kg 
IM 
during 3 d after birth or and for 3 d at 
weaning 
Tylosin: improvement of ADG 
no beneficial effect on FCR and CS for both 
antibiotics 
 40 
 
Ch. 1 GENERAL INTRODUCTION 
References Antibiotic and dosage Scheme Effects* 
Binder et al., 
1993 
Tilmicosin 300 ppm 
in-feed 
during 9 or 14 d 
improvement of ADG, CS and less 
secondary bacteria 
LeGrand and Kobisch, 
1996 
Tiamulin 200 ppm + Chlortetracycline 
600 ppm 
in-feed  
pulse medication: 2 d treatment/2 w 
during fattening period 
lower prevalence on MLL 
no beneficial effect on severity of MLL 
Kavanagh, 
1994 
Tiamulin 30 ppm + Oxytetracycline 300 
ppm 
in-feed  
pulse medication: 2 or 3 d treatment/w 
during fattening period 
improvement of ADG and FCR 
lower prevalence and severity of MLL 
financial benefit 
Jouglar et al., 
1993 
Tiamulin 40 ppm + Oxytetracycline 300 
ppm 
in-feed 
pulse medication: 2 d treatment/w 
during fattening period 
improvement of ADG and mortality rate 
no beneficial effect on FCR and severity of 
LL 
Bousquet et al., 
1998 
Marbofloxacin 1 or 2 mg/kg 
IM 
during 3 d starting 27 and 4 d after 
infection 
no beneficial effect on ADG, MLL 
Mh could still be isolated 
Nanjani et al., 
2005 
Tulathromycin 2.5 mg/kg IM 
Tiamulin 15mg/kg IM 
Florfenicol 15mg/kg IM 
at 0 d 
at 0, 1, 2 d 
at 0, 2 d 
similar beneficial effect for all 3 
antimicrobials on ADG 
Nutsch et al., 
2005 
Tulathromycin 2.5 mg/kg IM 
Ceftiofur 3mg/kg IM 
at 0 d 
at 0, 1, 2 d 
similar beneficial effect for both 
antimicrobials on cure and mortality rate 
Mateusen et al., 
2001 
Vaccination (two-shot) 
Tilmicosin 200 ppm in-feed 
 
at 4 and 22 d of age during 3 w (34-55 
d) and 2 w (77-98 d) 
similar improvement of ADG and FCR, CS, 
MLL 
Mateusen et al., 
2002 
Vaccination (two-shot) 
Lincomycin 200 ppm in-feed 
Lincomycin 200 ppm + Vaccination 
at 4 and 28 d of age during 3 w in 
fattening period 
similar improvement of ADG and FCR, CS, 
MLL 
* Adapted from Vicca (2005); IM: intramuscular; d: day(s); w: week(s); m: month(s); ADG: average daily gain; FCR: feed conversion ratio; LL: lung lesions; CS: clinical signs; MLL: 
macroscopic LL; mLL: microscopic LL; 
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1.6.2.4. Antimicrobial susceptibility of M. hyopneumoniae 
Few data is available concerning the antimicrobial susceptibility and resistance for M. 
hyopneumoniae. Additionally, the fastidious growth of M. hyopneumoniae and its time 
consuming isolation, complicate the consistency of susceptibility testing and the 
interpretation of results. 
Standard broth and agar dilution methods used for susceptibility testing of other 
bacteria have been adapted for use with mycoplasmas. The „International Research 
Programme on Comparative Mycoplasmology (IRPCM)‟ suggested the adoption of 
„Guidelines and recommendations for antimicrobial minimum inhibitory concentration 
testing against veterinary mycoplasma species‟ (Hannan, 2000). 
Nowadays, both broth dilution and microbroth dilution techniques have been adapted 
for mycoplasmas and are the most widely used. The test consists on the inoculation of a 
standardized number of Mycoplasma-organisms in 96-well microtiter plates. These 96-well 
microtiter plates are prepared with serial doubling concentrations of antimicrobial agents and 
then, a mycoplasmal medium is added to these broth dilutions. The mycoplasmal medium 
contains a constant number of microorganisms and a substrate (glucose, arginin or urea) 
which is metabolized by mycoplasmas. The degradation of this medium results in a pH 
change visible as color change, which implies mycoplasma growth. The presence of 
increasing antibiotic concentrations permits to determine the lowest antimicrobial 
concentration that inhibits mycoplasma growth. The minimum inhibitory concentration 
(MIC) is defined as the lowest concentration of an antimicrobial agent that prevents a color 
change at the same moment that the color in the control without antibiotic has changed, hence 
the lowest concentration that prevents mycoplasma growth (Vicca, 2005). The study of 
antimicrobial susceptibility by means of MIC determinations for M. hyopneumoniae has 
various limitations. Bacterial contamination may occur, resulting in turbidity or color change 
in broth controls. Since MIC determination of M. hyopneumoniae is time consuming and may 
last up to 14 days, MICs of unstable antibiotics (chlortetracycline, valnemulin) are unreliable. 
In addition, there are no specific clinical breakpoints for mycoplasmas. 
Antimicrobial resistance in Mycoplasma spp. may be categorized in two types: intrinsic 
or acquired resistance. Intrinsic, innate or natural resistance may be defined as the relative 
insensitivity of all members of a bacterial species or genus against an antimicrobial agent 
(Vicca, 2005). Members of the class Mollicutes lack a cell wall and are therefore resistant to 
all β-lactam antibiotics, such as penicillins and cephalosporins, as well as antibiotics targeting 
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the cell wall, like glycopeptides. Additionally, mycoplasmas are also resistant to polymyxins, 
sulfonamides, trimethoprim, naladixic acid and rifampin. Within Mycoplasma species, 
macrolides present specific patterns of innate resistance depending on the structure of the 
lactone ring. The 14-membered lactone ring macrolides are ineffective against M. 
hyopneumoniae, M. flocculare, M. bovis, M. pulmonis and M. fermentans (Williams, 1978; 
Tanner et al., 1993; Chambaud et al., 2001; Bébéar and Bébéar, 2002; Francoz et al., 2005), 
whereas M. pneumoniae and M. genitalium are susceptible to this subgroup of macrolides 
(Bébéar et al., 2000; Kenny and Cartwright, 2001). In general terms, there are three main 
biochemical mechanisms of both intrinsic and acquired antimicrobial resistance in 
mycoplasmas, e.g. active efflux mechanisms, enzymatic modification of the drug or alteration 
in the drug target site. A complete overview of the biochemical mechanisms involved in the 
antimicrobial acquired resistance for Mycoplasma spp. was published by Vicca (2005). 
In vitro susceptibility of M. hyopneumoniae to antimicrobials used in pig veterinary 
medicine has been studied. Apart of intrinsic antimicrobial resistance, acquired antimicrobial 
resistance of M. hyopneumoniae has also been documented. Inconsistent results have been 
reported in susceptibility testing of tetracyclines (Williams, 1978; Etheridge et al., 1979; 
Yamamoto and Koshimizu, 1984). Shortly afterwards, Inamoto et al. (1994) reported 
acquired antimicrobial resistance to tetracyclines (chlortetracycline and oxytetracycline) 
occurring in M. hyopneumoniae field strains isolated in Japan between 1970 and 1990. More 
recently also acquired antimicrobial resistance to macrolides (tylosin, tilmicosin), 
lincosamides (lincomycin) and fluoroquinolones (enrofloxacin, flumequine) (Vicca et al., 
2004) has been documented. 
Despite some reports on resistance against tetracyclines, macrolides, lincosamides and 
fluoroquinolones in M. hyopneumoniae (Stakenborg et al., 2005a; Le Carrou et al., 2006; 
Vicca et al., 2007), resistance against other antimicrobials has not yet been detected. This 
indicates that antimicrobial resistance does not constitute a major problem for treatment of M. 
hyopneumoniae infections (Vicca et al., 2004; Maes et al., 2008a).  
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1.6.3. Vaccination against Mycoplasma hyopneumoniae 
1.6.3.1. Commercial vaccines 
Vaccination against M. hyopneumoniae is practiced in most of the swine producting 
countries, being in some cases applied in more than 70 per cent of the herds (Maes et al., 
2008a). Vaccination with commercial bacterins is considered as an important and effective 
tool to control M. hyopneumoniae infections. 
Commercial bacterins, consisting of inactivated, adjuvanted whole-cell preparations, 
have been commonly demonstrated efficacious to control the disease. The benefit of 
vaccination is based on reduction of losses caused by poor performance (average daily gain, 
ADG; 2-8 per cent), poor feed efficiency (feed conversion ratio; 2-5 per cent) and mortality 
(Maes et al., 2008a). A shorter time to reach market weight, decreased clinical signs and lung 
lesions and lower costs for antimicrobial medication and vaccination are contributors to this 
economic benefit (Dohoo and Montgomery 1996; Jensen et al., 2002; Maes et al., 2003; 
Maes et al., 2008a). A summary of experiments conducted under field conditions and the 
benefits observed after vaccination is presented in table 6. 
Despite all these advantages, commercial vaccines present various limitations. Thacker 
et al. (2000) suggested that current bacterins provided only partial protection and do not 
prevent colonization of the respiratory tract by M. hyopneumoniae. However, Sibila et al. 
(2007b) also demonstrated that vaccination may reduce the infection level in a herd. This 
corroborates previous observations from Haesebrouck et al. (2004), which indicated that 
maximum beneficial effects of vaccination are reached several months after the initiation of 
vaccination. Recent studies demonstrated that vaccination significantly reduced the number 
of M. hyopneumoniae organisms in the lungs of experimentally infected pigs (Vranckx et al., 
2012b), but the fact that M. hyopneumoniae DNA could still be detected by PCR confirmed 
previous results from experimental and field transmission studies (Meyns et al., 2006, 
Villarreal et al., 2011). These studies showed a limited reduction in transmission in 
vaccinated pigs. Therefore, all these findings suggest that, similarly to antimicrobials, 
vaccination alone does not prevent infection, and it is not able to eliminate M. 
hyopneumoniae from infected pig herds. 
During the past 15 years, few studies have investigated the immune mechanisms 
involved in induction of protection after vaccination with bacterins. All these studies 
indicated that both systemic and mucosal immune responses play a central role in the control 
of M. hyopneumoniae infections. However, the exact mechanism of protection conferred by 
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vaccination against M. hyopneumoniae is not yet fully understood. Thacker et al. (1998) 
compared the level of protection of four different commercial bacterins induced after 
experimental challenge. All four induced the production of specific antibodies in serum, but 
only a partial protection against clinical signs was conferred. Djordjevic et al. (1997) further 
confirmed this observation. A reduction in pneumonia was observed after vaccination, but 
antibody concentrations (in serum and respiratory tract washings) were not correlated with 
protection from the disease. Nowadays it is generally accepted that the presence and 
concentration of serum antibodies are not correlated with protection. Therefore, this is not 
suitable for the evaluation of protective immunity (Maes et al., 2008a; Marchioro et al., 
2013). 
Because M. hyopneumoniae is a mucosal pathogen which mainly adheres to the cilia of 
the epithelial cells from the respiratory tract, local M. hyopneumoniae-specific antibodies 
seem to play an important role in protection. Thacker et al. (2000) suggested that both local 
mucosal antibodies and systemic cell-mediated immunity responses are important for 
protection. These observations were confirmed by Marchioro et al. (2013). These authors 
illustrated the induction of both local and systemic immune responses involving both specific 
antibodies and cellular immunity following vaccination against M. hyopneumoniae with a 
commercially available bacterin. 
An inconsistent immune response and protection conferred by different commercial 
vaccines has been reported (Thacker et al., 1998). This variability may be due to several 
factors, such as different adjuvants included by commercial vaccines and possible antigenic 
differences (e.g. absence of specific epitopes) between the vaccine strain and the strains 
circulating in the field (Marchioro et al., 2013). 
1.6.3.2. Strategies of vaccination 
Many studies have been conducted in order to investigate the efficacy of the 
commercial bacterins under field conditions (Jensen et al., 2002). However, to decide 
whether vaccination in a specific herd should be implemented has to be based not only on 
efficacy parameters, but also on a cost-benefit analysis (Maes et al., 2003). Type of the herd, 
production system, infection pattern, health status of the population at risk, as well as easy 
implementation at practical level are main variables playing a role in the design of a 
successful vaccination strategy. 
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First, it has to be decided which population at risk should be vaccinated. In practice in 
Europe, sow vaccination is rarely practiced, whereas the main strategy of M. hyopneumoniae 
control is vaccination of piglets before or at weaning (Haesebrouck et al., 2004). 
Vaccination of sows ensures immunization of the newborn piglets through the passage 
of maternal derived antibodies via colostrum. However, colostral immunity does not prevent 
colonization of the piglets with M. hyopneumoniae (Thacker et al., 2000; Sibila et al., 2008). 
The main objective of vaccinating sows is to decrease vertical transmission from the dam to 
the off-spring via nose-to-nose contact (Ruiz et al., 2003). 
Vaccination of gilts before entering into the sow herd may avoid destabilization of the 
herd immunity (Bargen, 2004). 
Vaccination of suckling piglets (early vaccination; <4 weeks of age) is often practiced 
in single-site herds, where early infections are common (Maes et al., 2008a). Because M. 
hyopneumoniae infections can take place in piglets already during the first (from 1 to 3) 
weeks of life (Calsamiglia and Pijoan 2000, Ruiz et al., 2003, Fano et al., 2007, Sibila et al., 
2007a, Nathues et al., 2010, Villarreal et al., 2010, 2011, Vranckx et al., 2012a, Fablet et al., 
2012a), and because vaccination is most likely effective if active immunity can be established 
before the exposure to the pathogen, vaccination is commonly applied in suckling piglets. 
When compared with weaned piglets, suckling piglets are less infected with pathogens, such 
as PRRSV and PCV-2, which may cause problems after weaning and interfere with the 
establishment of a protective immune response to M. hyopneumoniae vaccination (Maes et 
al., 2008a). A limitation of early vaccination is the presence of maternal antibodies and its 
possible interference with vaccine efficacy (grosse Beilage et al., 2005; Martelli et al., 2006; 
Bandrick et al., 2008). However, the majority of the pig herds in Europe vaccinate piglets in 
the presence of maternal antibodies and the efficacy is apparently not affected (Martelli et al., 
2006; Maes et al., 2008a). 
Vaccination of weaners/growers/early fattening pigs (late vaccination; between 4 and 
10 weeks) is frequently applied in multi-site systems, where late infections are more common 
(Maes et al., 2008a). Late vaccination may evade the possibility of interference with 
maternally derived antibodies. However, it may elongate the age-window between decline of 
maternal immunity and age of infection, leading to a higher risk of infection before 
immunization. In addition, nursery pigs may already be infected with M. hyopneumoniae, 
since the onset of infection may vary between herds and also within a herd among successive 
batches (Sibila et al., 2004b, 2007b, Fano et al., 2007, Segalés et al., 2012). 
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Vaccination programs have become even more complicated with the introduction of 
single-dose formulations in addition to traditional two-dose formulations. The first 
commercially available bacterins indeed required two intramuscular injections and were 
demonstrated efficacious to control the disease. However, with the appearance of single-dose 
vaccines, which were confirmed as equally efficacious as the two-dose formulations (Kriakis 
et al., 2001; Dawson et al., 2002), the newer bacterins became more popular. This was 
mainly due to the reduced labor costs, easy implementation at farm level, less stress inflicted 
to the pigs, while a similar protection is conferred when compared with two-shot vaccines 
(Roof et al., 2001; Roof et al., 2002; Alexopoulos et al., 2004; Lillie et al., 2004; Baccaro et 
al., 2006; Greiner et al., 2011). Despite the acceptable efficacy of single-dose vaccines, there 
are still some situations in which two-dose formulations may be indicated (Yeske et al., 
2001). These situations include critical periods (pigs placed in fall months) and production 
systems (multi-source, multi-age, continuous flow) with serious M. hyopneumoniae 
challenges. It is also recommended in large herds with unstable situation to PRRSV, as well 
as when vaccination compliance is doubtful (Yeske et al., 2001). 
Variation in protection between different bacterins may be associated with the different 
adjuvants. Although all commercial bacterins are made from inactivated M. hyopneumoniae 
cells, they differ in the type of adjuvant (aluminium hydroxide, carbopol, mineral oil or 
biodegradable oil) and the solution included. Vaccines containing carbopol or aluminium 
hydroxide are produced as water based suspensions, whereas the oil adjuvant vaccines are 
produced as different emulsions. It is generally accepted that aqueous-based adjuvants 
produce a lesser stimulation of the immune system, and, consequently re-vaccination (two-
shot) is needed. Oil-based adjuvants are more reactive and often take a longer time to be 
processed. Therefore, they provide a prolonged release of the antigen and a better stimulation 
of the immune system. Generally speaking, bacterins containing oil-based adjuvants are 
capable to stimulate the immune system over time, mimicking conventional two-shot 
vaccines. Oil-based adjuvants can be divided in two types: oil in water emulsions and water 
in oil emulsions. Oil in water emulsions present relatively good immune stimulating 
properties, but a quick release of the antigen, which may shorten the duration of immune 
stimulation. In order to achieve a long term protection, commercial vaccines include mineral 
oil, which may cause significant local reactions. These local side effects may be minimized 
by water in oil emulsions, which are made of very small droplets of antigenic medium 
dispersed in biodegradable oil. This formulation based in biodegradable oil ensures an initial 
fast immune response and a subsequent slow release of the antigen. This provides a smooth 
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but long lasting stimulation of the immune system. Therefore, the onset of immunity is 
modulated by the progressive liberation of the antigen after only a few days and this 
immunity is maintained for a long period, compared to other adjuvant models (Herbach, 
personal communication, 2005; Aucouturier et al., 2002). 
The efficacy of all different commercial vaccines has been widely demonstrated during 
the last years. Numerous clinical trials both under experimental and field conditions have 
been carried out. Numerous parameters of comparison have been included. A summary of the 
experiments carried out in the past is presented in table 6. It includes type of vaccine, doses 
and age of vaccination, conditions of the experiment, parameters of evaluation, and 
significant results obtained. 
The route of vaccine administration has also to be taken into account when designing 
a vaccination strategy. Traditionally, intramuscular administration has been used. Apart from 
intramuscular vaccination, the effect of intraperitoneal (Sheldrake et al., 1991), oral (Weng et 
al., 1992), aerosol (Murphy et al., 1993), intranasal (Shimoji et al., 2003) and intradermal 
(Jones et al., 2005) vaccination against M. hyopneumoniae has also been investigated. 
Nowadays, intradermal vaccination has arisen as an alternative to intramuscular 
administration. It has been shown to be as efficacious as the intramuscular route in reducing 
performance losses and providing a better protection against clinical signs and lung lesions 
(Tassis et al., 2012). Main advantages of intradermal administration include lower risk of 
disease transmission through the application (no needles) and the consistent delivery of the 
vaccine. The lower volume and higher dispersion of the antigen during administration is 
associated with a total reduction of side effects at the injection site and a decrease of 
condemnation rate of carcasses at slaughter. Less pain and stress is inflicted to the animals 
and it is considered to be a safe procedure for the operators. Disadvantages of intradermal 
vaccination include the high cost for purchasing and maintaining the device for the ID 
application, and the fact that training of the person using it is needed. 
The use of combination vaccines has increased in the last years. Combination vaccines 
are those that contain antigens from different pathogens in the same formulation. Combined 
vaccination may maximize vaccine benefits, while minimizing costs, labor and the stress 
inflicted to the animals (Drexler et al., 2010). Although they are widely used in U.S., they 
lack popularity in Europe. A few studies have been carried out to investigate the effect of 
different combinations of vaccines against different pathogens [PRRSV and M. 
hyopneumoniae (Drexxler et al., 2010); PRRSV, M. hyopneumoniae and A. 
pleuropneumoniae (Delisle and Rigaut, 2007); PCV-2 and PRRSV (Bretey et al., 2010); 
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PCV-2 and M. hyopneumoniae (Hayes and Saltzman, 2009)]. These studies showed that 
vaccines against different pathogens can be combined without compromising the efficacy and 
safety, when used according to the manufacturer‟s instructions. 
1.6.3.3. Development of new vaccines 
Commercial vaccines are whole cell, adjuvanted bacterins (Okada et al., 1999). 
Nowadays, the availability of complete genome sequences has contributed to a new 
approach in vaccine development (Scarselli et al., 2005), called reverse vaccinology 
(Rappuoli, 2001). The reverse vaccinology approach starts from the genomic sequence and, 
by computer analysis, predicts those antigens that are most likely to be vaccine candidates. 
This method may be used for the development of both subunit and DNA vaccines. 
The use of recombinant proteins contributed to the development of subunit vaccines. 
The recombinant subunit vaccines are based on fractions of the organism and are produced 
using heterologous protein expression systems. These heterologous proteins can be produced 
in e.g. Escherichia coli cells and, once expressed and purified, can be administered to the 
animals. Specific antigens of M. hyopneumoniae include surface proteins (P46, P65, P97), 
cytosolic proteins (P36) and functional enzymes (L-lactate dehydrogenase, ribonucleotide 
reductase) (Kim et al., 1990; Strasser et al., 1991; Futo et al., 1995; Zhang et al., 1995; Fagan 
et al., 1996), and may be considered as potential vaccine candidates. 
Recently, several experimental recombinant subunit vaccines have been developed and 
tested for immune responses in mice (Marchioro et al., 2012) or pigs (Marchioro et al., 
unpublished). Excellent reviews have been published by Simionatto et al. (2013) and 
Marchioro (2013). Significant immune responses have been demonstrated in mice and pigs 
immunized with these experimental vaccines. Thus, recombinant subunit vaccines might 
represent a promising strategy for developing more effective vaccines against M. 
hyopneumoniae. 
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Table 6. Field studies investigating the effect of vaccination against M. hyopneumoniae in pig herds clinically affected with enzootic pneumonia. 
Reference 
Number 
of herds 
and pigs 
Commercial 
vaccine 
 
Schedule 
(age at vaccination 
in w) 
Efficacy parameters 
Increase in 
ADG 
g/pig/d (%) 
FCR 
% 
Pneumonia lesions at 
slaughter Mortality Other variables improved 
prevalence extent 
Vraa-
Andersen and 
Christensen, 
1993 
5 herds/ 
1500 pigs 
Suvaxyn 
two-shot 
1+3 w 
4+6 w 
 
 
+10 (2%) 
+25 (4%) 
- -49% 
Significantly 
decreased 
NI - 
Scheidt et al., 
1994 
1 herd/  
150 pigs 
Respisure 
two-shot 
1+3 w 
6+8 w 
 
 
+60 (8%) 
+60 (8%) 
 
NI 
 
NI 
 
 
-6% 
-8% 
- 
More feed consumption 
Less coughing 
Dohoo and 
Montgomery, 
1996 
1 herd/  
220 pigs 
Respisure 
two-shot 
3+6 w 
- - -33% 
Significantly 
decreased 
- 
Age to reach 80 kg carcass weight: -
11d or -2d 
Carcass weight: +1 kg 
Less carcasses under 70 kg 
LeGrand and 
Kobisch, 
1996 
1 herd/  
911 pigs 
Stellamune 
two-shot 
1+4 w 
 
 
+16 (2%) 
- -24% -1% - 
Age at 100 kg: -2.4d 
Carcass weight: +0.76 kg 
Less coughing 
Meat %: +0.64 
Schatzmann 
et al., 1996 
1 herd/  
120 pigs 
Stellamune 
two-shot 
1+3 w 
 
 
+60 (8%) 
- -10% 
Significantly 
decreased 
- Vaccinated pigs still excrete Mhyo 
Diekman et 
al., 1999 
1 herd/  
216 gilts 
Respisure 
two-shot 
1+4 w 
-20 (-3%) NI -10% -6% 
 
- 
Okada et al., 
1999 
3 herds/ 
212 pigs 
Mycobuster 
two-shot 
3-to-7 + 7-to-11 w 
 
NI 
+44 (7%) 
 
NI 
 
 
-43% 
-54% 
Significantly 
decreased 
- Age to market weight: -12d 
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Maes et al., 
1998 
5 herds/ 
468 pigs 
Stellamune 
two-shot 
1+3 w 
+25 (4%) - -27% -11% NI 
Age to reach 100kg liveweight: -5d 
Medication costs/pig: -11% 
% pigs with healthy lungs: +22% 
Maes et al. 
1999 
14 herds/ 
7000 pigs 
Stellamune 
two-shot 
1+3 w 
+22 (3%) -0.1% -14% -3% NI 
Age to reach 100kg liveweight: -5d 
Medication costs/pig: -40% 
% pigs with healthy lungs: +36% 
Coughing index: reduction 
Kyriakis et 
al., 2001 
1 herd/  
390 pigs 
Hyoresp 
two vs one-shot 
1+4 w 
10 w 
Significant 
increase 
 
 
+13% 
+5% 
- 
 
 
-2% 
<1% 
- 
Significant reduction in medication 
costs 
Dawson et al., 
2002 
2 herds/ 
1392 pigs 
Stellamune 
one-shot 
3-to-5 w 
+23 (4%) - - 
Significantly 
decreased 
- - 
Llopart et al., 
2002 
3 herds/ 
706 pigs 
Mypravac suis 
two-shot 
1+4 w 
+82 (12%) -0.3 -7% 
Significantly 
decreased 
NI - 
Moreau et al., 
2004 
1 herd/ 
59740 pigs 
Ingelvac Mhyo 
one-shot 
9 w 
+42 (5%) NI - - -1.5% - 
Baccaro et al., 
2006 
1 herd/  
520 pigs 
Respisure1 vs 
Ingelvac Mhyo 
one-shot 
4 w 
+30 (4%) 
+40 (5%) 
 
 
NI 
-51% 
-31% 
 
 
Significantly 
decreased 
- - 
Villarreal et 
al., 2011 
1 herd/    
72 pigs 
Suvaxyn MH-one 
one-shot 
3 w 
+49 (8%) - -8% NI - 
Vaccination does not reduce 
transmission of M. hyopneumoniae 
Tassis et al., 
2012 
1 herd/ 
1051 pigs 
Porcilis-Mhyo 
ID vs IM 
One-shot 4 w 
+23(4%) 
+5 (1%) 
- 
-14% 
-5% 
Significantly 
decreased 
- 
Better protection in reducing lung 
lesions by ID 
* Adapted from Maes (1998); IM: intramuscular; ID: intradermal; d: day(s); w: week(s); ADG: average daily gain; FCR: feed conversion ratio; “-“ not applicable; NI: numerical increased 
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1.6.4. Preventive medication vs vaccination 
It is well known that neither vaccination nor preventive medication can prevent 
adherence of M. hyopneumoniae to the ciliated cells of the respiratory tract and infection (Le 
Grand and Kobisch, 1996). However, the advantages and disadvantages of both strategies 
may be complementary in the control of M. hyopneumoniae infections (Table 7). 
Antimicrobial medication has a flexible and immediate effect whereas the effect of 
vaccination will be only evident in a long term and at herd level, when practiced for at least 
several months. Antimicrobial medication is less labor-intensive than individual vaccination, 
since antimicrobials can be administered orally. On the other hand, vaccination does not 
select for antimicrobial resistance and also avoids the risks of antimicrobial residues in the 
carcasses of slaughter pigs. Although antimicrobials can be often effective against several 
(respiratory) pathogens and vaccination is mostly focused on the control of M. 
hyopneumoniae infections, other secondary infections causing lung damage are less frequent 
after vaccination (Maes et al., 1999; Maes et al., 2000). However, even in herds vaccinating 
against M. hyopneumoniae, clinical disease can occur, and antimicrobials may remain 
necessary (Mateusen et al., 2002). Combined strategies using antimicrobial medication and 
vaccination are often used under field conditions, especially in herds with a high pressure of 
M. hyopneumoniae infection and/or deficiencies in housing and management. This approach 
may result in additional clinical and performance benefits (Mateusen et al., 2001; 2002). 
Table 7. Comparison of antimicrobial medication versus vaccination 
Antimicrobial medication Vaccination 
more flexible long-term strategy 
less laborious more laborious 
against different pathogens 
(e.g. multiple disease challenges) 
against one pathogen 
(combination vaccines possible) 
risk for residues no risk for residues 
risk for antibiotic resistance (especially in case of 
inappropriate or long term use) 
no risk for antibiotic resistance 
against bacterial infections, not against viruses vaccines available against limited number of 
diseases 
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AIMS OF THE STUDY 
Mycoplasma hyopneumoniae is the primary agent of enzootic pneumonia, a chronic 
respiratory disease in pigs resulting from mixed respiratory infections with M. 
hyopneumoniae and other bacterial pathogens. M. hyopneumoniae infections lead to major 
economic losses due to the reduced growth, increased mortality and feed conversion, costs 
for antimicrobials and immunoprophylaxis and increased time to market. 
The control of M. hyopneumoniae infections can be afforded by three different 
strategies, namely optimization of housing and management practices, antimicrobial 
treatment and vaccination. Both, antimicrobial treatment and vaccination have been shown to 
be able to reduce infections with M. hyopneumoniae, but not to eliminate this micro-organism 
from infected pigs. Despite vaccination, clinical outbreaks of respiratory disease due to M. 
hyopneumoniae infections may still occur. Therefore, better control strategies for this disease 
are required. 
The general aim of this thesis is to obtain better insights regarding different treatment 
and control strategies against M. hyopneumoniae infections. 
The specific objectives are: 
1. To determine the efficacy of a new florfenicol formulation to treat pigs by means of a 
single intramuscular injection against experimental M. hyopneumoniae infection. Whether 
this innovative metaphylactic medication established at onset of disease and characterized by 
a higher concentration of active substance can provide clinical efficacy is unknown. 
However, it can help to reduce the antimicrobial use in pig herds. 
2. To assess the efficacy of a one-shot vaccination applied at either one or three weeks 
of age in a Belgian farrow-to-finish pig herd with mixed respiratory disease including 
infections with M. hyopneumoniae and viral pathogens late in the fattening period. 
3. To compare the efficacy of in-feed medication with chlortetracycline, and tylosin 
phosphate against a clinical outbreak of respiratory disease in fattening pigs vaccinated 
against M. hyopneumoniae. Whether this chlortetracycline medication established at onset of 
disease and administered during two consecutives or alternating weeks can provide clinical 
efficacy is unknown. However, it can help to reduce the antimicrobial use and treatment 
duration in pig herds. 
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Abstract 
This study investigated the efficacy of a single intramuscular injection of florfenicol to 
treat clinical respiratory disease following experimental Mycoplasma hyopneumoniae 
infection. M. hyopneumoniae-free piglets were allocated to three groups namely a treatment 
(TG) and positive control group (PCG), which were both inoculated endotracheally with a 
highly virulent isolate of M. hyopneumoniae, and a negative control group. At onset of 
clinical disease, TG received a single injection of a new florfenicol formulation (30 mg/kg). 
All pigs were euthanized 4 weeks post-infection. Clinical symptoms were significantly 
reduced in TG in comparison with PCG (P<0.05). Average daily gain, feed conversion ratio, 
mortality and lung lesions were improved in TG compared to PCG, but the differences were 
not statistically significant. 
 
Keywords: Pigs; Mycoplasma hyopneumoniae; Florfenicol; Treatment 
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Introduction 
Mycoplasma hyopneumoniae plays a primary role in enzootic pneumonia, a chronic 
respiratory disease that occurs worldwide and causes major economic losses to the pig 
industry. M. hyopneumoniae is also one of the most important agents involved in the porcine 
respiratory disease complex, together with other bacterial and viral infections. M. 
hyopneumoniae infections lead to reduced performance, increased antimicrobial use and extra 
costs for control measures such as vaccination (Maes et al., 2008). 
Control of M. hyopneumoniae infections should be based primarily on optimizing 
housing and management practices, and on using vaccination. These measures are however 
not always effective, as even in herds with proper management and housing and applying 
vaccination, clinical outbreaks of M. hyopneumoniae infections may still occur (Maes et al., 
2008). Therefore, the use of antimicrobial agents may be warranted and even necessary to 
treat and/or control M. hyopneumoniae infections, and to safeguard the health and welfare of 
the animals. In such cases, it is important that antimicrobials are used judiciously and that 
strategic or preventive antimicrobial medication during long periods at risk is minimized 
(Dewulf et al., 2007). Compared to vaccination, antimicrobial medication has the advantage 
that it can be implemented more quickly and in a more flexible way, and that antimicrobials 
may also act against bacterial respiratory pathogens other than M. hyopneumoniae. 
The most frequently used antimicrobials against M. hyopneumoniae are tetracyclines, 
pleuromutilins, fluoroquinolones and macrolides (Thacker, 2006). Florfenicol is an antibiotic 
that is widely used in different farm animal species including pigs. It inhibits the microbial 
protein synthesis by abolishing the activity of the bacterial enzyme peptidyl transferase and is 
typically classified as a bacteriostatic antibiotic (Lobell et al., 1994). However, bactericidal 
activity was shown against major swine respiratory pathogens (A. pleuropneumoniae, P. 
multocida, H. parasuis). Florfenicol is active against many Gram-positive and Gram-negative 
bacteria, including aerobes, anaerobes, rickettsia, chlamydia and mycoplasmas (Shin et al., 
2005). 
The aim of this study was to investigate the efficacy of a new florfenicol formulation to 
treat pigs by means of a single intramuscular injection against experimental M. 
hyopneumoniae infection. The use of a single injection at onset of disease, provided it is 
effective, could significantly reduce the use of antimicrobials in pig herds in comparison with 
oral treatments which are usually established for extended periods of time. 
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Material and methods 
Study population, experimental infection and study design 
Forty-nine, 3-week-old, cross-bred piglets were purchased from a herd free of M. 
hyopneumoniae and porcine reproductive and respiratory syndrome virus (PRRSV). After 
weaning (at 3 weeks of age, Day -7), they were transported to the faculty of veterinary 
medicine (Ghent University). They were randomly allocated in three groups and housed in 
three different experimental rooms equipped with absolute filters to avoid possible 
transmission of infection. All pigs received ad libitum a commercial, antibiotic-free feed. On 
day 0 (D0), pigs of the treatment group (TG) (n = 22) and the positive control group (PCG) (n 
= 22) were inoculated endotracheally with 7 mL inoculum containing 10
7
 color-changing-
units/mL of the highly virulent M. hyopneumoniae F7.2C strain (Vicca et al., 2003). Pigs of 
the negative control group (NCG) (n = 5) were inoculated with 7 mL of sterile culture 
medium. For inoculation, the piglets were anesthetized with 0.22 mL/kg of a mixture of 
xylazine (Xyl-M 2%®, VMD) and zolazepam (Zoletil 100®, Virbac) applied 
intramuscularly. The treatment was applied when at least 10 per cent of the animals over the 
two infected groups showed coughing (D14). Animals were injected intramuscularly once 
with the test florfenicol formulation (Nuflor Swine Once®, MSD Animal Health; florfenicol 
450 mg/mL) (TG) or with physiological saline solution (PCG and NCG) at the dose of 1 
mL/15 kg bodyweight. All pigs were euthanized on day 28 (D28). 
Parameters of comparison 
Rectal temperature and severity of coughing were recorded daily for each piglet. The 
severity of coughing was assessed using a respiratory disease score (RDS) (Halbur et al., 
1996). Individual bodyweights and feed intake were measured on D0, D14 and D28 in order 
to evaluate average daily weight gain (ADG) and feed conversion ratio (FCR). Mortality was 
recorded during the whole experiment. 
After euthanasia, post-mortem parameters were studied. Mycoplasma-like macroscopic 
lung lesions were quantified using a lung lesion score (Hannan et al., 1982). Two lung tissue 
samples per lobe (apical, cardiac and diaphragmatic) were collected for histopathological 
examinations (percentage of tissue occupied by air; severity of peribronchiolar and 
perivascular lymphohistiocytic infiltration and nodule formation) (Morris et al., 1995) and 
immunofluorescence testing (Kobisch et al., 1978). Bronchoalveolar lavage (BAL) was 
performed and the fluid recovered was divided into two aliquots. The first aliquot was used 
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for the detection of M. hyopneumoniae-organisms by nested PCR (nPCR) (Stärk et al., 1998) 
and quantitative PCR (qPCR) (Marois et al., 2010). The second aliquot was used for 
bacteriological culture to detect the presence of live M. hyopneumoniae (Friis, 1975) and 
other respiratory pathogens (Quinn et al., 1994). Blood samples were collected (D0 and D28) 
and analysed to detect serum antibodies against M. hyopneumoniae and PRRSV. The post-
mortem lung lesion score was the primary efficacy criterion. Parameters with continuous 
variables were analysed using a one-way ANOVA, categorical variables were analysed using 
chi-square tests. 
Results 
A graphical representation of the rectal temperatures and RDS is given in Fig. 1 and 2, 
respectively. Results of clinical, performance, pathological, pathogen recovery and 
serological parameters in TG and PCG are shown in table 1. All pigs of the infected groups 
were positive by nPCR in BAL fluid. M. hyopneumoniae could not be isolated from the BAL 
fluid, whereas the routine bacteriological culture led to isolation of other bacterial species, 
particularly Bordetella bronchiseptica, Haemophilus parasuis and Streptococcus suis. All 
animals were serologically negative for PRRSV (D28).  
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Figure 1. Course of average (+/- SD) Rectal Temperature. Average Rectal Temperature (°C) 
from day 0 until day 28 in the treatment group (TG = 39.80 ± 0.30 °C), the positive control 
group (PCG = 39.86 ± 0.24 °C) and the negative control group (NCG = 39.48 ± 0.14 °C). 
Pigs were challenged endotracheally with a virulent strain of M. hyopneumoniae at D0, 
injected with florfenicol (TG) or physiological saline solution (PCG) at D14, and necropsied 
at D28. 
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Figure 2. Course of average (+/- SD) respiratory disease score (RDS). Average RDS from 
day 0 until day 28 in the treatment group (TG), the positive control group (PCG) and the 
negative control group (NCG). Pigs were challenged endotracheally with a virulent strain of 
M. hyopneumoniae at D0, injected with florfenicol (TG) or physiological saline solution 
(PCG) at D14 and necropsied at D28. 
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Table 1. Results (average ± standard deviation) of the clinical, pathological, performance, 
infection and serological parameters in the treatment group (TG) and the positive control 
group (PCG). Pigs were challenged endotracheally with a virulent strain of M. 
hyopneumoniae at D0, injected with florfenicol (TG) or physiological saline solution (PCG) 
at D14, and necropsied at D28. 
  
TG 
n = 20 
PCG 
n = 20 
P value 
Rectal Temperature (°C) 39.80 ± 0.30 39.86 ± 0.24 0.503 
RDS D0 to D28
 
8.69 ± 7.90 17.16 ± 12.35 0.024 
RDS D14 to D28 8.72 ± 7.94 17.10  ± 12.26 0.015 
ADG D0 to D28
 
(g/day)
 
220 ± 88 212 ± 94 0.768 
ADG D14 to D28 (g/day) 341 ± 120 275 ± 127 0.100 
FCR 1.69 2.03 - 
Mortality Rate (%) 0.00 10.00 0.232 
Macroscopic LLS
 
4.51 ± 3.87 5.94 ± 3.47 0.232 
Microscopic LLS 3.85 ± 0.65 3.72 ± 0.67 0.540 
Percentage Air Analysis 21.94 ± 6.28 22.20 ± 5.31 0.892 
IF
 
0.92 ± 0.73 0.95 ± 0.65 0.892 
qPCR testing: Log copies of M. 
hyopneumoniae/ml (mean±sd)
 4.91 + 5.96 4.74 + 4.92 0.952 
% of pigs serologically positive for 
M. hyopneumoniae
 14.3% 26.3% 0.290 
Rectal Temperature (average from D0 to D28); RDS (average Respiratory Disease Score; ADG (Average Daily Weight 
Gain); FCR (Feed Conversion Ratio: no statistical analysis, since FCR has been calculated at pen level, with only one 
observation); LLS (Lung Lesion Score); Microscopic LLS (peribronchiolar and perivascular lymphohistiocytic infiltration 
and nodule formation); IF (Immunofluorescence); qPCR (quantitative PCR: number of M.hyopneumoniae-organisms);  per 
cent of pigs serologically positive for M. hyopneumoniae at D28. 
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Discusion 
The present study assessed the efficacy of a florfenicol formulation administered 
intramuscularly for the treatment of respiratory disease caused by an experimental M. 
hyopneumoniae infection. 
According to the RDS, onset of clinical disease took place between 12 and 15 days 
after endotracheal inoculation and the decision to start the treatment was made on D14. The 
results showed that the treatment was efficacious only for improving clinical respiratory 
symptoms. The RDS is indeed an important indicator of the severity of M. hyopneumoniae 
infections (Vicca et al., 2003), and hence to assess the clinical effectiveness of the treatment. 
The injection of florfenicol significantly decreased the RDS in TG, especially on days 16 and 
17. However, this score increased again on day 18, i.e. four days post-treatment. 
Also, at necropsy (D28 or 29) only a numerical benefit was observed for the 
macroscopic and the histopathological lung lesions. The percentage of air in the lung tissue 
and the qPCR results were very similar for the TG and PCG (P>0.05). This suggests that the 
studied parameters may be delayed shortly after treatment, but 14 days later, no significant 
differences can be found between the groups. Liu et al. (2003) reported a long duration of the 
therapeutic plasma level of florfenicol in pigs experimentally infected with Actinobacillus 
pleuropneumoniae. Our findings suggest that a single injection with this antibiotic only 
partially controls M. hyopneumoniae infection during a period of approximately four days. 
All infected pigs were positive by nPCR in the BAL fluid, indicating that the challenge 
infection was successful and that the treatment did not eliminate M. hyopneumoniae from the 
lungs. The latter confirms previous reports, stating that antimicrobial treatment does not 
eliminate the pathogen from the lung tissue nor heal existing lesions (Thacker, 2006). 
Antimicrobial agents may delay infection, but cannot avoid colonization, nor assure total 
elimination of M. hyopneumoniae. 
However, M. hyopneumoniae could not be isolated from the lungs because of 
overgrowth of other bacterial species, particularly Bordetella bronchiseptica, Haemophilus 
parasuis and Streptococcus suis which were isolated in high numbers. All animals were 
serologically negative for PRRSV (D28). 
The performance parameters (ADG, FCR) and mortality were numerically improved in 
the treated group. More animals would have been needed to obtain statistically significant 
results, but the tendencies indicate that an economical improvement could be obtained when 
florfenicol is injected. 
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The present study showed that the tested florfenicol formulation, when administered 
intramuscularly as a single dose of 30 mg/kg bodyweight, was effective in reducing the 
clinical respiratory symptoms in pigs experimentally infected with a highly virulent M. 
hyopneumoniae strain. Despite these findings, optimizing housing and management practices, 
as well as vaccination should still be the key processes used in the control of M. 
hyopneumoniae infections. 
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Abstract 
The present field study investigated the efficacy of early Mycoplasma hyopneumoniae 
(M. hyopneumoniae) vaccination in a farrow-to-finish pig herd with respiratory disease late in 
the fattening period due to combined infections with M. hyopneumoniae and viral pathogens. 
Five-hundred-and-forty piglets were randomly divided into three groups of 180 piglets each: 
two groups were vaccinated (Stellamune Once®) at either 7 (V1) or 21 days of age (V2), and 
a third group was left non-vaccinated (NV). The three treatment groups were housed in 
different pens within the same compartment during the nursery period, and were housed in 
different but identical compartments during the fattening period. The efficacy was evaluated 
using performance and pneumonia lesions. The average daily weight gain during the 
fattening period was 19 (V1) and 18 g/day (V2) higher in both vaccinated groups when 
compared with the NV group. However, the difference was not statistically significant 
(P>0.05). The prevalence of pneumonia was significantly lower in both vaccinated groups 
(V1:71.5 and V2:67.1 per cent) when compared with the NV group (80.2 per cent) (P<0.05). 
There were no significant differences between the two vaccination groups. In conclusion, in 
the present herd with respiratory disease during the second half of the fattening period caused 
by M. hyopneumoniae and viral infections, prevalence of pneumonia lesions were 
significantly reduced and growth losses numerically (not statistically significant) decreased 
by both vaccination schedules. 
 
Keywords: Mycoplasma hyopneumoniae; pig; early vaccination; one-shot 
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Introduction 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the causative agent of enzootic 
pneumonia in pigs and is one of the primary agents involved in the porcine respiratory 
disease complex (PRDC). This disease is distributed worldwide and leads to a significant 
reduction of economical profit in pig production, mainly due to decreased growth, higher 
feed conversion ratios and higher costs for treatments (Maes et al., 2008; Thacker and Minion 
2012). Control of M. hyopneumoniae infections can be accomplished by improving 
management and housing practices, by the use of antimicrobials and by vaccination (Maes et 
al., 2008). Vaccination is frequently practiced worldwide. The major advantages of 
vaccination include a reduction of the losses of average daily gain (ADG; 2-8 per cent), feed 
conversion ratio (2-5 per cent) and mortality (Maes et al., 2008). Additionally, shorter time to 
reach slaughter weight, reduced clinical signs and lung lesions and lower treatments costs are 
observed (Maes et al., 2008). 
Different vaccination strategies can be implemented, depending on the type of herd, the 
production system and management practices, the infection pattern and the preferences of the 
pig producer. Currently, one-shot vaccination is more often practiced than two-shots 
vaccination, mainly because it requires less labor, it confers similar results than two-shots 
vaccination (Roof et al., 2001, 2002; Alexopoulos et al., 2004; Lillie et al., 2004; Greiner et 
al., 2011), and it can be implemented more easily in routine management practices on the 
farm. Because M. hyopneumoniae infections can take place in piglets already during the first 
weeks of life (Calsamiglia and Pijoan 2000; Ruiz et al., 2003; Fano et al., 2007; Sibila et al., 
2007; Nathues et al., 2010; Villarreal et al., 2010, 2011b; Vranckx et al., 2012a; Fablet et al., 
2012a), and because vaccination is most likely effective if active immunity can be established 
before the exposure to the pathogen, vaccination is commonly applied in suckling piglets. 
When compared with weaned piglets, suckling piglets are less infected with pathogens, such 
as porcine reproductive and respiratory syndrome virus (PRRSV) and porcine circovirus type 
2 (PCV-2), which may cause problems after weaning and interfere with the establishment of 
a protective immune response to M. hyopneumoniae vaccination (Maes et al., 2008). Early 
vaccination has also the advantage that immunity is induced at a young age. This may be 
important as the onset of infection may vary between herds and also within a herd among 
successive batches (Sibila et al., 2004b, 2007; Fano et al., 2007; Segalés et al., 2012). Apart 
from inducing early protection, it is also important that early vaccinated pigs remain 
 88 
 
Ch. 3.2 EXPERIMENTAL STUDIES 
protected until the end of the fattening period, as in most pig herds, the highest infection 
levels of M. hyopneumoniae occur during the grow-finishing period (Sibila et al., 2004c). 
Several studies have assessed the efficacy of vaccination at seven days of age against 
M. hyopneumoniae challenge infection under experimental conditions. This early vaccination 
at seven days of age has been demonstrated effective in reducing lung lesions and/or clinical 
signs in several challenge infections either at two (Reynolds et al., 2006), four (Reynolds et 
al., 2009, Villarreal et al., 2011a), six (Meyns et al., 2006), eight (Villarreal et al., 2011a) or 
nineteen (Kim et al., 2011) weeks post-infection. However, the duration of the effect of one-
shot early vaccination under field conditions with mixed respiratory disease is less clear. 
Mixed respiratory disease is commonly identified as PRDC and results from infections with 
several primary and secondary respiratory pathogens, such as PRRSV, PCV-2, swine 
influenza virus (SIV), M. hyopneumoniae, Pasteurella multocida, Bordetella bronchiseptica, 
Actinobacillus pleuropneumoniae and Streptococcus suis (Opriessnig et al., 2011). As the 
disease course and lung lesions can be largely influenced by viral respiratory pathogens such 
as PRRSV (Thacker et al., 1999), PCV-2 (Opriessnig et al., 2004) and swine influenza virus 
(Thacker et al., 2001), it is important to investigate whether M. hyopneumoniae vaccination is 
also beneficial under such circumstances. The objective of this study was to investigate the 
efficacy of a one-shot vaccination applied at either one or three weeks of age in a Belgian 
farrow-to-finish pig herd with mixed respiratory disease late in the fattening period and 
including infections with M. hyopneumoniae and viral pathogens.  
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Materials and methods 
Herd description and study population 
The study was conducted between April and October 2011 in a Belgian farrow-to-finish 
pig herd comprising 1000 commercial hybrid sows (Topigs 20) that operated a four-week 
batch production system. Semen from Piétrain boars was used for artificial insemination. The 
sows were vaccinated against swine influenza virus (Gripovac 3®, Merial), Atrophic Rhinitis 
(Rhiniffa–T®, Merial), Escherichia coli (E. coli) (Neocolipor®, Merial), porcine parvovirus 
and Erysipelothrix rhusiopathiae, combined according to the manufacturer´s instructions 
(Parvoruvax®, Merial). The piglets received an iron injection (Uniferon®, Pharmacosmos) 
(intramuscular, 1 ml/pig) and toltrazuril per os (Baycox®, Bayer; 20 mg/kg), both according 
to the manufacturer´s instructions, at three days of age, and they were surgically castrated 
during the first week of life. Toltrazuril was administered as preventive treatment for 
coccidiosis. At weaning (three weeks of age), the pigs were moved to a nursery unit where 
they stayed until 10 weeks of age. Thereafter, they were transferred to a fattening unit, in 
which they were kept until slaughter weight (approximately 28 weeks of age). Colistin in-
feed medication (Promycine 400®, VMD) was prophylactically administered (according to 
the manufacturer´s instructions) after weaning for seven days to prevent problems with post-
weaning E. coli infections. All pigs received anthelmintic treatment at 10 weeks of age via 
the feed with flubendazole (Flubenol 5 %®, Elanco Animal Health) for five days. 
At weaning, all piglets included in the experiment were allocated into one compartment 
of the nursery (n=576 pigs). This compartment consisted of 32 pens (18 pigs per pen) with a 
partially slatted floor and there was mechanical channel ventilation. At 10 weeks of age, all 
study piglets were moved to six identical compartments of a fattening unit. The three 
different treatment groups were housed in different compartments (two compartments for 
each treatment group). Each compartment consisted of eight pens (12 pigs per pen) with a 
fully slatted floor and there was mechanical door ventilation. The nursery unit and the 
fattening unit were equipped with an automatic ventilation system controlled by computer. 
During the entire experiment, water and feed (meal) were supplied ad libitum.  
Before the start of the study, clinical signs of respiratory disease, namely coughing and 
sneezing, were evident in nursery piglets from six-to-seven weeks of age onwards. Limited 
sampling using nasal swabs in 20 two-week-old piglets and broncho-alveolar lavage (BAL) 
fluids in 20 six-week-old piglets and 10 ten-week-old piglets showed that 0/20, 0/20 and 5/10 
piglets, respectively, were positive for M. hyopneumoniae by nested polymerase chain 
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reaction (PCR) (nPCR) (Stärk et al., 1998). Blood samples taken from 20 randomly selected 
pigs at 19 weeks of age revealed that 75 per cent of the pigs were serologically positive for 
M. hyopneumoniae and 100 per cent for PRRSV using a blocking Enzyme-Linked 
Immunosorbent Assay (ELISA) (IDEI, Mycoplasma hyopneumoniae EIA kit, Oxoid, UK) for 
M. hyopneumoniae and the HerdChek PRRS X3 (IDEXX) for PRRSV. Gross examination of 
the lungs from fattening pigs (n=826) slaughtered during 12 months before the start of the 
study indicated an average pneumonia prevalence of 35 per cent. 
Experimental design 
In total, 540 pigs originating from one batch of sows were selected for this study. 
Although the original group comprised 250 sows, only the offspring of 60 sows was included 
in the trial. These 60 sows were selected at random from the group of 250 sows to obtain a 
representative sample of sows (all parities represented) and piglets. The pigs were 
individually ear-tagged and randomly allocated to one of the three treatment groups. Within 
each litter (n=60), an equal number of pigs (n=3) was allocated to each treatment group 
(blocked randomization). Therefore, in total, each treatment group consisted of 180 pigs. One 
group was vaccinated intramuscularly at 7 days of age with two ml of a commercial 
inactivated M. hyopneumoniae vaccine (Stellamune Once®, Elanco Animal Health) 
(designated group V1), a second group was vaccinated intramuscularly at 21 days of age with 
the same vaccine (designated group V2), a third group was left unvaccinated (designated 
group NV). Non-vaccinated animals were not injected with a placebo. Upon weaning, piglets 
were moved to a nursery unit, where they were partly re-grouped according to pen-size, 
weight and sex. Pigs of the different treatment groups were housed in different pens within 
the same compartment. The stocking density in the nursery unit was 0.27 m
2
 per pig. Pens 
were separated by solid pen partitions. As the capacity of the nursery unit (576) was slightly 
higher than the number of study pigs (540), two pens (36 pigs) were not included in the trial. 
Twelve of these pigs had been vaccinated at one week, twelve at three weeks, and twelve had 
not been vaccinated. 
The pigs were moved to a fattening unit at approximately 70 days of age. At that time, 
they were partly re-grouped according to pen size and weight. Barrow and gilts were housed 
in different pens, and pigs of different treatment groups were housed in different 
compartments (two compartments for each treatment group). The 36 extra pigs were divided 
in three pens, one in each treatment group. They were not included in the study as the 
approval for the ethical committee before the study included 540 pigs. The stocking density 
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in the fattening unit was 0.75 m
2
 per pig. Fattening pigs of neighbouring pens could have 
direct nose-to-nose contact. All other factors that could possibly influence the outcome 
parameters e.g. environment and management factors, sex ratio, and feed composition were 
the same for the three groups. The person responsible for assessing the efficacy parameters 
was unaware of the allocation of the groups. All animals were housed and reared in 
accordance with EU animal welfare regulations and in accordance with EU experimental 
animal legislation (Directive 86/609/EEC). The study was approved by the ethical committee 
for animal experiments of the Faculty of Veterinary Medicine, Ghent University 
(EC2011/068). 
Parameters of comparison 
Performance parameters 
Pigs were individually weighed at one week of age (7 days), at weaning (21 days), at 
the end of the nursery period (74 days) and prior to slaughter (200 days) to determine the 
average daily gain (ADG). The ADG (g/pig/day) was computed for the different production 
stages (lactation, nursery and fattening period) as the difference between starting and final 
weights divided by the number of days during that period. 
Clinical and pathological parameters 
All pigs that died during the study were necropsied to assess the possible cause of 
death. Where appropriate, necropsied pigs were processed for further laboratory 
examinations. When the dead animals were suspected to be infected with M. hyopneumoniae, 
nPCR testing (Stärk et al., 1998) was performed on the lungs. DNA was extracted using the 
DNA easy kit (Quiagen, Blood and tissue kit, Belgium). 
When individual signs of respiratory disease (coughing, sneezing, dyspnea, tachypnea) 
were observed by the farmer and confirmed by the veterinarian, individual treatment against 
respiratory disease was allowed. Concomitant antimicrobial treatment of study pigs 
(parenterally or orally) was only allowed with antimicrobials ineffective against M. 
hyopneumoniae, such as β-lactam antibiotics (penicillins and cephalosporins). For parenteral 
treatment, ceftiofur (Excenel RTU®, Pfizer Animal Health) or amoxicillin (Duphamox Long 
Acting®, Pfizer Animal Health) could be used, for group treatment, amoxicillin applied via 
the drinking water (Amoxicilline 70 %®, Kela Laboratoria) could be used. The total number 
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of treatment days against respiratory disease (based on individual or group treatment) was 
recorded in the different treatment groups. 
At slaughter (201-214 days of age), the prevalence of Mycoplasma-like pneumonia 
lesions and adhesive pleurisy and the extent of macroscopically visible pneumonia were 
recorded by the first author in a blinded manner. Mycoplasma-like pneumonia lesions were 
defined as red to purplish consolidated areas on the cranio-ventral portions of the lungs in a 
lobular pattern. Adhesive pleurisy was defined as fibrotic adherence between the visceral and 
parietal membranes of the pleural sac. Due to practical reasons, only the visceral membrane 
was evaluated for the detection of pleurisy. The extent of macroscopically visible pneumonia 
was quantified based on a score described by Morrison et al. (1985). Briefly, this lung lesion 
score expresses the total area (percentage) of the lung tissue affected by pneumonia. Each 
lobe represents a percentage of the total lung surface area: apical (10 per cent), cardiac (7 per 
cent), accessory (6 per cent) and diaphragmatic (30 per cent). An average score was 
calculated for each group based on the lung lesion score of the individual animals. 
Detection of M. hyopneumoniae by nested PCR (nPCR) 
Nasal swabs, tracheo-bronchial swabs (Marois et al., 2007; Fablet et al., 2010) and 
broncho-alveolar lavage (BAL) fluids (Villarreal et al., 2011b) were collected from 
approximately 30 randomly selected animals per group that were serially sampled at different 
ages (Table 1). Nasal swabs (Copan®, Italy) were collected at weaning (21 days), halfway 
through the nursery period (49 days), at the end of the nursery period (74 days), halfway 
through the fattening period (136 days) and prior to slaughter (200 days). Tracheo-bronchial 
swabs (Euromedis®, Neuilly-sous-Clermont, France) were collected at the same time points 
as the ones for nasal swabs, but not at 200 days of age. BAL fluids were collected at 49, 74 
and 136 days of age. DNA was extracted with the DNA easy kit (Quiagen, Blood and tissue 
kit, Belgium) and a nPCR was performed (Stärk et al., 1998). 
Serological examinations 
Blood samples were collected from the same 30 animals per group (Table 1) at 7, 21, 
74, 136, and 200 days of age. Serological examination to detect antibodies to M. 
hyopneumoniae was carried out using a blocking ELISA (IDEI, Mycoplasma hyopneumoniae 
EIA kit, Oxoid, UK). Sera with optical density (OD) values <50 per cent of the ODbuffer-control 
were considered as positive. Sera with OD values ≥50 per cent of the ODbuffer-control were 
considered as negative. Fifteen blood samples were randomly selected from the 30 blood 
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samples collected at 74, 136, and 200 days of age and additionally tested for antibodies to 
PRRSV (HerdChek PRRS X3, IDEXX), PCV-2 (Ingezim Circovirus IgG/IgM, Ingenasa), 
subtypes H1N1, H1N2, and H3N2 of swine influenza virus (SIV) (standard 
haemagglutination-inhibition test), and serotype 2 (Swinecheck APP 2, Biovet) and serotypes 
1, 9 or 11 (Swinecheck APP 1,9,11, Biovet) of Actinobacillus pleuropneumoniae. 
Carcase quality 
At slaughter, carcase quality, including the percentage of meat, back fat thickness and 
muscle thickness of the Longissimus dorsi, was automatically recorded by the abattoir 
services. 
Statistical analysis 
The number of animals in each treatment group (180) allowed to assess a difference of 
20 g (sd=70) in ADG with 95 per cent certainty and 80 per cent statistical power (Win 
Episcope 2.0, CLIVE, Edinburgh, UK). The pig was considered as statistical unit. To correct 
for the effects of hierarchical data, pen and compartment were included as random effects. 
Analysis of variance (ANOVA) models were used to analyse the continuous variables 
(weight, number of treatment days against respiratory disease, carcase quality parameters). 
Some other continuous variables (ADG and lung lesion scores) did not fulfill the criteria of 
normality and homogeneity of variances, and they were analysed using a non-parametric 
Kruskal-Wallis ANOVA. Mortality and prevalence of pneumonia and pleurisy were analysed 
using logistic regression analysis. Differences were considered as statistically significant 
when P-values were lower than 0.05 (two-sided test). Statistical analyses were performed 
using the software package SPSS version 20.0 (SPSS Institute Inc., Illinois, USA). Results 
are presented as mean ± sd unless stated otherwise.  
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Table 1. Sampling scheme for nasal (NS) and tracheo-bronchial swabs (TBS), broncho-
alveolar lavage (BAL) fluids and blood samples. Thirty pigs per group were randomly 
selected. NS, TBS and BAL fluid samples were analysed using nested PCR to detect the 
presence of M. hyopneumoniae, blood samples were analysed using ELISA to detect 
antibodies to M. hyopneumoniae. 
Age (d) of sampling
*
 NS TBS BAL fluids Blood 
7 no no no yes 
21 yes yes no yes 
49 yes yes yes no 
74 yes yes yes yes 
136 yes yes yes yes 
200 yes no no yes 
*At 7 (one week), 21 (at weaning), 49 (halfway nursery period), 74 (end of nursery period), 136 (halfway fattening period) 
and 200 days (prior to slaughter). 
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Results 
Performance parameters 
The weights of the pigs at 7, 21, 74, and 200 days of age are presented in Table 2. On 
average, pigs of the V1 and V2 groups gained 2.3 kg (group V2) to 2.4 kg (group V1) more 
than pigs in the NV group between 7 and 200 days of age. The ADG during the lactation 
period (7 to 21 days), the nursery period (21 to 74 days), the fattening period (74 to 200 
days), and during the entire study period (7 to 200 days) are presented in Table 3. Over the 
entire fattening period, the ADG in the V1 and V2 group was 19 and 18 g/pig/day, 
respectively, higher than in the NV group. These differences were not statistically significant 
(P>0.05). 
Clinical and pathological parameters 
None of the pigs died between the first and second vaccination. In total, 15 pigs (2.8 per 
cent) died from 21 days of age until slaughter. Four of them died following either sampling or 
weighing (1 in the V1 group, 3 in the NV group). The other dead animals occurred as follows 
in the three treatments groups: V1 (n=4; 2.2 per cent), V2 (n=1; 0.6 per cent), and NV (n=6; 
3.3 per cent) (P>0.05). Pneumonia was the major post-mortem finding in five out of 15 
necropsied pigs (1 in the V2 group, 4 in the NV group). Mycoplasma hyopneumoniae was not 
detected by nPCR in any of these five lungs. 
Sporadic non-productive coughing was observed at approximately 151 days of age. 
Pigs showing clinical respiratory disease signs were treated parenterally with long-acting 
amoxicillin or ceftiofur (V1=13; V2=8; NV=9). At 161 days of age, respiratory disease was 
observed in many pigs of the three groups. The three groups were more or less similarly 
affected. Therefore, all pigs of the study were treated for five days with amoxicillin via the 
drinking water. The total numbers of days (±sd) of additional antibiotic treatment were 5.06 ± 
0.28 (V1), 5.02 ± 0.13 (V2) and 5.03 ± 0.26 (NV) (P>0.05). 
At slaughter, the prevalence of Mycoplasma-like pneumonia lesions and pleurisy and 
the extent of macroscopically visible pneumonia were recorded in 505 pigs (V1: 165; V2: 
173; NV: 167). Because of practical reasons (pigs with lost ear tags and/or lungs that did not 
reach the examination stand at the slaughterhouse), a few plucks could not be scored in the 
slaughterhouse (10, 6 and 4 in V1, V2 and NV, respectively). 
The percentage of pigs with pneumonia was significantly lower in both vaccinated 
groups V1 (118/165 pigs; 71.5 per cent) and V2 (116/173 pigs; 67.1 per cent) when 
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compared with the NV group (134/167 pigs; 80.2 per cent) pigs (P<0.05). The prevalence of 
pleurisy was also lower in both vaccinated groups (V1, 7.6 per cent; V2, 11.6 per cent) when 
compared with NV group (12.3 per cent), however it was not statistically significant 
(P>0.05). The average pneumonia scores in the V1, V2, and NV group were 13.0, 9.8, and 
14.4, respectively (P<0.05) (Table 2). In accordance with this score, 51 per cent of the pigs 
presented mild pneumonia lesions characterized by an extent lower than 10 per cent of the 
overall lung surface, which is indicative of a recent (late in fattening period) and mild 
respiratory disease. 
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Table 2. Average (± sd) bodyweight at 7, 21, 74, and 200 days (d) of age, and carcase quality (% meat, back fat thickness and muscle thickness), 
prevalence and extent of pneumonia and prevalence of pleurisy at slaughter in pigs vaccinated at 7 days of age (V1), 21 days of age (V2) and in 
pigs not vaccinated (NV) against Mycoplasma hyopneumoniae. 
Parameters Age (d)
 †
 V1 V2 NV 
Number of pigs at the beginning n=180 n=180 n=180 
Average bodyweight (kg) 
7 2.51 ± 0.56 2.57 ± 0.60 2.53 ± 0.66 
21 5.42 ± 1.05 5.58 ± 1.04 5.54 ± 1.11 
74 22.95 ± 4.24 23.04 ± 3.77 23.20 ± 4.82 
200  119.79 ± 14.13 119.67 ± 13.10 117.42 ± 14.86 
Mortality (%)  4/180 (2.2) 1/180 (0.6) 6/180 (3.3) 
Number of pigs at slaughter  n=165* n=173 n=167 
Prevalence of pneumonia (%) 201-214 71.5
A
 67.1
A
 80.2
B
 
Prevalence of pleurisy (%) 201-214 7.6 11.6 12.3 
Extent of pneumonia 201-214 12.96 ± 14.36
AB
 9.76 ± 10.61
A
 14.38 ± 14.43
B
 
% Meat  201-214 59.99 ± 4.05 61.47 ± 3.56 60.12 ± 3.85 
Back fat thickness (mm) 201-214 17.29 ± 3.67 14.93 ± 2.82 15.89 ± 3.58 
Muscle thickness (mm) 201-214 66.61 ± 7.43 65.46 ± 5.94 64.65 ± 6.80 
A,B Values with different superscripts within a row are significantly different (P<0.05). 
*The number of pigs that were investigated at slaughter in groups V1, V2 and NV were 165, 173 and 167, respectively. 
† 201-214 days = slaughter age 
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Table 3. Average (± sd) daily weight gain (ADG) during the lactation period (7-21 days), the 
nursery period (21-74 days), the fattening period (74-200 days), and during the entire study 
period (7-200 days) in pigs vaccinated at 7 days of age (V1), at 21 days of age (V2) and not 
vaccinated (NV) against Mycoplasma hyopneumoniae. Differences between groups were not 
statistically significant (P>0.05). 
Age range (days) 
ADG (± sd) (g/pig/day)  
V1 V2 NV 
7-21 209 ± 46 215 ± 47 216 ± 44 
21-74 334 ± 62 329 ± 59 337 ± 67 
74-200 771 ± 89 770 ± 88 752 ± 100 
7-200 610 ± 67 608 ± 66 598 ± 73 
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Detection of M. hyopneumoniae by nested PCR (nPCR) 
The numbers of nPCR-positive nasal swabs, tracheo-bronchial swabs and BAL fluids at 
21, 49, 74, 136, and 200 days of age are presented in Table 4. All samples tested at 21 and 49 
days of age were negative for M. hyopneumoniae. At 74 days of age, the percentage of M. 
hyopneumoniae-positive tracheo-bronchial swabs and BAL fluids in the non-vaccinated (NV) 
group was 7.7 per cent (2/26 pigs) and 4.0 per cent (1/25 pigs), respectively, whereas all 
samples collected at that age in the vaccinated groups remained negative. At 136 days of age, 
the percentage of M. hyopneumoniae-positive BAL fluids was 24.1 per cent (7/29 pigs), 20.0 
per cent (5/25 pigs), and 30.4 per cent (7/23 pigs) in the V1, V2, and NV group, respectively. 
At 200 days of age, the percentage of M. hyopneumoniae-positive nasal swabs was 14.3 per 
cent (4/28 pigs), 8.7 per cent (2/23 pigs) and 23.1 per cent (6/26 pigs) in the V1, V2, and NV 
group, respectively. 
Serological examinations 
The number of pigs seropositive for M. hyopneumoniae at 7, 21, 74, 136, and 200 days 
of age is presented in Table 5. Briefly, the percentage of seropositive pigs remained low 
during lactation (7 days: 13 per cent; 21 days: 14 per cent), decreased during the nursery 
period (74 days: 2 per cent) and increased during the fattening period (136 days: 5 per cent; 
200 days: 21 per cent). 
The number of pigs seropositive for PRRS(V), PCV-2 (IgG and IgM), subtypes H1N1, 
H1N2 and H3N2 of SIV, serotypes 1, 9 or 11 and serotype 2 of A. pleuropneumoniae at 74, 
136, and 200 days of age is presented in Table 6. 
Carcase quality 
The results of the carcase quality are included in Table 2. There were no significant 
differences between the different groups (P>0.05). 
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Table 4. Results of nested polymerase chain reaction (nPCR) assays on nasal swabs (NS), tracheo-bronchial swabs (TBS) and broncho-alveolar 
lavage fluids (BALF) at 21, 49, 74, 136, and 200 days (d) of age in pigs vaccinated at 7 days of age (V1), vaccinated at 21 days of age (V2) and 
not vaccinated (NV) against Mycoplasma hyopneumoniae. 
Age (d) of 
pigs at 
sampling 
Number (%) of nPCR-positive pigs/total number of pigs sampled 
V1 V2 NV 
NS TBS BALF NS TBS BALF NS TBS BALF 
21  
0/30 
(0.0%) 
0/30 
(0.0%) 
NA* 
0/30 
(0.0%) 
0/30 
(0.0%) 
NA 
0/30 
(0.0%) 
0/30 
(0.0%) 
NA 
49  
0/30 
(0.0%) 
0/30 
(0.0%) 
0/30 
(0.0%) 
0/30 
(0.0%) 
0/30 
(0.0%) 
0/30 
(0.0%) 
0/30 
(0.0%) 
0/30 
(0.0%) 
0/30 
(0.0%) 
74  
0/29 
(0.0%) 
0/29 
(0.0%) 
0/29 
(0.0%) 
0/28 
(0.0%) 
0/28 
(0.0%) 
0/28 
(0.0%) 
0/26 
(0.0%) 
2/26 
(7.7%) 
1/25 
(4.0%) 
136  
0/29 
(0.0%) 
4/29 
(13.8%) 
7/29 
(24.1%) 
0/26 
(0.0%) 
0/26 
(0.0%) 
5/25 
(20.0%) 
4/25 
(16.0%) 
7/25 
(28.0%) 
7/23 
(30.4%) 
200  
4/28 
(14.3%) 
NA NA 
2/23 
(8.7%) 
NA NA 
6/26 
(23.1%) 
NA NA 
*NA: not applicable 
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Table 5. Number (%) of pigs with serum antibodies to Mycoplasma hyopneumoniae at 7, 21, 74, 136, and 200 days (d) of age in pigs vaccinated 
at 7 days of age (V1), vaccinated at 21 days of age (V2) and not vaccinated (NV) against Mycoplasma hyopneumoniae. 
Age (d) of pigs at 
sampling 
Number (%) of seropositive pigs for M. hyopneumoniae/total number of pigs sampled 
V1 V2 NV 
7 
5/30 
(16.7%) 
3/30 
(10.0%) 
4/30 
(13.3%) 
21 
3/29 
(10.3%) 
5/29 
(17.2%) 
4/30 
(13.3%) 
74 
2/29 
(6.9%) 
0/27 
(0.0%) 
0/30 
(0.0%) 
136 
0/27 
(0.0%) 
2/24 
(8.3%) 
2/27 
(7.4%) 
200 
8/26 
(30.8%) 
2/23 
(8.7%) 
6/27 
(22.2%) 
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Table 6. Number of pigs with serum antibodies to PRRSV, PCV-2 (IgM and IgG), SIV (subtypes H1N1, H1N2 and H3N2) and A. 
pleuropneumoniae (serotypes 1, 9, 11 and 2) at 74, 136 and 200 days (d) of age in pigs vaccinated at 7 days of age (V1), vaccinated at 21 days of 
age (V2) and not vaccinated (NV) against Mycoplasma hyopneumoniae. 
 
Number of seropositive pigs/total number of pigs sampled 
V1 V2 NV 
74 d 136 d 200 d 74 d  136 d 200 d 74 d  136 d 200 d 
PRRSV 1/15 13/13 12/12 0/14 15/15 11/11 0/14 13/14 14/14 
PCV-2 IgM 0/15 3/13 1/12 0/14 8/15 0/11 0/14 10/14 0/14 
PCV-2 IgG 0/15 1/13 12/12 0/14 8/15 10/11 0/14 7/14 14/14 
Influenza H1N1 15/15 1/13 11/12 14/14 2/14* 11/11 14/14 2/12* 14/14 
Influenza H1N2 15/15 2/13 5/12 14/14 1/14* 8/11 14/14 2/12* 6/14 
Influenza H3N2 12/15 0/13 0/12 6/14 0/14* 1/11 8/14 0/12* 0/14 
A. pleuropneumoniae 
Serotype 1, 9, 11 
0/15 0/13 0/12 0/14 0/15 0/11 0/14 0/14 0/14 
A. pleuropneumoniae 
Serotype 2 
0/15 0/13 0/12 0/14 0/15 7/11 0/14 0/14 2/14 
*At 136 days of age, 15 and 14 pigs were sampled in V2 and NV groups, but three blood samples (one from V2; two from NV group) were collected in a limited amount and analysis for swine 
influenza viruses could not be performed, therefore results are shown over the total number of samples analyzed (V2: n=14; NV: n=12). 
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Discussion 
The present study demonstrated that a single vaccination against M. hyopneumoniae 
applied at either 7 or 21 days of age reduced the prevalence and extent of pneumonia lesions 
in a pig herd with clinical respiratory disease during the second half of the fattening period. 
Numerical, but not statistically significant improvements of performance and reduction of the 
prevalence of pleurisy lesions were observed. 
The clinical respiratory disease signs occurred first in a few pigs at approximately 150 
days of age, and one-to-two weeks later, more pronounced clinical signs were observed in 
many pigs. Therefore, initially only individual treatments were applied, whereas in the 
second stage, a group treatment with antimicrobials was initiated. Based on the diagnostic 
testing, it is clear that infections with many different pathogens had occurred from 
approximately halfway through the fattening period and onwards. At slaughter age, almost all 
pigs were seropositive for PRRSV, PCV-2 and H1N1, and approximately half of them for 
H1N2. Infections with M. hyopneumoniae were also involved, but the precise role of M. 
hyopneumoniae infections in the present outbreak is difficult to assess. At day 136, 20-30 per 
cent of the pigs were positive based on nPCR testing of BAL fluid, but the serological 
prevalence at slaughter age was rather low namely approximately 10-30 per cent. Andreasen 
et al. (2001) also found a low seroprevalence of M. hyopneumoniae close to slaughter in pigs 
with high percentage of pneumonia at slaughter. This may be due to the long and variable 
time (3-to-11 weeks) needed for seroconversion after infection with this pathogen (Morris et 
al., 1995). A. pleuropneumoniae had likely not played a major role as most of the animals 
remained seronegative at slaughter age, the mortality remained rather low and no typical 
lesions were found in the dead animals at postmortem examination. The severity of the 
clinical signs warranted an antimicrobial treatment, but in general, the signs were not very 
severe and a short group treatment of five days was sufficient. However, there was a very 
high percentage of pigs with pneumonia lesions (80 per cent in the NV group) at slaughter 
age. This high percentage can likely be explained by the fact that multiple viral infections and 
M. hyopneumoniae were involved, and that the infections mainly took place during the 
second half the fattening period, allowing insufficient time for the lesions to be healed at 
slaughter age (Blanchard et al., 1992). Pneumonia lesions at slaughter are not pathognomonic 
for infections with M. hyopneumoniae. Apart from M. hyopneumoniae, it is well known that 
infections with viruses and in particular swine influenza virus may cause similar pneumonia 
lesions and may be involved in PRDC (Thacker et al., 2001; Sibila et al., 2009). 
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The respiratory problems in the present batch were different from those in the previous 
batches in this herd. They occurred later in the present batch, M. hyopneumoniae infections 
were less prevalent and mainly occurred from halfway the fattening period and onwards 
(serology and PCR on swabs and BAL fluid), and there were complicating viral infections 
(serology). In previous batches, respiratory problems mainly occurred in the nursery and were 
clearly related to M. hyopneumoniae infections. This confirms that the infection pattern of M. 
hyopneumoniae is not constant over time within the same herd, and that important variations 
may occur between successive batches (Fano et al., 2007; Sibila et al., 2007). Previous 
studies showed a seasonal variation of M. hyopneumoniae infections, i.e. higher prevalence 
and severity of lung lesions (Straw et al., 1986), higher seroprevalence to M. hyopneumoniae 
(Maes et al., 2000), and higher probability of being M. hyopneumoniae-PCR positive 
(Segalés et al., 2012) during winter period. The absence of a constant infection pattern, i.e. 
infection in younger or older pigs depending on the batch, is one of the major reasons why 
vaccination of piglets during the first weeks of life is commonly practiced worldwide. Using 
this strategy, piglets are immunized before infection, irrespective of whether infection takes 
place in the nursery, growing or fattening unit. 
Both vaccination schedules (V1 and V2) led to a numerical, but not statistically 
significant, increase of the ADG during the fattening period of 19 and 18 g/pig/day, 
respectively, when compared with the NV pigs. The fact that the improvement was not 
statistically significant may be due to the high standard variations (88-100 g/day), the fact 
that the respiratory problems occurred only late in the fattening period, and that different viral 
infections were involved in the outbreak. Similar improvements in ADG following M. 
hyopneumoniae vaccination were obtained in a meta-analysis of 28 published field trials 
(Jensen et al., 2002). In that study, the ADG in pigs vaccinated against M. hyopneumoniae 
was on average 21 g higher when compared with non-vaccinated pigs. An ADG improvement 
of 20 g is associated with an important economic profit (Maes et al., 2003). Additionally, 
Pagot et al. (2007) described a negative association between growth during fattening period 
and prevalence of pneumonia at slaughter. Our study results corroborate with these 
observations: in a population with high prevalence of pneumonia (67 to 80 per cent), 
vaccination results in an increase of 2.5 per cent of ADG, when compared with non-
vaccinated pigs. 
Vaccination also significantly reduced the percentage of slaughter pigs with pneumonia 
lesions, which is in agreement with previous studies using challenge infections more than five 
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months after vaccination (Reynolds et al., 2009). Our data showed a low prevalence of 
pleurisy (7-12 per cent) in the slaughter pigs of this herd, when compared with prevalence 
figures (i.e. 15 to 60 per cent) obtained in several epidemiological studies carried out recently 
in Europe (Fraile et al., 2010; Meyns et al., 2011; Fablet et al., 2012b; Merialdi et al., 2012). 
This low prevalence of pleurisy may indicate a low impact on respiratory disease in this 
study. 
In addition, the percentage of pigs that tested positive with PCR was lower and positive 
pigs were detected at a later stage in the vaccinated groups than in the control group, 
illustrating that vaccination had decreased the infection level of M. hyopneumoniae in this 
herd during the experiment. By using qPCR, Vranckx et al. (2012b) recently showed that 
vaccination also significantly reduced the number of M. hyopneumoniae organisms in the 
lungs of experimentally infected pigs. The fact that M. hyopneumoniae DNA could still be 
detected by PCR confirms previous results from previous experimental and field transmission 
studies with different M. hyopneumoniae vaccines (Meyns et al., 2006; Villarreal et al., 
2011b). These studies showed that vaccination does not prevent infection, and suggested that 
vaccination alone is not able to eliminate M. hyopneumoniae from infected pig herds. 
More M. hyopneumoniae-positive pigs were found using nPCR in both tracheo-
bronchial swabs and BAL fluids than in nasal swabs. This confirms previous reports (Kurth 
et al., 2002; Sibila et al., 2004a, 2007; Marois et al., 2007; Fablet et al., 2010) and is 
consistent with the fact that not the nose, but the trachea and bronchi are the main 
multiplication sites of M. hyopneumoniae (Blanchard et al., 1992). In total, 90 pigs were 
restrained five times for collecting blood and BAL fluid, tracheo-bronchial and nasal swabs 
samples. These sampling procedures likely caused stress to the animals and may have 
increased their susceptibility to respiratory disease and affected growth. The number of 
sampled pigs was the same in three groups. To keep a sufficient number of animals per group 
in the study, the sampled pigs were also included for the data analysis. 
Assuming that the detected antibodies at 7 and 21 days of age in all three groups are 
maternally-derived antibodies, the present study further confirms that vaccination of piglets 
against M. hyopneumoniae either in the first or third week of age in the presence of 
maternally-derived serum antibodies is efficacious to control M. hyopneumoniae infections 
(Martelli et al., 2006; Ritzmann et al., 2006; Reynolds et al., 2009). The low percentages 
(<10 per cent) of pigs seropositive for M. hyopneumoniae at 74 and 136 days of age in both 
vaccinated groups further confirms that one-shot vaccination does not lead to significant 
 106 
 
Ch. 3.2 EXPERIMENTAL STUDIES 
increases in serum antibodies, and that serum antibody concentrations are not correlated with 
protection against M. hyopneumoniae (Djordjevic et al., 1997; Thacker et al., 1998). It also 
implies that testing for the presence of serum antibodies is not reliable to evaluate whether 
pigs have been vaccinated properly in herds endemically infected with M. hyopneumoniae. 
In conclusion, the present study demonstrated that vaccination against M. 
hyopneumoniae at 7 or 21 days of age significantly reduced pneumonia lesions in a herd with 
clinical respiratory problems during the second half of the fattening period due to combined 
M. hyopneumoniae and viral infections. A numerical, but not statistically significant 
reduction of growth losses was also observed. 
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Abstract 
The efficacy of chlortetracycline in-feed medication to treat pigs with clinical 
respiratory disease was investigated in a farrow-to-finish pig herd infected with Mycoplasma 
hyopneumoniae and with clinical respiratory disease in growing pigs. In total, 533 pigs were 
included. The animals were vaccinated against M. hyopneumoniae and porcine circovirus type 
2 at weaning. At onset of clinical respiratory disease, they were randomly allocated to one of 
the following treatment groups: chlortetracycline 1 (CTC1) (two consecutive weeks, 500 
ppm), chlortetracycline 2 (CTC2) (two non-consecutive weeks, with a non-medicated week-
interval in between, 500 ppm) or tylosin (T) (three consecutive weeks, 100 ppm). 
Performance (daily weight gain, feed conversion ratio), pneumonia lesions at slaughter and 
clinical parameters (respiratory disease score) were assessed. Only numeric differences in 
favour of the CTC2 group were obtained for the performance and the clinical parameters. The 
prevalence of pneumonia lesions was 20.5
AB
, 13.1
A
 and 23.0
B
 per cent (P<0.05) for the 
CTC1, CTC2 and T groups, respectively. The study demonstrated that chlortetracycline, when 
administered at onset of clinical respiratory disease via the feed at a dose of 500 ppm during 
two alternative weeks, was able to decrease the prevalence of pneumonia lesions, and 
numerically reduce performance losses and clinical signs. 
 
Keywords: Pig; Mycoplasma hyopneumoniae; Treatment; Chlortetracycline 
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Introduction 
The porcine respiratory disease complex (PRDC) causes major economic losses to the 
swine industry. One of the main pathogens of PRDC is Mycoplasma hyopneumoniae (Dee, 
1996), which together with porcine reproductive and respiratory syndrome virus (PRRSV) 
and porcine circovirus type 2 (PCV-2), are considered to play an important role in this 
complex (Opriessnig et al., 2004; Thacker, 2006; Sibila et al., 2009). Moreover, M. 
hyopneumoniae is also the primary etiological agent of enzootic pneumonia, a chronic 
respiratory disease in swine. The organism attaches to cilia and colonizes the mucosal surface 
of the ciliated epithelium of the trachea, bronchi and bronchioles. This adhesion to the cilia on 
the epithelial surface provokes a disruption in the mucosal clearance system and predisposes 
to concurrent infections with other respiratory pathogens (Maes et al., 2008), such 
Actinobacillus pleuropneumoniae, Haemophilus parasuis, Pasteurella multocida and 
Streptoccocus suis (Opriessnig et al., 2011). Additionally, the organism modulates the 
immune system of the respiratory tract (Thacker et al., 2006). Mycoplasmal pneumonia is 
characterised by chronic non-productive coughing, reduced growth rate and higher feed 
conversion ratio in grow-finishing pigs. This decreased performance of the pigs, as well as the 
increased use of medication to treat and control respiratory disease, imply additional 
economic losses to pig producers (Maes et al., 2008). 
Control of M. hyopneumoniae infections can be achieved by different strategies, such as 
improvements in management and housing conditions, vaccination and antimicrobial 
treatment. Vaccination has been demonstrated in previous field studies to significantly reduce 
performance losses and the severity of clinical signs and lung lesions (Maes et al., 1998, 
1999, Jensen et al., 2002). However, vaccination is not able to prevent colonization of the 
respiratory tract with M. hyopneumoniae, to significantly reduce the transmission of M. 
hyopneumoniae, nor to eliminate M. hyopneumoniae from infected herds (Meyns et al., 2006, 
Villarreal et al., 2011). Consequently, respiratory disease problems caused by M. 
hyopneumoniae infections are only partially alleviated by vaccination, and in some herds, 
clinical problems may still be present. In that case, pigs need to be medicated with 
antimicrobials active against M. hyopneumoniae such as tetracyclines, macrolides, 
pleuromutilins, lincosamides, fluoroquinolones, aminocyclitols, aminoglycosides and 
florfenicol (Vicca, 2005). 
The present study compared the efficacy of in-feed medication with chlortetracycline 
and tylosin phosphate against a clinical outbreak of respiratory disease in fattening pigs. 
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Chlortetracycline is a broad spectrum bacteriostatic antimicrobial. It inhibits bacterial protein 
synthesis, by irreversible binding to receptors of the 30S bacterial ribosome (Prescott et al., 
2000). It is active against many Gram-positive and Gram-negative bacteria, chlamydia, 
rickettsia, mycoplasmas and some protozoa. Tetracyclines, as amphoteric molecules, diffuse 
readily through biological barriers. Oral bioavailability of tetracyclines is very low when 
administered as in-water or in-feed medication (Pijpers et al., 1991; Mason et al., 2009), due 
to the fact that bivalent cations decrease the absorption and activity by chelating tetracycline 
(Luthman and Jacobsson, 1983). 
Tylosin belongs to the macrolides. These are bacteriostatic antibiotics inhibiting 
bacterial protein synthesis by binding on the 50S ribosomes (Weisblum, 1998). They are 
active against many Gram-positive and selected Gram-negative bacteria, mycoplasmas and 
anaerobes (Prescott et al., 2000). From a pharmacokinetic point of view, they present good 
absorption and tissue distribution, and accumulate principally in lysozomes of phagocytes 
(Scorneux and Shryock, 1998). 
Both chlortetracycline and tylosin have already been shown to be efficacious to treat 
and control respiratory disease due to M. hyopneumoniae under experimental conditions 
(Hannan et al., 1982; Ueda et al., 1994; Thacker et al., 2006; Vicca et al., 2005), but only a 
few field studies are reported in the literature (Kunesh, 1981; Ganter et al., 1995). The present 
study included a large number of pigs, measured different clinical, pathological and 
performance parameters, and was conducted in a herd practising vaccination against M. 
hyopneumoniae and PCV-2. 
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Material and Methods 
Study herd 
The study was conducted in a single-site farrow-to-finish Belgian pig herd, operating a 
one-week batch production system for the sows. There were approximately 270 commercial 
hybrid sows (Topigs 20), and semen from Piétrain boars was used for the inseminations. They 
were vaccinated against PRRSV (Ingelvac PRRS MLV®, Boehringer Ingelheim; mass 
vaccination twice per year), Atrophic Rhinitis (Porcilis AR-T®, MSD), Escherichia coli 
(Porcilis coli®, MSD), Porcine Parvovirus and Erysipelothrix rhusiopathiae, both combined 
according to the manufacturer´s instructions (Parvoruvax®, Merial). The breeding gilts were 
purchased from a breeding herd, transferred to the quarantine facilities of the farm and kept 
there during six weeks. During this quarantine period, all gilts were vaccinated against 
PRRS(V) (Ingelvac PRRS MLV®, Boehringer Ingelheim; two weeks after arrival), M. 
hyopneumoniae and PCV-2 (both combined according to the manufacturer´s instructions; 
Comboflex®, Boheringer Ingelheim), Athrophic rhinitis (Porcilis AR-T®, MSD), Escherichia 
coli (Porcilis coli®, MSD), Porcine Parvovirus and Erysipelothrix rhusiopathiae 
(Parvoruvax®, Merial). 
The piglets received an iron injection (Ferraject®, Eurovet) during the first week of life. 
Approximately one third (31 per cent) of the males included in this study were surgically 
castrated, the remainder of the males were vaccinated against boar taint (Improvac®, Pfizer) 
when they were 10 and 18 weeks old. At three weeks of age, the piglets were weaned and 
vaccinated with a one-shot commercial vaccine against M. hyopneumoniae (Mycoflex®, 
Boehringer Ingelheim) and PCV-2 (Circoflex®, Boehringer Ingelheim). 
At weaning, the piglets were moved to a nursery unit until 10 weeks of age, the were 
separated by sex and partly re-grouped according to weight. The nursery unit consisted of 
three compartments with four pens each and one compartment with two pens (partial slatted 
floor, channel ventilation, central heating with delta tubes on the walls and in the channels, 40 
pigs/pen). At 10 weeks of age, they were transferred to a fattening unit and kept separated by 
treatment group and sex until slaughter weight (approximately six months of age). The 
fattening unit consisted of four compartments. Three of them had similar housing 
characteristics (fully slatted floor, mechanical ceiling ventilation, eight pens, 15 pigs/pen). 
The other one was slightly different (partially slatted floor, mechanical door ventilation, 12 
pens, 15 pigs/pen). As the pen size was different between the nursery and fattening unit, the 
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pigs were re-grouped at 10 weeks but mixing was minimized as much as possible. During the 
entire experiment, water and commercial feed (meal) were supplied ad libitum to the pigs. 
Description of clinical problems in the herd and serological data before the study 
Chronic respiratory disease was commonly observed in this herd from 14 weeks of age 
onwards. Approximately one month before the onset of the trial, serological and pathological 
evaluations were carried out to establish the major pathogen(s) involved in the respiratory 
problems. Blood samples were taken from 15 randomly selected pigs per age group (8, 12, 16 
and 20 weeks of age) to detect possible antibodies against M. hyopneumoniae (DAKO Mh 
ELISA, Dako Citomation, Denmark), PRRSV (HerdCheck PRRS ELISA, IDEXX, Idexx 
Laboratories, Westbrook, USA), PCV-2 (IgG and IgM, Ingezim PCV2 ELISA, Ingenasa, 
Madrid, Spain), Swine Influenza virus (SIV) (H1N1, H1N2, H3N2, standard 
haemagglutination-inhibition test) and Actinobacillus pleuropneumoniae (A. 
pleuropneumoniae) (App Serotypes 1, 9 or 11 and Serotype 2; Actinobacillus 
pleuropneumoniae 1, 9, 11 Antibody Test Kit ELISA and Actinobacillus pleuropneumoniae 2 
Antibody Test Kit ELISA, Biovet Inc. CA). At 8 and 12 weeks of age, all pigs were 
serologically negative for M. hyopneumoniae, whereas at 16 and 20 weeks of age, all pigs had 
antibodies against M. hyopneumoniae. All pigs were seropositive for PRRSV. For PCV-2, 
none of the animals were positive for IgM antibodies before 12 weeks of age. At this time 
point, most of the animals became positive. The number of positive animals for anti-PCV-2 
IgM antibodies decreased in the following weeks. The presence of PCV-2 IgG was only 
detected from week 12 onwards and at week 16, most of the tested animals were positive. The 
first seropositive pigs against SIV (H3N2) and A. pleuropneumoniae serotypes 1, 9 or 11 were 
found at 12 weeks of age. No antibodies against other SIV subtypes were found. Most of the 
pigs tested at 20 weeks were seropositive against A. pleuropneumoniae serotype 2, but not 
earlier. Slaughterhouse examination on 100 fattening pigs showed that 53 per cent of them 
had Mycoplasma-like lung lesions. 
Study population and experimental design 
In total, 533 fattening pigs were included. At the start of the fattening period (10 weeks 
of age), they were randomly assigned at pen level to one of the three treatment groups. Four 
weeks later (14 weeks of age), at the onset of disease, in-feed medication was administered 
(D1 or beginning of treatment). The three treatment groups were: CTC1 (500 ppm 
chlortetracycline chlorhydrate in-feed medication, during two consecutive weeks; Aurofac 
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100 mg/g Granular®, 100 mg/g, Pfizer Animal Health; n=180), CTC2 (500 ppm 
chlortetracycline in feed, one week medication, one week no medication and again one week 
medication; n=180) and T (100 ppm tylosin phosphate in-feed medication, during three 
weeks; Tylan 250 Vet Premix®, 250 mg/g, Eli Lilly and Company Limited; n=173). The 
treatment durations complied with the label directions of both products (chlortetracycline: at 
least one week; tylosin: three weeks) to treat and control porcine respiratory disease caused by 
pathogens susceptible to these products. Animals housed within the same pen were included 
into the same treatment group. All other factors that could possibly influence the outcome 
parameters, e.g. environment and management factors, stocking densities, sex distribution, 
castration versus vaccination against boar taint, feed composition (apart from the medication) 
were the same for the three groups. The investigator responsible of the trial was blinded for 
the allocation of the treatment groups. Concomitant antimicrobial treatment of study pigs (via 
parenteral, drinking water of feed) was only allowed for antimicrobials ineffective against M. 
hyopneumoniae such as β-lactam antibiotics (penicillins and cephalosporins). A pooled 
medicated feed sample was taken at the beginning of the trial from each treatment group to 
determine the concentration of the two antimicrobials (one sample for CTC1 and CTC2, one 
sample for T). The measured concentrations were very close to the recommended dose: CTC 
508 mg chlortetracycline/kg, T 108 mg tylosin phosphate/kg. 
The study was approved by the ethical committee for animal experiments of the faculty 
of veterinary medicine, Ghent University (EC2010/156). 
Parameters of comparison 
Performance parameters 
To calculate average daily weight gain (ADG; g/pig/day) and feed conversion ratio 
(FCR), the individual bodyweight (BW) of all pigs was measured at three different time 
points: at 14 weeks (D0; onset of the clinical signs just before treatment), 17 weeks (D24; 
shortly after treatment) and 26 weeks (D84; end of fattening period). ADG was calculated 
during the treatment period (BW at D24 – BW at D0/ 25 days), the post-treatment period (BW 
at D84 – BW at D24/ 60 days) and for the overall period (BW at D84 – BW at D0/ 85 days). 
The feed intake was recorded at pen level during the treatment period. The FCR was 
calculated by dividing the feed intake per pen by the difference between final and starting 
BW. The number of dead pigs was recorded, as well as the weight and the age of each dead 
pig. Data from dead pigs were included in the analysis in order to calculate the mortality rate. 
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To establish the possible cause of death, post-mortem examination of a representative number 
of dead pigs (9 pigs out of 12) and additional laboratory examinations (bacteriological culture 
and PCR testing) were done. When Haemophilus parasuis was suspected to be cause of death 
and was not isolated by bacteriological culture, PCR testing was performed on lung samples, 
in order to detect the presence of DNA from this bacteria (Oliveira and others 2001). DNA 
was extracted using a DNA kit manufactured by Qiagen (Qiamp DNA mini kit, The 
Netherlands). 
Days of additional treatment for each pig 
The total number of days that a pig was treated individually against respiratory disease 
was recorded. Since concomitant antimicrobial treatment was allowed only with antibiotics 
ineffective against M. hyopneumoniae, pigs with clinical respiratory symptoms were treated 
parenterally either with ceftiofur (Excenel RTU®, Pfizer Animal Health) or amoxicillin 
(Duphamox Long Acting®, Pfizer Animal Health). Concomitant antimicrobial treatment via 
drinking water or feed was allowed, however it was not required. 
Lung lesions 
The prevalence of Mycoplasma-like pneumonia lesions, fissures and pleuritis was 
recorded at slaughter from 488 pigs. Mycoplasma-like pneumonia lesions (active lesions) 
were defined as red to purplish consolidated areas on the cranial-ventral parts of the apical, 
cardiac, accessory and diaphragmatic lobes. Fissures (recovering lesions) were defined as red 
to purplish interlobular scar retractions with the same location as Mycoplasma-like lesions. 
Pleuritis was defined as fibrotic adherence between the visceral and pleural membranes of the 
pleural sac. The severity of Mycoplasma-like pneumonia lesions (lung lesion score) was 
assessed for each individual pig. The lung lesion score was based on the total percentage of 
affected lung tissue, with the different lung lobes representing the following percentage of the 
total lung surface area: apical (10 per cent), cardiac (7 per cent), accessory (6 per cent) and 
diaphragmatic (30 per cent) (Morrison et al., 1985). An average score was calculated for each 
treatment group based on the lung lesion score of the individual animals. 
Respiratory disease score (RDS) 
The severity of respiratory symptoms was assessed every two days during the first week 
of the treatment and twice per week during the remainder of the trial until slaughter age. To 
this end, the pigs were moved up and the number of pigs coughing per pen during 10 minutes 
was counted in all pens. A RDS was calculated by dividing the number of pigs per pen that 
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coughed during 10 min, by the total number of pigs in that pen, multiplied by 100 (Mateusen 
et al., 2002). The RDS was summarised for three periods: pre-treatment (D-7/D0), treatment 
(D1/D22) and post-treatment (D22/D84) period. 
Isolation of M. hyopneumoniae and MIC testing 
In order to cultivate and isolate M. hyopneumoniae, affected lungs showing 
Mycoplasma-like lesions were collected at slaughter and transported to the laboratory, where 
they were processed according to previous reports (Friis, 1975). Isolates were identified as M. 
hyopneumoniae using a species specific PCR (Vranckx et al., 2011). Minimum inhibitory 
concentration (MIC) testing of tylosin phosphate, chlortetracycline and oxytetracycline 
against M. hyopneumoniae was performed as described by Vicca et al. (2004). MIC was 
defined as the lowest concentration of the antimicrobial that completely inhibited visible 
growth. The M. hyopneumoniae strain ATCC 25634 (J-strain) was used as control strain. For 
the susceptibility testing, tylosin phosphate, chlortetracycline and oxytetracycline were tested 
for concentrations ranging from 0.015 µg/ml to 16 µg/ml. 
Presence of M. hyopneumoniae in broncho-alveolar lavage (BAL) fluid and bacteriology 
The BAL fluid was collected from 30 randomly selected pigs in each group just prior to 
the beginning of the treatment (14 weeks; D0) and after treatment (17 weeks; D25). 
Therefore, the animals were anaesthetised by administrating intramuscularly 0.22 ml/kg of a 
mixture of xylazine (Xyl-M 2 %®, VMD) and zolazepam + tiletamine (Zoletil 100®, Virbac). 
The recovered BAL fluid was divided into three aliquots. 
The first aliquot was used for detection of M. hyopneumoniae-organisms. DNA was 
extracted using a DNA easy Kit manufactured by Qiagen (Blood and Tissue kit, Belgium) and 
a quantitative PCR (qPCR) test was performed on the extract (Marois et al., 2010). The qPCR 
analysis was carried out by CFX96 real-time PCR detection system (Bio-Rad), using a ten-
fold dilution series of M. hyopneumoniae DNA in order to transform the threshold values to 
the number of organisms, considering values below the last dilution as negative. The second 
aliquot of the BAL fluid was used for bacteriological culture to detect the presence of main 
respiratory pathogens. It was inoculated on Columbia agar and Columbia CNA agar plates, 
both supplemented with 5 per cent sheep blood (Oxoid, Hampshire, UK). The Columbia agar 
plates were streaked with a Staphylococcus pseudintermedius strain to support growth of 
NAD-dependent bacterial species, such as Actinobacillus pleuropneumoniae biotype 1 and 
Haemophilus parasuis. Plates were incubated overnight in a 5 per cent CO2-enriched 
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environment at 35 °C and identification of isolated bacteria was performed (Quinn et al., 
1994). A disk diffusion sensitivity testing was performed on isolated pathogens following the 
standards of Clinical and Laboratory Standards Institute (CLSI, 2008). Chlortetracycline disks 
were obtained from AlPharma-Pfizer and tylosin phosphate disks from Rosco (Neo-sensitabs, 
Denmark). Reading of the inhibition zones (in mm) was performed as recommended by the 
manufacturers based on clinical breakpoints, namely, diameter zones ≥ 23 mm (susceptible) 
and < 19 mm (resistant) for chlortetracycline, whereas diameter zones ≥ 26 mm (susceptible) 
and < 22 mm (resistant) for tylosin phosphate. The third aliquot was frozen (-80 °C) and kept 
as reserve. 
Serology 
Blood samples were taken from 45 randomly selected pigs per group (the same 30 pigs 
from which BAL fluid was collected plus 15 other pigs) at two time-points, namely before 
treatment (D0) and 35 days later. The sera were analysed to detect antibodies against M. 
hyopneumoniae, PRRSV, PCV-2 (IgG and IgM), SIV (H1N1, H1N2, H3N2) and A. 
pleuropneumoniae (serotypes 1, 9 or 11; serotype 2) as described previously in the clinical 
outbreak section. 
Statistical analysis 
The number of 144 animals in each treatment group permitted to assess a difference of 
20 g (sd=60) in ADG and 3 points (sd=9) in lung lesion score with 95 per cent certainty and 
80 per cent statistical power (Win Episcope 2.0, CLIVE, Edinburgh, UK). The ADG and lung 
lesion score were considered as major parameters. 
The ADG, lung lesion score and qPCR were measured at the individual level, FCR and 
RDS at pen level. Analysis of variance (ANOVA) models were used to analyse the 
continuous variables ADG, FCR, qPCR (treatment effect) and DAT. In these models, 
treatment, compartment and sex were included as fixed factor and pen as random variable. In 
case of significant differences, pairwise comparisons between the different treatment groups 
were made using Scheffé‟s test. Data that did not fulfil the criteria of normality and 
homogeneity of variances (ADG) were analysed using non-parametric Kruskal-Wallis 
ANOVA. Lung lesion scores were compared between groups using a non-parametric 
Wilcoxon test. RDS and qPCR (time and group-effect) data were analysed using repeated 
measures ANOVA. Mortality rate, the percentage of pigs showing Mycoplasma-like lesions, 
fissures and pleuritis and the percentage of pigs showing M. hyopneumoniae antibodies and 
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that were PCR positive were analysed using logistic regression analysis, with treatment group 
and pen as fixed factors. Differences were considered as statistically significant when P-
values were lower than 0.05 (two-sided test). Statistical analyses were performed using the 
software package SPSS version 18.0 (SPSS Institute Inc., Illinois, USA). Results are 
presented as mean ± sd unless stated otherwise. 
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Results 
Performance parameters 
The results of ADG, FCR and mortality are presented in Table 1. The overall ADG 
(g/pig/day) for CTC1, CTC2 and T groups were 659 ± 147, 656 ± 145 and 638 ± 255, 
respectively. The overall FCR for CTC1, CTC2 and T groups were 2.59 ± 0.17, 2.32 ± 0.17 
and 2.57 ± 0.22, respectively. There were no significant differences between groups in ADG 
(P=0.567) and FCR (P=0.511). 
Mortality rate was 1.1, 1.1 and 4.6 per cent for the CTC1, CTC2 and T groups, 
respectively (P=0.076). In total, 12 pigs died during the trial (2/12 CTC, 2/12 CTC2 and 8/12 
T) and nine out of 12 were necropsied. Only pigs that died during the clinical outbreak and 
the following two months (n=9) were necropsied. The three pigs (one in each group) that died 
during the last month of the fattening period were not further investigated, as the cause of 
death was not considered to be related to the respiratory disease outbreak. A peak in mortality 
was registered during treatment period (first two weeks), affecting five pigs from group T 
(5/12). All of them had suffered from clinical respiratory disease; pathological findings 
showed pneumonia (5/5), fibrinous pleurisy (3/5) and meningitis (4/5), and M. 
hyopneumoniae was detected by PCR in the lungs (4/5). Streptococcus suis (1/5), Pasteurella 
multocida (1/5) and Bordetella bronchiseptica (2/5) were isolated from the lungs. P. 
multocida and B. bronchiseptica were isolated from the pig in which M. hyopneumoniae 
DNA was not detected. This pig showed pneumonia but no meningitis. 
The four pigs that died during the two months after the treatment were distributed as 
follows: CTC1 (1/4), CTC2 (1/4) and T (2/4). All of them had suffered from clinical 
respiratory disease. Pathological findings showed pneumonia (4/4) and meningitis (2/4), and 
M. hyopneumoniae DNA was not detected by PCR in the lungs. H. parasuis was detected 
(PCR) in the lungs of one pig affected by fibrinous pleurisy (CTC1), as well as A. 
pleuropneumoniae biotype 1 (serotype 2) and a moderate viral load of PCV-2 (PCR; 2.7x10
6 
organisms/gram) in the lungs of a wasted pig affected by purulent bronchopneumonia 
(CTC2). S. suis was isolated from the lungs and brain of two wasting pigs affected by 
bronchopneumonia and meningitis (T). Trueperella pyogenes (previously Arcanobacterium 
pyogenes) was isolated from the lungs of one wasting pig affected by bronchopneumonia and 
meningitis (T). All these bacteria isolated from necropsied animals were susceptible towards 
chlortetracycline and tylosin, based on the described clinical breakpoints. 
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Days of additional treatment of each pig 
The average number of days of additional treatment per pig were 2.18 ± 1.74, 1.65 ± 
1.11 and 2.54 ± 2.10 for CTC1, CTC2 and T groups (P=0.297), respectively (Table 1). The 
use of ceftiofur/amoxicillin between groups was similar. 
 
Table 1. Performance parameters (mean ± sd) (average daily weight gain ADG, feed 
conversion ratio FCR, mortality and days of additional treatment (DAT) in the different 
treatment groups: CTC1, CTC2 and T. Treatment started at D1 (when pigs were 14 weeks 
old). 
 
Period 
CTC1  
(n=180) 
CTC2 
(n=180) 
Tylosin 
(n=173) 
P-value 
ADG 
(g/pig/day) 
Treatment (D1-22) 542 ± 195 536 ± 183 517 ± 315 0.657 
Post-Treatment (D23-84) 704 ± 234 694 ± 339 726 ± 187 0.284 
Overall (D1-84) 659 ± 147 656 ± 145 638 ± 255 0.567 
FCR Treatment 2.59 ± 0.17 2.32 ± 0.17 2.57 ± 0.22 0.511 
Mortality* Overall 2/180 (1.1) 2/180 (1.1) 8/173 (4.6) 0.076 
DAT Overall 2.2 ± 1.7 1.7 ± 1.1 2.5 ± 2.1 0.297 
*Mortality: number (per cent) of dead pigs 
CTC1: chlortetracycline in feed (500 ppm) during two consecutive weeks; CTC2: chlortetracycline in feed (500 ppm) every 
other week during three weeks; Tylosin: tylosin phosphate in feed (100 ppm) during three consecutive weeks. 
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Lung lesions 
The results of the lung lesions are shown in Table 2. The prevalence of Mycoplasma-
like lesions was lower (P=0.046) and the prevalence of recovering lesions (fissures) was 
higher (P=0.031) in the CTC2 compared to the T group. The lung lesion scores, namely 15.0 
± 11.4 (CTC1), 13.4 ± 10.9 (CTC2) and 14.9 ± 12.3 (T), were not significantly different 
between the groups (P=0.355). There were no significant differences in the prevalence of 
pleuritis (P=0.135). 
Respiratory disease score (RDS) 
For all groups, the average RDS during the pre-treatment (12.92 ± 6.73) and treatment 
(12.97 ± 5.50) period was very similar, but it was significantly lower during the post-
treatment period (6.88 ± 2.86). There were no significant differences between the groups 
(Table 3). The interaction terms treatment x compartment (P=0.981) and treatment x sex 
(P=0.807) were not significant. 
 
Table 2. Percentage of slaughter pigs in the three groups with M. hyopneumoniae-like lesions 
(Mhyo), fissures and pleuritis, and severity of lung lesions expressed as lung lesion score 
(mean ± sd). 
 
CTC1 
(n=166) 
CTC2 
(n=161) 
Tylosin 
(n=161) 
P-value 
Percentage Mhyo-like 
lesions 
20.5
ab
 13.1
a
 23.0
b
 0.046 
Percentage fissures 72.9
ab
 78.1
a
 66.5
b
 0.031 
Percentage pleuritis 21.7 25.5 18.0 0.133 
Lung lesion score 15.0 ± 11.4 13.4 ± 10.9 14.9 ± 12.3 0.355 
a,b Values with different superscripts within a row are significantly different (P<0.05) 
Treatment groups: CTC1: chlortetracycline in feed (500 ppm) during two consecutive weeks; CTC2: chlortetracycline in feed 
(500 ppm) every other week during three weeks; Tylosin: tylosin phosphate in feed (100 ppm) during three consecutive 
weeks. 
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Table 3. The average respiratory disease score (RDS) of the pigs during pre-treatment, 
treatment, post-treatment period in the three groups. RDS was based on the percentage of pigs 
coughing per pen during 10 minutes,15 pigs were present in each pen. 
 
CTC1 
(n=180) 
CTC2 
(n=180) 
Tylosin 
(n=173) 
P-value 
Pre-treatment (D-7-D0) 13.14 ± 5.34
a
 13.06 ± 7.53
a
 12.57 ± 7.33
a
 0.976 
Treatment (D1-22) 12.94 ± 4.16
a
 12.11 ± 6.16
a
 13.86 ± 6.19
a
 0.747 
Post-treatment (D23-84) 6.93 ± 1.96
b
 6.99 ± 2.32
b
 6.73 ± 4.30
b
 0.961 
a,b Values with different superscripts within a column are significantly different (P<0.05) 
Treatment groups: CTC1: chlortetracycline in feed (500 ppm) during two consecutive weeks; CTC2: chlortetracycline in feed 
(500 ppm) every other week during three weeks; Tylosin: tylosin phosphate in feed (100 ppm) during three consecutive 
weeks. 
 
Isolation of M. hyopneumoniae and MIC testing 
The MIC of tylosin phosphate for the M. hyopneumoniae isolate obtained from the 
lungs of a slaughter pig was 0.12 µg/ml, of chlortetracycline 8 µg/ml and of oxytetracycline 
0.5 µg/ml. For the J-strain, the following MIC values were obtained: tylosin phosphate 0.12 
µg/ml, chlortetracycline > 8 µg/ml and oxytetracycline 1 µg/ml. 
Presence of M. hyopneumoniae in broncho-alveolar lavage (BAL) fluid and bacteriology 
The number of M. hyopneumoniae-organisms tested by qPCR in the BAL fluid was not 
significantly different between the groups (P=0.411). No time-effect was demonstrated on the 
load of M. hyopneumoniae-organisms in BAL fluid (P=0.732). Also, the interaction term 
between sampling time and treatment group was not significant (P=0.538) (Table 4). 
S. suis was isolated from BAL fluid of four different pigs. Two out of these four 
isolates, belonging both to the T group and isolated from BAL fluid on sampled pigs, were 
resistant to tylosin phosphate, but not to chlortetracycline. 
Serology 
The percentage of seropositive pigs for M. hyopneumoniae before treatment was 60, 67 
and 86 per cent in the CTC1, CTC2 and T groups, respectively. After treatment, the 
percentage of seropositive animals was 73, 80 and 86 per cent in the CTC1, CTC2 and T 
groups, respectively (Table 4). The serological results for the other respiratory pathogens are 
shown in Table 4. 
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Table 4. Number of pigs with serum antibodies against M. hyopneumoniae, PRRSV, PCV-2 (IgG and IgM), SIV (H1N1, H1N2 and H3N2) and A. 
pleuropneumoniae (serotype 1, 9, 11 and 2), and PCR testing for M. hyopneumoniae in the BAL fluid before (D0) and after treatment (D35). 
 
Before treatment (D0) After treatment (D35) 
 
CTC1 CTC2 Tylosin CTC1 CTC2 Tylosin 
Number of pigs with serum antibodies 
against … 
n=15 n=15 n=14 n=15 n=15 n=14 
M. hyopneumoniae 9 10 12 11 12 12 
PRRSV 14 14 14 15 15 14 
PCV-2 Ig M / Ig G 3 / 5 7 / 8 5 / 6 3 / 13 3 / 15 5 / 14 
SIV H1N1 / H1N2 / H3N2 1 / 0 / 5 0 / 0 /1 1 / 0 /7 2 / 0 / 9 1 / 0 / 7 2 / 0 / 8 
A. pleuropneumoniae Serotype 1, 9 or 11 3 4 5 5 5 4 
A. pleuropneumoniae Serotype 2 8 6 6 10 8 9 
PCR testing for M. hyopneumoniae n=10 n=10 n=10 n=10 n=10 n=10 
Number of qPCR-positive pigs 8 7 8 9 9 10 
Log copies of M. hyopneumoniae/ml (mean±sd) 3.49 ± 2.00 3.01 ± 1.98 3.58 ± 1.45 3.00 ± 1.21 3.38 ± 1.61 4.10 ± 1.14 
There were no significant differences between the groups (P>0.05). 
CTC1: chlortetracycline in feed (500 ppm) during two consecutive weeks; CTC2: chlortetracycline in feed (500 ppm) every other week during 3 weeks; Tylosin: tylosin phosphate in feed (100 ppm) 
during three consecutive weeks. 
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Discussion 
The present study demonstrated that chlortetracycline, when administered in the feed 
during two alternative weeks starting at the onset of clinical respiratory disease, was able to 
decrease the prevalence of pneumonia lesions, and to numerically but not significantly reduce 
performance losses and clinical signs in a herd infected with M. hyopneumoniae. The 
treatment was compared with tylosin phosphate medication during three weeks in the feed. 
The tylosin treated group was considered as a positive control group, as the efficacy of this 
antibiotic to treat and control respiratory disease due to M. hyopneumoniae infections had 
been shown in previous studies. Kunesh (1981) reported an improvement of ADG after 
intramuscular administration of tylosin (4 mg/kg), and Vicca et al. (2005) demonstrated that 
pigs treated in-feed with tylosin (100 ppm during 21 days) had less pneumonia lesions and 
clinical signs following an experimental M. hyopneumoniae infection. It is likely that more 
pronounced effects of chlortetracycline medication would have been obtained when a 
negative (non-treated) control was used. A negative control group was not included because 
not treating clinically diseased pigs when efficacious products are available is ethically not 
acceptable, and also the pig producer would not have allowed to leave diseased pigs untreated 
(Dohoo et al. 2009). 
The infection level for M. hyopneumoniae was high in the present herd, as evidenced by 
the high prevalence of slaughter pigs with pneumonia lesions and the fact that M. 
hyopneumoniae was detected in many necropsied pigs. The necropsy findings and the 
serological and bacteriological analyses also showed that other pathogens were involved in 
the respiratory problem. The number of pigs with serum antibodies against PCV-2 (IgG), SIV 
H3N2 and A. pleuropneumoniae increased during the treatment period, and also bacterial 
pathogens such as S. suis, B. bronchiseptica, P. multocida and T. pyogenes were found in the 
lungs of necropsied pigs. PRDC is a complex disease and it may be difficult to understand and 
interpret field outbreaks of respiratory disease, because of the multiple interactions of 
different pathogens with environmental conditions (Opriessnig et al., 2011). Polymicrobial 
co-infections have been widely described in the literature being focused on the nature of the 
pathogens (virus vs bacteria), the role (primary vs opportunistic) and the mode of action 
(additive vs synergic) of these pathogens, and the sequencing of infection (concurrent vs 
simultaneous). All these factors have a crucial role on the nature of the mixed infections and, 
therefore, have implications on the large variability of this PRDC on field conditions. Co-
infection of pigs with M. hyopneumoniae in conjunction with PRRSV (Thacker et al., 1999), 
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PCV-2 (Opriessnig et al., 2004) and SIV (Thacker et al., 2001) showed potentiation and 
increased severity of the respiratory disease. However, during the respiratory outbreak of the 
present herd, no clinical signs and mortality associated to these pathogens (PRRSV, PCV-2, 
SIV) were seen, nor DNA was detected by PCR in dead animals. Only in one necropsied pig, 
a moderate PCV-2 viral load in the lungs was detected. Co-infection of pigs with M. 
hyopneumoniae in conjunction with bacteria, such P. multocida (Ciprián et al., 1988) and A. 
pleuropneumoniae (Marois et al., 2009) is also characterised by an increased severity of 
respiratory disease and enhancement of lesions, respectively. P. multocida was isolated from 
the lungs of only one dead pig, which was negative by PCR for M. hyopneumoniae. A. 
pleuropneumoniae was isolated in only one necropsied pig, nevertheless the prevalence of 
pleuritis at slaughter was lower than 22 per cent. Therefore, the presence of these bacteria 
could suggest an opportunistic infection. Analysis of the stable climate and the ventilation 
pattern could not elucidate major deficiencies in housing conditions or management practices 
(e.g. stocking density, management, deworming). Since the size of the nursery and the 
fattening unit was not the same, all-in/all-out management was not strictly followed, but only 
a limited number of pigs were mixed. This could also have contributed to respiratory disease 
by transmission and spread of pathogens. However, the statistical interaction terms (treatment 
x compartment and treatment x sex) were calculated for each parameter and no significant 
differences were assessed. The study illustrated that clinical problems of respiratory disease, 
requiring antimicrobial treatment, are still possible in herds without major deficiencies in 
housing and management conditions, and that practice vaccination against two major 
pathogens (M. hyopneumoniae and porcine PCV-2) involved in the PRDC. 
The fact that chlortetracycline treatment performed similar or even better than a known 
efficacious treatment is in line with previous studies showing the efficacy of chlortetracycline. 
Ganter et al. (1995) reported that chlortetracycline-medicated feed (800 ppm, during 21 days) 
was able to reduce clinical signs of respiratory disease under field conditions, and Thacker et 
al. (2006) found that in-feed medication with chlortetracycline (500 ppm, during 14 days) was 
effective against an experimental M. hyopneumoniae infection. However, the medication 
schemes were definitively not completely efficacious. The RDS in all groups remained very 
similar during the treatment period as before onset of treatment, a considerable number of 
pigs had pneumonia lesions at slaughter, and M. hyopneumoniae could still be detected by 
PCR in the lung tissue. The latter was not unexpected and confirmed previous reports 
indicating that similar to vaccination, antimicrobial medication is not able to eliminate M. 
hyopneumoniae from the respiratory tract (Thacker et al., 2006). It is not known why there 
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was no significant decrease in RDS after medication had started. It may be due to the fact that 
other pathogens e.g. viruses or bacteria not susceptible to the antimicrobials, were involved in 
the respiratory problem. The high mortality in the T group, nearly significantly different from 
the other groups, may be due to the presence of concurrent other bacterial pathogens such as 
P. multocida, A. pleuropneumoniae, which are less susceptible to tylosin (Barigazzi et al., 
1994) or S. suis strains with acquired resistance to tylosin. Indeed two S. suis strains isolated 
from BAL fluid showed resistance to this antimicrobial. 
Based on the MIC testing performed by Vicca et al. (2004), the M. hyopneumoniae 
strain collected at slaughter did not show acquired resistance to tylosin and oxytetracycline. 
However, a high MIC value of chlortetracycline was obtained, but MIC testing of 
chlortetracycline is not reliable as the antimicrobial is not stable during the cultivation 
procedure. When chlortetracycline is incorporated in broth medium and rehydrated, it is 
quickly degraded: activity reduces to 1/3 after 12 h, to less than 10 per cent after 24 h and to 
about 2 per cent after 72 h (Pommier, 2006). Growth of M. hyopneumoniae on the other hand 
takes several days. Williams (1978) found a lower in vitro susceptibility of chlortetracycline 
against M. hyopneumoniae compared to oxytretracycline and doxycycline. Inamoto et al. 
(1994) also observed higher MIC values of chlortetracycline than of oxytetracycline against 
M. hyopneumoniae. Other studies also showed high MIC values (≥ 40 µg/ml) (Yamamoto and 
Koshimizu, 1984) or a high variation in the MIC values (1.6 – 25 µg/ml) of chlortetracycline 
(Etheridge et al., 1979). Our finding that the M. hyopneumoniae isolate did not show acquired 
resistance to oxytetracycline strongly indicates that acquired resistance was also not present 
against chlortetracycline, since there exists cross-resistance between both antibiotics (CLSI, 
2008). 
There were only small and non-significant differences between the CTC1 and CTC2 
group, but for most parameters (e.g. prevalence and severity of pneumonia lesions), the CTC2 
group performed slightly better. An exact explanation is not available, but it may be due to the 
fact the pigs of the CTC2 had a better possibility to generate an active immune response 
during the non-medicated week in between the two medicated weeks. Walter et al. (2000) 
stated that metaphylactic pulse medication might permit a sufficient natural exposure to the 
pathogen and more effective stimulation of active immunity against M. hyopneumoniae when 
compared to continuous medication. Continuous medication may lead to animals that might 
remain immunological naïve and potentially susceptible to subsequent re-exposure to M. 
hyopneumoniae when the medication is withdrawn. 
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Chlortetracycline hydrochloride, when administered via the feed at the dose of 500 ppm 
during two alternative weeks at onset of clinical outbreak of respiratory disease, decreased the 
prevalence of M. hyopneumoniae-like lesions, and numerically reduced performance losses 
and clinical signs compared with tylosin phosphate at the dose of 100 ppm administered 
during three weeks. Vaccination and medication may significantly reduce but do not prevent 
infections with M. hyopneumoniae, implying that optimal housing and management practices 
remain important to keep the infection pressure at acceptable levels. 
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GENERAL DISCUSSION 
Respiratory disease in pigs is one of the most important problems in modern pig 
production worldwide. It mostly results from infections with primary and opportunistic 
infectious agents, both viral and bacterial pathogens. Adverse environmental and 
management conditions may exacerbate this mixed respiratory disease resulting in the PRDC. 
M. hyopneumoniae is considered as one of the main pathogens involved in the PRDC. 
Infections with M. hyopneumoniae are present in almost all countries with an intensive swine 
production, and they lead to major economic losses due to the reduced growth, increased 
mortality and feed conversion, costs for antimicrobials and vaccination and increased time to 
market weight (Maes et al., 2008). 
The control of M. hyopneumoniae infections can be accomplished by optimization of 
management practices and housing conditions, antimicrobial treatment and vaccination. The 
present thesis investigated the treatment and control of M. hyopneumoniae infections. First, 
the efficacy of a new florfenicol formulation to treat pigs by means of a single intramuscular 
injection against experimental M. hyopneumoniae infection was investigated (chapter 3.1). 
Secondly, the efficacy of a one-shot vaccination against M. hyopneumoniae applied at either 
one or three weeks of age in a Belgian farrow-to-finish pig herd with mixed respiratory 
disease late in the fattening period and including infections with M. hyopneumoniae and viral 
pathogens was studied (chapter 3.2). Thirdly, the efficacy of in-feed medication with 
chlortetracycline and tylosin phosphate against a clinical outbreak of respiratory disease in 
fattening pigs that were vaccinated against M. hyopneumoniae was compared (chapter 3.3). 
The present chapter will provide a general discussion of the findings obtained in the 
different studies. We will successively focus on (1) the major parameters used in this thesis to 
assess efficacy, (2) the different antimicrobial treatments (chapter 3.1 and 3.3), and (3) the 
different vaccination strategies (chapter 3.2 and 3.3) applied in this thesis. Finally, (4) general 
conclusions and (5) perspectives for further research are provided. 
Assessment of efficacy under in vivo (experimental, field) conditions 
This thesis includes the assessment of efficacy of antimicrobial treatment and 
vaccination against M. hyopneumoniae infections in different in vivo studies, conducted 
either under experimental or field conditions. 
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The importance of the measured efficacy parameters may depend whether a study is 
conducted under experimental or field conditions. Therefore, a table with the main 
advantages and disadvantages of field and experimental studies is first shown (Table 1). 
Table 1. Comparison between in vivo studies, both laboratory and field trials. 
 Laboratory experiment Field trial 
Housing conditions controlled real 
Animals homogeneous heterogeneous 
Management controlled real 
Disease model real 
Infection dose standard for all animals unknown 
Time of infection standard for all animals unpredictable 
Concurrent diseases avoided present 
Variability of the outcome low high 
External validity of the study limited high 
 
Different parameters can be measured to assess efficacy of treatment and control 
measures against M. hyopneumoniae infections. The most commonly used parameters are 
clinical signs, lung lesions and in case of field studies also performance data. 
Coughing is the main clinical sign of respiratory disease. Clinical examination of pigs 
affected by respiratory disease does not provide a specific aetiological diagnosis. Non-
productive coughing is not a pathognomonic sign of M. hyopneumoniae infection, but it is 
commonly associated with this pathogen. The assessment of the RDS in laboratory 
experiments may be useful to evaluate the severity of the challenge infection, to determine 
the moment of the intervention (mainly treatment) and to assess the efficacy of this 
intervention. Regarding field experiments, it can be used in the diagnosis of enzootic 
pneumonia at onset of respiratory disease (Nathues et al., 2012). A quantification of the 
severity of coughing, for instance by using a RDS, may indeed be an important indicator. 
Scoring the respiratory symptoms by means of a RDS may be valuable to select an 
appropriate antimicrobial treatment or vaccination strategy (type of product, route of 
administration, duration of treatment) required to treat and control respiratory disease (e.g. 
acute coughing present in a few pigs from the same pen should be treated at individual or at 
pen level), but also in the assessment of the clinical effectiveness of the treatment/vaccination 
established. 
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Lung lesions, such as pneumonia and adhesive pleurisy, are common findings in 
slaughter pigs reared under field conditions and both have been associated with respiratory 
disease (Fraile et al., 2010; Meyns et al., 2011; Fablet et al., 2012b; Merialdi et al., 2012). 
Slaughter examinations (prevalence of pneumonia and pleurisy lesions) are an excellent 
method to monitor the respiratory health in a herd and to evaluate the efficacy of 
treatments/vaccinations applied under field conditions. However, this technique has some 
limitations. The lack of diagnostic specificity and the subjectivity of the visual assessment are 
major disadvantages (Sibila et al., 2009). Subclinical infections may not be detected and 
lesions occurring early in the fattening period may be healed by the time of slaughter (Regula 
et al., 2000). In most experimental studies, only a limited number of animals are available 
due to practical and economic reasons. The current EU regulations on experimental animals 
also indicate to limit the number of laboratory animals as much as possible because of animal 
welfare reasons. However, a low number of animals can lead to not finding possible 
differences between groups. This disadvantage may partially be overcome by estimating the 
extent of lung lesions in each animal, as well as by evaluating the extent and severity of 
microscopic lung lesions (e.g. percentage of air in lung tissue, severity of peribronchiolar and 
perivascular lymphohistiocytic infiltration and nodule formation). 
Preventing the performance losses is the main goal when treatment/vaccination against 
M. hyopneumoniae infections are established under field conditions. Although performance 
parameters are also commonly measured under experimental conditions, usually, no 
significant differences are obtained due to the limited number of animals used. Challenge 
infection models, are only able to provide a general tendency regarding the differences 
between treated and non-treated/vaccinated and non-vaccinated animals. When looking for 
biological, relevant and statistically significant differences, a much larger number of animals 
reared under commercial conditions should be included. 
Serological examinations are mainly used in both experimental and field trials as a 
descriptive parameter to better understand the dynamics of the infection in the studied 
population. However, nowadays this parameter is not a good indicator to assess efficacy of 
current commercial vaccines against M. hyopneumoniae, since vaccination does not always 
induce seroconversion and the presence of antibodies induced after vaccination is not 
correlated with protection from colonization and disease (Djordjevic et al., 1997). 
Nevertheless, serological examinations can also provide information regarding other 
pathogens circulating within the population and causing disease. 
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In vivo trials, especially when conducted under field conditions, may be largely 
influenced by environmental conditions. To provide standard climatic environment and 
management conditions to the animals will minimize the effect of this variability on the 
outcome of the experiments. Control systems are already available on the market to control 
and prevent adverse conditions. The installation of sensors capable to measure variation in 
temperature and ventilation, as well as feed and water intake, may be useful to understand 
respiratory disease course and to detect failures in antimicrobial treatment, due to deficient 
administration/intake, respectively. This early detection would favour an early prevention or 
correction of these treatment failures. Application of computerized systems may help also to 
reduce the variation due to subjective measurements. A smart monitoring system has been 
recently developed by the University of Leuven, the “Pig Cough Monitor” (Exadaktylos et 
al., 2008). This is based on the detection of sounds produced by pigs, recognition of coughing 
and therefore, monitoring of frequency of this coughing. Similar applied technology based on 
visual detection may be also useful for recognizing macroscopic lung lesions at slaughter, and 
therefore for calculation of the extent of pulmonary lesions in slaughter pigs. 
Antimicrobial treatment and control of M. hyopneumoniae infections 
It is generally accepted that optimization of the housing and management conditions 
should be the first to be accomplished for the prevention and control of enzootic pneumonia. 
However, even in herds with optimal management and housing conditions, clinical outbreaks 
of M. hyopneumoniae can still occur (Vicca et al., 2002). Thus, antimicrobial treatment 
remains an important tool to control respiratory disease caused by this bacterium. 
Additionally, under field conditions, infections with M. hyopneumoniae are commonly 
accompanied by other bacterial infections (Sorensen et al., 1997; Maes et al., 1999; Maes et 
al., 2000) that may increase the severity of the disease and the lesions. Antimicrobial 
treatment may be effective also against bacterial respiratory pathogens other than M. 
hyopneumoniae, and it can be implemented faster and in a more flexible way compared to 
vaccination. However, antimicrobial treatment is able to reduce the number of M. 
hyopneumoniae organism from the lung tissue, but complete elimination of this pathogen 
cannot be achieved (Vicca et al., 2005; Thacker and Minion, 2012). 
The in vitro activity of all three antibiotics tested in this thesis, florfenicol (chapter 2.1), 
chlortetracycline and tylosin (chapter 2.3), has been widely investigated. It has been shown 
that M. hyopneumoniae is intrinsically susceptible to all three antimicrobials (Prieb and 
Schwarz, 2003; Vicca et al., 2004). However, in vivo activity seems to vary, likely due to the 
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location of M. hyopneumoniae at the cilia, where therapeutic levels of antimicrobials may not 
be easily reached (Vicca, 2005). An antimicrobial may only be effective against M. 
hyopneumoniae infection when it is able to achieve significant levels within the mucous and 
fluids of the respiratory tract (Thacker and Minion, 2012). Therefore, in vivo studies are still 
needed to evaluate the efficacy of antimicrobials against this pathogen. 
Our first study (3.1) showed that florfenicol applied once intramuscularly at the onset 
of disease was effective in controlling the acute disease caused by an experimental challenge 
with M. hyopneumoniae organisms. It is well known that observations from experimental 
challenges must be interpreted with caution before generalization to field conditions. The 
amount of M. hyopneumoniae organisms inoculated during experimental challenge (7 mL of 
inoculum containing 10
7
 CCU/mL) is high, but the infection takes place only once. Under 
field conditions, the infection dose is not known, but pigs are exposed for several days and 
weeks to the infection. Additionally, under experimental conditions, the inoculum is directly 
placed in the trachea, whereas in case of natural infections, the first contact surface is the 
nasal mucosa. Clinical and acute outbreaks of respiratory disease are characterized by the 
lack of appetite in affected animals, and consequently by a reduction of the feed and water 
intake. Therefore oral medication is less appropriate in controlling acute outbreaks, and 
individual (parenteral) treatment, i.e. intramuscular injection, would be required. 
Immediately after intramuscular injection, florfenicol presents a high initial blood 
concentration as well as a high tissue distribution (bioavailability approximately 100 per cent) 
(Liu et al., 2003). This rapid distribution (mean distribution half-life: 0.15 h) ensures a quick 
initial response, making this antimicrobial suitable for the treatment of acute outbreaks of M. 
hyopneumoniae infections. Florfenicol has a high in vitro antimicrobial activity against M. 
hyopneumoniae (Hannan et al., 2000; Wilhelm et al., 2012). Florfenicol is eliminated slowly 
(mean elimination half-life: 14h), enabling therapeutic plasma levels up to 53h (Liu et al., 
2003). This guarantees a long acting effect, which makes it particularly convenient to treat 
nursery and fattening pigs. Additionally, the therapeutic plasma level remains above the MIC 
of important other respiratory bacteria (A. pleuropneumoniae, P. multocida, H. parasuis) for 
at least 48h. This ensures a prolonged protection, which may enable the immune system to 
control secondary bacterial infections (Voorspoels et al., 1999). 
Scarce data is available in the literature regarding the clinical efficacy of florfenicol in 
pigs (Dowling, 2013). A recent field study in a pig herd infected with M. hyopneumoniae 
(Ciprián et al., 2012) showed that in-feed medication with florfenicol during 35 days 
significantly improved performance. However, such a prolonged antimicrobial therapy may 
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select resistant bacteria. Thus, if a single injection at onset of disease is effective to treat M. 
hyopneumoniae in pig herds, this could significantly reduce the antimicrobial use in pig herds 
in comparison with oral treatments which are usually established for longer periods of time. 
The florfenicol formulation used in chapter 3.1 differs from the reference veterinary 
medicinal product by the higher concentration of active substance (450 mg/mL), the single 
administration but also by a different therapeutic indication. Metaphylaxis is considered 
superior to prophylaxis in terms of a rational and minimized use of antimicrobials (Catry et 
al., 2008). A metaphylactic medication (single injection of florfenicol) established at onset of 
disease and characterized by a higher concentration of active substance may guarantee 
low/very low risk of mutant selection bacteria (Drlica, 2003; Burch, 2012), while providing 
clinical efficacy. Altough this metaphylactic strategy has been already demonstrated 
efficacious to treat bovine respiratory disease (Catry et al., 2008), no reports are available 
regarding porcine respiratory disease. 
The treatment significantly decreased the RDS in treated pigs, especially two days post-
treatment. However, the clinical symptoms increased again four days later. Also, at necropsy 
only a numerical benefit was observed for the macroscopic and the histopathological lung 
lesions. Our findings suggested that a single injection with this antibiotic only partially 
controls M. hyopneumoniae infection during a period of approximately four days. 
The performance losses and mortality were numerically improved in the treated group. 
Including more animals might result in statistically significant improvement, but the 
tendencies indicate that an economical improvement might be obtained when florfenicol is 
injected. 
All infected pigs were positive by nPCR in the BAL fluid, indicating that the challenge 
infection was successful and that the treatment did not eliminate M. hyopneumoniae from the 
lungs. The latter confirms previous reports, stating that antimicrobial treatment does not 
eliminate the pathogen from the lung tissue nor heal existing lesions (Thacker and Minion, 
2012). Antimicrobial agents may delay infection, but cannot avoid colonization, nor assure 
total elimination of M. hyopneumoniae. 
Our third study (3.3) showed that chlortetracycline administered via the feed during 
two consecutive weeks at onset of clinical outbreak of respiratory disease was effective in 
reducing the prevalence of pneumonia, the performance losses and the severity of clinical 
signs in a herd infected with M. hyopneumoniae and that practiced vaccination against M. 
hyopneumoniae. The chronic respiratory disease observed in this problem herd was 
associated with a high infection level of M. hyopneumoniae that was evidenced by the high 
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prevalence of pneumonia at slaughter and the large proportion of M. hyopneumoniae PCR-
positive pigs at necropsy. Also other respiratory pathogens were involved in the respiratory 
problems. Despite all the pigs were vaccinated against M. hyopneumoniae, sporadic acute 
outbreaks of respiratory disease prior to the study were observed at 14 weeks of age. 
Consequently, the medication can be considered as a metaphylactic treatment at group level. 
Clinically diseased animals, as well as subclinically infected animals were treated. From the 
viewpoint of prudent use of antimicrobials, strategic or preventive medication during periods 
at risk should be minimized and priority should be given to vaccination. However, as shown 
in the present herd, even in vaccinated pigs, clinical symptoms/outbreaks may occur 
(Mateusen et al., 2002) and antimicrobial medication may be necessary. 
Both chlortetracycline and tylosin medications administered in chapter 3.3 complied 
with the label directions of both products (chlortetracycline: between 7 to 14 days; tylosin: at 
least 21 days). However, two different treatments strategies were investigated for 
chlortetracycline medication: CTC1 (chlortetracycline in feed, two consecutive weeks) and 
CTC2 (two non-consecutive weeks, with a non-medicated week-interval in between). All 
three metaphylactic medications established at onset of disease and characterized by a high 
concentration of active substance may guarantee low/very low risk of mutant selection 
bacteria (Drlica, 2003; Burch, 2012), while providing clinical efficacy. However, this 
hypothesis has not yet been proven with M. hyopneumoniae. Additionally, both 
chlortetracycline medications (two weeks) shortened the duration of treatment when 
compared with tylosin medication (tylosin in feed, three consecutive weeks), hence reducing 
the risk of selection mutant bacteria. Although chlortetracycline has been proven efficacious 
in the control of porcine respiratory disease, no reports are available comparing the efficacy 
of this antimicrobial agent administered during two consecutives or alternating weeks. 
Both chlortetracycline (Thacker et al., 2006) and tylosin (Hannan et al., 1982; Ueda et 
al., 1994; Vicca et al., 2005) have already been shown to be efficacious to treat and control 
respiratory disease due to M. hyopneumoniae under experimental conditions, but only a few 
field studies are reported in the literature (Kunesh 1981; Ganter et al., 1995). In chapter 3.3, 
the efficacy of in-feed medication with chlortetracycline and tylosin phosphate against a 
clinical outbreak of respiratory disease in fattening pigs was compared. The study included a 
large number of pigs, measured different clinical, pathological and performance parameters, 
and was conducted in a herd practising vaccination against M. hyopneumoniae and PCV-2. 
Chlortetracycline, administered by ad libitum intake of medicated feed, has been shown 
to quickly (after 2h) reach peak serum concentrations. It has a good diffusion in lung tissue 
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(Kilroy et al., 1990; Del Castillo et al., 1998; Li et al., 2008). These two features ensure a 
quick and targeted initial response, making this antimicrobial suitable for the treatment of 
outbreaks of M. hyopneumoniae infections. Tetracyclines have been demonstrated to have a 
good in vitro activity against M. hyopneumoniae (Hannan et al., 2000). Inamoto et al. (1994) 
reported acquired antimicrobial resistance to tetracyclines occurring in M. hyopneumoniae 
field strains isolated in Japan. Generally speaking, results of in vitro susceptibility testing of 
M. hyopneumoniae for chlortetracycline should be interpreted with caution, since MIC testing 
of chlortetracycline is not reliable as the antimicrobial is not stable during the cultivation 
procedure, i.e. it quickly degrades (activity reduced to 2 per cent after 72h) (Pommier et al., 
2006) and M. hyopneumoniae grows slowly (more than 72h). Chlortetracycline is classified 
as a short-acting tetracycline due to its short half-life of elimination (4h) (Del Castillo et al., 
1998). This quick elimination justifies the use of in-feed medication in order to maintain 
therapeutic levels in diseased animals for a sufficiently long time. Additionally, 
chlortetracycline has also been shown to be effective and is recommended for the treatment 
of other respiratory bacteria, such as P. multocida and H. parasuis (Burch, 2012). 
Tylosin phosphate, administered via the feed, has been shown to present a good 
absorption and tissue distribution. Tylosin can be detected in plasma already 15 min after oral 
administration and the peak serum concentration are reached fast (after 4h) (summary of 
products characteristics). It presents a good lipid solubility, which favors its wide distribution 
among all tissues except for the brain (Guiguère, 2013). Tylosin is concentrated in the lungs 
and accumulated principally in lysozymes of macrophages (Scorneux and Shryock 1998). 
These characteristics ensure a quick and targeted initial response against respiratory bacterial 
infections. Tylosin has a good in vitro activity against M. hyopneumoniae (Hannan et al., 
2000). However, Vicca et al. (2004) reported acquired antimicrobial resistance in one out of 
21 M. hyopneumoniae field strains isolated in Belgium. The elimination half-life of tylosin in 
pigs is similar to chlortetracycline (approximately 4h) (Giguère, 2013). This quick 
elimination justifies the use of in-feed medication in order to maintain therapeutic levels in 
diseased animals for a sufficiently long time. Additionally, tylosin seems to be effective for 
the treatment of other respiratory bacteria (A. pleuropneumoniae, P. multocida, H. parasuis), 
although MICs are intrinsically high for these Pasteurellaceae (Burch, 2012). 
The bioavailability of antimicrobials after oral administration can be influenced by 
several factors, such as the pH of the stomach and gastric emptying. Tetracyclines present a 
low systemic bioavailability after oral administration, especially in non-fasting pigs (Del 
Castillo et al., 2013). The presence of mycotoxins may also alter the bioavailability of 
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antimicrobials administered per os (Goossens et al., 2012b). Recent in vitro studies showed 
that mycotoxins can damage intestinal epithelial cells resulting in increased passage of drugs 
(Goossens et al., 2012a). This was confirmed under in vivo conditions, where administration 
of feed contaminated with deoxynivalenol and T-2 toxin resulted in significant increased 
plasma concentrations of doxycycline (Goossens et al., 2012b) and chlortetracycline 
(Goossens et al., 2013), respectively. 
The tylosin treated group was considered as a positive control group, as the efficacy of 
this antibiotic to treat and control respiratory disease due to M. hyopneumoniae infections had 
been shown in previous studies (Kunesh, 1981; Vicca et al., 2005). A negative control group 
was not included because not treating clinically diseased pigs when efficacious products are 
available is ethically not acceptable, and also the pig producer would not have allowed to 
leave diseased pigs untreated (Dohoo et al., 2009). It is likely that more pronounced effects of 
chlortetracycline medication would have been obtained if a negative (non-treated) control had 
been used. 
The efficacy of chlortetracycline treatment was in line with previous field (Ganter et 
al., 1995) and experimental (Thacker et al., 2006) studies. However, it is clear that the 
medication schemes were definitively not completely efficacious. The RDS in all groups 
remained very similar during the treatment period and a considerable number of pigs had 
pneumonia lesions at slaughter. Despite antimicrobial medication, M. hyopneumoniae could 
still be detected by PCR in the lung tissue. It is not known why there was no significant 
decrease in RDS after medication had started. Other pathogens, e.g. viruses or bacteria not 
susceptible to the antimicrobials may have been involved in the respiratory problem. The 
high mortality in the treated pigs may be due to the presence of concurrent other bacterial 
pathogens such as P. multocida, A. pleuropneumoniae, which present intrinsically high MICs 
for tylosin (Barigazzi et al., 1994) or S. suis strains with acquired resistance to this 
antimicrobial. Indeed two S. suis strains isolated from BAL fluid showed resistance to 
tylosin. 
Based on the MIC testing procedure used by Vicca et al. (2004), the M. hyopneumoniae 
strain collected at slaughter did not show acquired resistance to tylosin and oxytetracycline. 
Although a high MIC value of chlortetracycline was obtained, our finding that the M. 
hyopneumoniae isolate did not show acquired resistance to oxytetracycline strongly indicates 
that acquired resistance was also not present against chlortetracycline, since cross-resistance 
exists between both antibiotics (CLSI, 2008). 
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There were only small and non-significant differences between the CTC1 and CTC2 
groups, but for most parameters (e.g. prevalence and severity of pneumonia lesions), the 
CTC2 group performed slightly better. An exact explanation is not available, but it may be 
due to the fact the pigs of the CTC2 group had a better possibility to generate an active 
immune response during the non-medicated week in between the two medicated weeks. 
Walter et al., (2000) stated that metaphylactic pulse medication might permit a sufficient 
natural exposure to the pathogen and more effective stimulation of active immunity against 
M. hyopneumoniae when compared to continuous medication. These authors suggested that 
continuous medication might lead to animals that remain potentially susceptible to 
subsequent re-exposure to M. hyopneumoniae when the medication is withdrawn. 
Analysis of the stable climate and the ventilation pattern could not elucidate major 
deficiencies in housing conditions or management practices (e.g. stocking density, 
management, deworming). This illustrated that clinical problems of respiratory disease, 
requiring antimicrobial treatment, are still possible in herds without major deficiencies in 
housing and management conditions, even if vaccination is practiced against two major 
pathogens (M. hyopneumoniae and porcine PCV-2) involved in the PRDC. 
A general observation from both chapters 3.1 and 3.3, is that treatment and control of 
outbreaks of respiratory disease represents a very complex decision-making process, 
including lots of variables. When there is an acute clinical outbreak of respiratory disease, 
injectable treatment is necessary in those animals in which water or feed intake is reduced 
and therefore, are not capable to consume antimicrobials orally. This parenteral 
administration ensures a fast response against acute outbreaks where urgency of treatment is 
required. When long-acting formulations are used, the labor of repeated injections is reduced. 
On the other hand, oral medication is especially suited for endemic or chronic diseases, in 
which the appetite of the affected animals is not reduced. The presence of subclinically 
infected animals may pose a threat to the herd health. The administration at group level 
enables the treatment of the clinically and subclinically infected animals. 
Vaccination against M. hyopneumoniae infections 
Commercial vaccines are used worldwide to control M. hyopneumoniae infections, and 
in many countries vaccination is applied in more than 70 per cent of the pig herds (Maes et 
al., 2008). Major advantages of vaccination include a reduction of performance losses, 
severity and extent of clinical signs and lung lesions, mortality, time to reach slaughter 
weight, and treatments costs (Maes et al., 2008). 
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However, the protection conferred by commercial vaccines against M. hyopneumoniae 
is often incomplete. Several studies demonstrated that the current vaccines are not able to 
prevent colonization (Thacker et al., 1998), to significantly reduce transmission under 
experimental conditions (Meyns et al., 2006), and to prevent infection under field conditions 
(Villarreal et al., 2011). Therefore, these studies suggested that vaccination alone is not able 
to eliminate M. hyopneumoniae from infected pig herds. Nevertheless, recent studies have 
demonstrated that vaccination may reduce the number of M. hyopneumoniae organisms in the 
respiratory tract of experimentally infected pigs (Meyns et al., 2006; Vranckx et al., 2012b), 
and therefore, may decrease the infection level in a herd (Sibila et al., 2007). This further 
confirms that maximum beneficial effects of vaccination are reached several months after the 
initiation of vaccination (Haesebrouck et al., 2004). 
Different vaccination strategies can be implemented to control M. hyopneumoniae 
infections at herd level. Currently, one-shot vaccination is more often practiced than two-shot 
vaccination, mainly because it requires less labor, and it confers similar results as two-shot 
vaccination (Roof et al., 2001, 2002; Alexopoulos et al., 2004; Lillie et al., 2004; Greiner et 
al., 2011). Early vaccination (<4 weeks of age) of piglets is commonly practiced in Europe 
(Haesebrouck et al., 2004). 
Our second study (3.2) showed that a single vaccination against M. hyopneumoniae 
applied at either 7 or 21 days of age reduced the prevalence and extent of pneumonia lesions 
in a pig herd with clinical respiratory disease during the second half of the fattening period. 
It is well known that vaccination is most likely effective if active immunity can be 
established before the exposure to the pathogen. It has been demonstrated that M. 
hyopneumoniae infections can take place in piglets already during the first weeks of life 
(Sibila et al., 2007; Nathues et al., 2010; Villarreal et al., 2010, 2011; Vranckx et al., 2012a; 
Fablet et al., 2012a). Therefore, an early vaccination has the advantage of inducing immunity 
before pigs become infected, not only with M. hyopneumoniae, but also with other pathogens 
that can interfere with immune response (Maes et al., 2008). The clinical course of the 
disease in this problem herd was characterized by a low infection level of M. hyopneumoniae. 
In previous batches before the start of the experiment, M. hyopneumoniae was evidenced in 
nursery piglets (6-7 weeks of age) by the clinical signs, the detection of M. hyopneumoniae 
PCR-positive pigs at 10 weeks of age and the presence of pneumonia at slaughter. Also other 
respiratory pathogens were involved in the clinical respiratory signs, but mainly during the 
fattening period. Consequently, this motivated the early vaccination of suckling piglets in 
order to control the respiratory disease in this herd. 
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However, the respiratory problems were different from those in the previous batches in 
this herd. They occurred later in the present batch, M. hyopneumoniae infections were less 
prevalent and mainly occurred from halfway the fattening period onwards, and there were 
complicating viral infections. This confirms that the infection pattern of M. hyopneumoniae is 
not constant over time within the same herd, and that important variations may occur between 
successive batches (Fano et al., 2007; Sibila et al., 2007). Other studies showed also a 
seasonal variation of M. hyopneumoniae infections (Straw et al., 1986; Maes et al., 2000; 
Segalés et al., 2012). The absence of a constant infection pattern i.e. infection in younger or 
older pigs depending on the batch, is one of the major reasons why vaccination of piglets 
during the first weeks of life is commonly practiced worldwide. Using this strategy, piglets 
are immunized before infection, irrespective of whether infection takes place in the nursery, 
growing or fattening unit. 
Several studies have demonstrated the efficacy of vaccination at seven days of age after 
M. hyopneumoniae challenge infection under experimental conditions in reducing lung 
lesions and/or clinical signs. Apart from inducing early protection, it is also important that 
early vaccinated pigs remain protected until the end of the fattening period, as in most pig 
herds, the highest infection levels of M. hyopneumoniae occur during the grow-finishing 
period (Sibila et al., 2004). In this case, the question remains as to whether the effect of one-
shot early vaccination under field conditions with mixed respiratory disease will last until the 
end of the fattening period. 
Despite vaccination against M. hyopneumoniae, there was a very high percentage of 
pigs with pneumonia lesions at slaughter age (80 and 67-71 per cent in non-vaccinated and 
vaccinated pigs, respectively). This may likely be due to the involvement of not only M. 
hyopneumoniae, but also multiple viral infections. The infections mainly took place during 
the second half the fattening period, allowing insufficient time for the lesions to be healed at 
slaughter age (Blanchard et al., 1992). Pneumonia lesions at slaughter are not pathognomonic 
for infections with M. hyopneumoniae. Apart from M. hyopneumoniae, swine influenza virus 
may cause similar pneumonia lesions (Thacker et al., 2001; Sibila et al., 2009). Clinical signs 
of respiratory disease were only present in the second half of the fattening period, while 
expected in nursery pigs. Additionally, because of the large number of efficacy parameters 
included in this experiment, it was decided to exclude the respiratory disease scoring from the 
efficacy assessment in order to reduce the complexity of the study design. 
Both vaccination schedules led to a numerical reduction of growth losses (18-19 
g/pig/day) during the fattening period. The fact that the improvement was not statistically 
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significant may be due to the high standard variations, the occurrence of respiratory problems 
only late in the fattening period, and the different viral infections that were involved in the 
outbreak. However, similar improvements in performance (21 g/pig/day) following M. 
hyopneumoniae vaccination were obtained in a meta-analysis of 28 published field trials 
(Jensen et al., 2002). 
Vaccination reduced the prevalence of nPCR-positive pigs, and therefore decreased the 
infection level of M. hyopneumoniae in this herd. However, M. hyopneumoniae DNA could 
still be detected by PCR. This further confirms that vaccination alone is not able to eliminate 
M. hyopneumoniae from infected pig herds (Meyns et al., 2006; Villarreal et al., 2011b). 
It was also further confirmed that vaccination in the presence of maternally-derived 
serum antibodies is efficacious to control M. hyopneumoniae infections (Martelli et al., 2006; 
Ritzmann et al., 2006; Reynolds et al., 2009). However, one-shot vaccination did not lead to 
significant increases in serum antibodies, confirming that serum antibody concentrations 
measured using the currently available ELISAs are not correlated with protection against M. 
hyopneumoniae (Djordjevic et al., 1997; Thacker et al., 1998). This implies that testing for 
the presence of serum antibodies is not reliable to evaluate whether pigs have been vaccinated 
properly in herds endemically infected with M. hyopneumoniae. 
A general observation from both field studies (chapters 3.2 and 3.3) is that different 
vaccination schemes and commercial bacterins can be used to control M. hyopneumoniae 
infections. In chapter 3.3, despite vaccination at 3 weeks of age, clinical outbreaks of M. 
hyopneumoniae were observed, making antimicrobial treatment necessary. Vaccination 
against M. hyopneumoniae (Mycoflex®) was routinely done on this farm. In chapter 3.2, both 
vaccination schedules (Stellamune Once®) were able to reduce the prevalence of pneumonia; 
however, other viral pathogens were involved in this respiratory disease. Different 
commercial bacterins were used in both field studies. However, both of them have been 
widely tested and proven efficacious against M. hyopneumoniae infections. It is generally 
accepted that optimization of the housing and management conditions should be the first to 
accomplish for the prevention and control of enzootic pneumonia. However, in the herds 
from both field studies, analysis of stable climate and ventilation pattern could not elucidate 
major deficiencies in housing and management conditions. Improvement of housing and 
ventilation remains as milestone in the control of respiratory disease in intensive swine 
production systems, and therefore, further research on this topic can guarantee a better 
understanding of the control of the PRDC. 
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Table 2. Summary of the results of the main efficacy parameters assessed in Chapters 3.1, 3.2 and 3.3. Differences are presented in percentage 
between control and intervention groups. 
 Chapter 3.1 Chapter 3.2 Chapter 3.3 
Housing conditions experimental field field 
Intervention groups** TG V1 V2 CTC1 CTC2 
Antimicrobial treatment Florfenicol (IM) NA NA Chlortetracycline (IF) Chlortetracycline (IF) 
Vaccination against             
M. hyopneumoniae 
NA 
1 weeks of age 
(Stellamune Once®) 
3 weeks of age 
(Stellamune Once®) 
*** *** 
Reduction (%) in:      
 Respiratory disease score -49%* NA NA -7% -13% 
 Prevalence of pneumonia -10% -11%* -16%* -11% -43%* 
 Extent of pneumonia -24% -10% -32%* +0.7% -10% 
Increase (%) in average daily 
gain (g/pig/day) 
 
+24.0% 
 
+2.5% 
 
+2.4% 
 
+3.3% 
 
+2.8% 
Detection of                          
M. hyopneumoniae (PCR) 
Yes Yes Yes Yes Yes 
*Differences between control and treatment/vaccination group were statistically significant (P<0.05). 
**Intervention groups: TG: pigs were injected with florfenicol 14 days after experimental challenge with M. hyopneumoniae; V1: pigs vaccinated at 7 days of age against M. hyopneumoniae; 
V2: pigs vaccinated at 21 days of age against M. hyopneumoniae; CTC1: pigs treated with chlortetracycline in feed (500 ppm) during two consecutive weeks; CTC2: pigs treated with 
chlortetracycline in feed (500 ppm) every other week during three weeks; 
*** all pigs on the farm were vaccinated against M. hyopneumoniae at 3 weeks of age (Mycoflex®) as part of the management practices on the farm; 
****IM: intramuscular; NA: not applicable; IF: in-feed; 
 
 151 
 
Ch. 4 GENERAL DISCUSSION 
General conclusions 
From the studies included in this thesis (Table 2), it was concluded that both 
antimicrobial medication and vaccination against M. hyopneumoniae were able to reduce 
clinical signs and extent and prevalence of pneumonia lesions, as well as to improve 
performance in pigs infected with M. hyopneumoniae. However, M. hyopneumoniae was not 
eliminated from infected animals by these control strategies. 
More specifically, it can be concluded that: 
 The tested florfenicol formulation, when administered intramuscularly as a single 
dose of 30 mg/kg bodyweight, was effective in reducing the clinical respiratory 
symptoms in pigs experimentally infected with a highly virulent M. hyopneumoniae 
strain. A temporary reduction of clinical signs (4 days) was suggested after 
treatment. This metaphylactic medication characterized by a higher concentration of 
active substance may significantly reduce the antimicrobial use in pig herds. 
 Vaccination against M. hyopneumoniae at either 7 or 21 days of age significantly 
reduced pneumonia lesions and numerically decreased growth losses in a herd with 
clinical respiratory problems during the second half of the fattening period due to 
combined M. hyopneumoniae and viral infections. 
 Chlortetracycline hydrochloride, when administered via the feed at a dose of 500 
ppm during two alternative weeks at onset of clinical outbreak of respiratory disease, 
decreased the prevalence of M. hyopneumoniae-like lesions, and numerically 
reduced performance losses and clinical signs compared with tylosin phosphate at a 
dose of 100 ppm administered during three weeks. This metaphylactic medication 
may significantly reduce the antimicrobial use in pig herds. 
 Clinical outbreaks of respiratory tract disease requiring antimicrobial medication 
may still occur in herds without major deficiencies in housing and management 
conditions, despite vaccination against two major pathogens (M. hyopneumoniae and 
porcine PCV-2) involved in PRDC. 
 Vaccination and antimicrobial medication may reduce but do not prevent infections 
with M. hyopneumoniae. 
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Further research 
Future research on antimicrobials should be focused on in vitro and in vivo efficacy. 
The creation of a Mycoplasmotheque including different M. hyopneumoniae strains, followed 
by testing their antimicrobial susceptibility (MIC) to the main antimicrobials used in practice 
may lead to a better understanding of the in vitro efficacy. A subsequent correlation of this in 
vitro efficacy with in vivo models should be investigated. The association between 
antimicrobial susceptibility (MIC values) and quantification of the reduction of M. 
hyopneumoniae shedding (by qPCR) after antimicrobial treatment might be studied. This 
standardization would facilitate the registration of new products according to the EU laws, 
the establishment of correct guidelines of prudent use of antimicrobials against M. 
hyopneumoniae, as well as a reliable monitoring of the antimicrobial resistance against this 
pathogen. A better understanding of the pharmacokinetics may be achieved by the 
quantification of the antimicrobial concentration in plasma and at the site of infection. Since 
M. hyopneumoniae is a mucosal pathogen which mainly adheres to the cilia of the epithelial 
cells from the respiratory tract, the concentration of antimicrobial in BAL fluid and its 
correlation with therapeutic levels and MIC values might be used as indicators of the 
expected in vivo efficacy. 
Early vaccination has been demonstrated to be efficacious against M. hyopneumoniae 
infections occurring late in the fattening period. So far, there are no reports investigating the 
effect of different early vaccination schemes in herds with infections occurring shortly after 
weaning. In addition, vaccination is often applied at weaning, as piglets are handled anyway 
at that time. However, weaning is also causing stress to the piglets. The effect of the stress 
due to weaning on efficacy of vaccination warrants further studies. 
Apart from treatment and vaccination, the prevention or control of M. hyopneumoniae 
infections in pig herds by optimizing housing conditions and management practices remains 
important. Further studies are guaranteed in this field. 
Further research to develop and validate technical devices that guarantee standard and 
controlled conditions along the experiments is required. Application of computerized systems 
able to recognize coughing of live pigs and to monitor the frequency of this coughing, as well 
as to recognize macroscopic lung lesions at slaughter and calculate the extent of pulmonary 
lesions may limit variability due to subjective measurements.  
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SUMMARY 
Mycoplasma hyopneumoniae is the primary agent of enzootic pneumonia, a chronic 
respiratory disease in pigs resulting from mixed respiratory infections with M. 
hyopneumoniae and other bacterial pathogens. M. hyopneumoniae infections lead to major 
economic losses due to the reduced growth, increased mortality and feed conversion, costs 
for antimicrobials and immunoprophylaxis and increased time to market. 
The control of M. hyopneumoniae infections can be accomplished by three different 
strategies, namely optimization of housing and management practices, antimicrobial 
treatment and vaccination. Both, antimicrobial treatment and vaccination have been shown to 
reduce infections with M. hyopneumoniae, but not to eliminate M. hyopneumoniae from 
infected pigs. Despite vaccination, clinical outbreaks of respiratory disease due to M. 
hyopneumoniae infections may still occur. Nevertheless, there are limited studies available 
describing the in vivo efficacy of antimicrobials under experimental M. hyopneumoniae 
induced infections. Similarly, scarce data is available regarding the efficacy of different 
treatment and vaccination strategies against M. hyopneumoniae in commercial herds infected 
with this bacterium and other pathogens involved in Porcine Respiratory Disease Complex 
(PRDC). These current control measures are beneficial from an economic point of view. 
Answers to these questions are necessary for a development of optimal treatment and control 
strategies for this disease. 
The general aim of this thesis was to obtain better insights regarding different treatment 
and control strategies against M. hyopneumoniae infections. 
In the first study (Chapter 3.1), the efficacy of a single intramuscular injection of 
florfenicol to treat clinical respiratory disease following experimental M. hyopneumoniae 
infection was investigated. M. hyopneumoniae-free piglets were allocated to three groups, 
namely, a treatment (TG) and positive control group (PCG), which were both inoculated 
endotracheally with a highly virulent isolate of M. hyopneumoniae, and a negative control 
group. At onset of clinical disease, TG received a single injection of a new florfenicol 
formulation (30 mg/kg). All pigs were euthanized 4 weeks post-infection. Clinical symptoms 
were significantly reduced in TG in comparison with PCG (P<0.05). Average daily weight 
gain, feed conversion ratio, mortality and lung lesions were improved in TG compared to 
PCG, but the differences were not statistically significant. The results showed that, following 
an experimental M. hyopneumoniae infection, a single injection with the tested florfenicol 
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significantly decreased clinical symptoms and numerically improved severity of lung lesions 
and performance when compared to a non-treated control group. 
In the second study (Chapter 3.2), the efficacy of early M. hyopneumoniae vaccination 
in a farrow-to-finish pig herd with respiratory disease late in the fattening period due to 
combined infections with M. hyopneumoniae and viral pathogens was investigated. Five-
hundred-and-forty piglets were randomly divided into three groups of 180 piglets each: two 
groups were vaccinated (Stellamune Once®) at either 7 (V1) or 21 days of age (V2), and a 
third group was left non-vaccinated (NV). The three treatment groups were housed in 
different pens within the same compartment during the nursery period, and were housed in 
different but identical compartments during the fattening period. The efficacy was evaluated 
using performance and pneumonia lesions. The average daily weight gain during the 
fattening period was 19 (V1) and 18 g/day (V2) higher in the vaccinated groups when 
compared with the NV group. However, the difference was not statistically significant 
(P>0.05). The prevalence of pneumonia at slaughter was significantly lower in both 
vaccinated groups (V1:71.5 and V2:67.1 per cent) when compared with the NV group (80.2 
per cent) (P<0.05). There were no significant differences between the two vaccination 
groups. In this herd with respiratory disease during the second half of the fattening period 
caused by M. hyopneumoniae and viral infections, prevalence of pneumonia lesions was 
significantly reduced and growth losses numerically (not statistically significant) decreased 
by both vaccination schedules. 
In the third study (Chapter 3.3), the efficacy of chlortetracycline in-feed medication to 
treat pigs with clinical respiratory disease was investigated in a farrow-to-finish pig herd 
infected with M. hyopneumoniae and with clinical respiratory disease in growing pigs. In 
total, 533 pigs were included. The animals were vaccinated against M. hyopneumoniae and 
PCV-2 at weaning. At onset of clinical respiratory disease, they were randomly allocated to 
one of the following treatment groups: chlortetracycline 1 (CTC1) (two consecutive weeks, 
500 ppm), chlortetracycline 2 (CTC2) (two non-consecutive weeks, with a non-medicated 
week-interval in between, 500 ppm) or tylosin (T) (three consecutive weeks, 100 ppm). 
Performance (average daily gain, feed conversion ratio), pneumonia lesions at slaughter and 
clinical parameters (respiratory disease score) were assessed. Only numeric differences in 
favour of the CTC2 group were obtained for the performance and the clinical parameters. The 
prevalence of pneumonia lesions was 20.5, 13.1 and 23.0 per cent (P<0.05) for the CTC1, 
CTC2 and T groups, respectively. The study demonstrated that chlortetracycline, when 
administered at onset of clinical respiratory disease via the feed at a dose of 500 ppm during 
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two alternative weeks, was able to decrease the prevalence of pneumonia lesions, and 
numerically reduce performance losses and clinical signs. 
From the studies included in this thesis, it was concluded that both antimicrobial 
medication and vaccination against M. hyopneumoniae were able to reduce clinical signs and 
extent and prevalence of pneumonia lesions, as well as to improve performance in pigs 
infected with M. hyopneumoniae. Although M. hyopneumoniae was not eliminated from 
infected animals by these control strategies, metaphylactic medication and vaccination may 
contribute to the reduction of antimicrobial use in pig herds. 
Future research on antimicrobials could focus on in vitro and in vivo efficacy, e.g. to 
better understand the association between antimicrobial susceptibility (MIC values) and 
quantification of the reduction of M. hyopneumoniae shedding (by qPCR) after antimicrobial 
treatment. In addition, the quantification of antimicrobial concentration in plasma and at the 
site of infection and its correlation with MIC values might be used as indicators of the 
expected in vivo efficacy. Interesting further research on vaccination against M. 
hyopneumoniae could address the effect of different early vaccination schemes in herds with 
infections occurring shortly after weaning. The effect of stress at vaccination, for example at 
weaning, on efficacy of vaccination warrants further studies. Development and validation of 
technical devices that guarantee standard and controlled conditions along the experiments 
may be required. Future studies might focus on the application of computerized systems to 
recognize coughing of live pigs as well as on macroscopic lung lesions at slaughter in order 
to reduce variability of subjective measurements. 
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Mycoplasma hyopneumoniae is het causaal agens van een chronische respiratoire ziekte 
bij varkens genaamd enzoötische pneumonie. Deze ziekte ontstaat door menginfecties van M. 
hyopneumoniae en andere bacteriële pathogenen. Infectie met M. hyopneumoniae leidt tot 
grote economische verliezen, verminderde groei, een hoger sterftecijfer, hogere 
voederconversie, meer kosten aan profylactische en antimicrobiële middelen en de varkens 
hebben meer tijd nodig om slachtgewicht te bereiken. 
Drie strategieën om M. hyopneumoniae-infecties onder controle te houden worden 
aangeraden: optimaliseren van huisvesting en management, antimicrobiële medicatie en 
vaccinatie. Deze twee laatste strategieën zijn in staat om infecties met M. hyopneumoniae te 
reduceren, maar niet te elimineren. Niettegenstaande vaccinatie wordt uitgevoerd, kunnen er 
nog steeds infecties met M. hyopneumoniae voorkomen. Er is slechts weinig onderzoek 
beschikbaar dat de werkzaamheid van antimicrobiële middelen tegen experimenteel 
geïnduceerde M. hyopneumoniae-infecties beschrijft. Eveneens is er weinig kennis omtrent 
de werkzaamheid van behandelings- en vaccinatiestrategieën tegen M. hyopneumoniae in 
commerciële varkensbedrijven waar M. hyopneumoniae en andere pathogenen betrokken in 
het Porcine Respiratoir Ziekte Complex (PRDC) een rol spelen. Deze huidige 
controlemaatregelen zijn interessant vanuit economisch oogpunt, bijgevolg zijn antwoorden 
op deze vragen noodzakelijk voor de ontwikkeling van een optimale behandelings- en 
controlestrategie voor deze ziekte. 
Het doel van deze doctoraatsthesis was om een beter inzicht te verkrijgen wat 
verschillende behandelings- en controlestrategieën tegen M. hyopneumoniae betreft. 
In de eerste studie (hoofdstuk 3.1) werd de werkzaamheid van een éénmalige 
intramusculaire injectie met florfenicol voor de behandeling van een experimentele M. 
hyopneumoniae infectie nagegaan. Biggen, vrij van M. hyopneumoniae, werden aan drie 
groepen toegewezen: een behandelingsgroep (BH), een positieve controlegroep (PCG) en een 
negatieve controlegroep. De BH en PCG werden beiden endotracheaal geïnoculeerd met een 
hoogvirulent isolaat van M. hyopneumoniae. Bij de aanvang van de klinische symptomen 
kreeg de BH een enkelvoudige dosis van een nieuwe florfenicol-formulatie (30 mg/kg). Alle 
biggen werden vier weken  na infectie geëuthanaseerd. De klinische symptomen waren 
significant lager in de BH in vergelijking met de PCG (P<0.05). De dagelijkse groei, de 
voederconversie, het sterftecijfer en de longletsels in de BH werden positief beïnvloed in 
vergelijking met de PCG, maar de verschillen waren niet statistisch significant. Uit deze 
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resultaten kon worden besloten dat een injectie met de geteste florfenicol-formulatie na een 
experimentele M. hyopneumoniae infectie de klinische symptomen significant deed afnemen 
en dat een numerieke verbetering kon gezien worden in de ernst van longlesies en productie 
in vergelijking met de niet behandelde groep. 
In de tweede studie (hoofdstuk 3.2) werd de werkzaamheid van een vroege M. 
hyopneumoniae vaccinatie onderzocht in een gesloten bedrijf met respiratoire ziektetekenen 
die optraden laat in de afmestperiode te wijten aan een combinatie van M. hyopneumoniae en 
virale pathogenen. Vijfhonderd veertig biggen werden at random verdeeld over drie groepen 
van 180 biggen: twee groepen werden gevaccineerd (Stellamune Once®) op respectievelijk 7 
(V1) of 21 (V2) dagen leeftijd en een derde groep werd niet gevaccineerd (NV). In de 
biggen-batterij werden de biggen gehuisvest in verschillende hokken binnen dezelfde stal en 
tijdens de afmestperiode in verschillende maar gelijkaardige compartimenten. De 
werkzaamheid werd beoordeeld door middel van productieparameters en pneumonielesies. 
De dagelijkse groei tijdens de afmestperiode was 19 (V1) en 18 g/dag (V2)  hoger in de 
gevaccineerde groepen in vergelijking met de NV groep, hoewel het verschil niet statistisch 
significant was (P>0.05). De prevalentie van pneumonie aan de slachtlijn was significant 
lager in beide gevaccineerde groepen (V1: 71.5 en V2: 67.1 per cent) wanneer vergeleken 
werd met de NV groep (80.2 per cent) (P<0.05). Tussen de twee gevaccineerde groepen 
werden er geen significante verschillen gezien. In dit bedrijf met late respiratoire symptomen 
te wijten aan een combinatie van M. hyopneumoniae en virale infecties werd dus bij 
toepassing van beide vaccinatieschema‟s een statistisch significante verbetering gezien van 
de pneumonie prevalentie en een numeriek (niet statistisch significant) betere groei. 
In de derde studie (hoofdstuk 3.3) werd de werkzaamheid nagegaan van 
chloortetracycline toegediend in het voeder om varkens in een gesloten bedrijf geïnfecteerd 
met M. hyopneumoniae en met klinische respiratoire ziekte te behandelen. Vijfhonderd 
drieëndertig varkens werden opgenomen in de studie. De varkens werden gevaccineerd tegen 
M. hyopneumoniae en PCV-2 bij het spenen. Bij aanvang van de klinische respiratoire 
symptomen werden de dieren at random verdeeld tot een van de volgende 
behandelingsgroepen: chloortetracycline 1 (CTC1) (twee opeenvolgende weken, 500 ppm), 
chloortetracycline 2 (CTC2) (twee niet-opeenvolgende weken, met een niet gemedicineerde 
week als interval tussen de twee weken, 500 ppm) en tylosine (T) (drie opeenvolgende 
weken, 100 ppm). Productieparameters (dagelijkse groei, voeder conversie ratio), pneumonie 
lesies bij slacht en klinische parameters (respiratoire ziekte score) werden beoordeeld. Voor 
de productie- en klinische parameters werden enkel numerieke verschillen ten gunste van de 
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CTC2-groep verkregen. De pneumonie prevalentie was 20.5, 13.1 en 23.0 per cent (P<0.05) 
voor respectievelijk de CTC1, CTC2 en de T-groep. Deze studie toonde aan dat wanneer 
chloortetracycline toegediend via het voeder in een dosis van 500 ppm tijdens twee niet-
opeenvolgende weken bij de aanvang van de klinische respiratoire symptomen in staat was 
om de pneumonie prevalentie te verminderen en om de productie parameters en klinische 
symptomen numeriek te verbeteren. 
Uit de studies die in deze doctoraatsthesis werden beschreven, kon besloten worden dat 
zowel antimicrobiële middelen als vaccinatie tegen M. hyopneumoniae in staat waren om de 
klinische symptomen en de uitgebreidheid en prevalentie van pneumonie-letsels te reduceren 
en de productieresultaten van varkens geïnfecteerd met M. hyopneumoniae te optimaliseren. 
Alhoewel deze controlemaatregelen niet in staat waren om M. hyopneumoniae uit de 
geïnfecteerde dieren te elimineren, kunnen metafylactische medicatie en vaccinatie wel 
bijdragen tot het reduceren van gebruik van antimicrobiële middelen in de varkensbedrijven. 
Verder onderzoek i.v.m. antimicrobiële middelen zou zich kunnen toespitsen op de in 
vitro en in vivo werkzaamheid, bv. om de associatie tussen antimicrobiële gevoeligheid 
(MIC-waarden) en de kwantificering van de reductie van M. hyopneumoniae na 
antimicrobiële behandeling (d.m.v. qPCR) na te gaan. Bovendien kan de kwantificering van 
de antimicrobiële concentratie in het plasma en t.h.v. de infectiehaard gecorreleerd met de 
MIC-waarde aangewend worden als indicator voor de verwachte in vivo werkzaamheid. 
Verder onderzoek aangaande vaccinatie tegen M. hyopneumoniae zou het effect van 
verschillende vroege vaccinatieschema‟s kunnen nagaan in bedrijven waar de biggen vroeg 
na het spenen geïnfecteerd worden. Er is verder onderzoek nodig naar het effect van stress, 
bv. tijdens het spenen, op de werkzaamheid van de vaccinatie. Ontwikkeling en validatie van 
technische apparatuur waarbij klinische symptomen en longletsels op een objectieve en 
gestandaardiseerde manier gemeten worden, kunnen hun nut hebben. Verder onderzoek kan 
zich aldus toespitsen op het gebruik van geautomatiseerde systemen voor het registreren van 
hoesten bij varkens en het herkennen van macroscopische longlesies aan de slachtlijn, om zo 
de variabiliteit van subjectieve metingen  te verminderen. 
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To my sister. Marina. Eres de las pocas personas a las que miro a la cara y sé que están 
pensando. Ahora me doy cuenta de que todo lo que compartimos cuando éramos niños, me ha 
servido para entender la vida de otra forma. Siempre hay varias perspectivas para todo, la 
tuya, la mía y la de Papá y Mamá. Ninguna es menos buena que las demás, pero todas son 
válidas. 
To my parents. A mis padres. Mamá, Papá, porque todo lo que soy y todo lo que no soy 
os lo debo a vosotros. Nunca os podré demostrar todo lo agradecido que os estoy por todo lo 
que me habéis dado en esta vida. Consejos, apoyo moral, sabiduría, y el conocimiento 
necesario para saber decidir por mi solo. Gracias por apoyarme cuando decidí estudiar 
Veterinaria. Espero que este día lo recordéis siempre y que estéis orgullosos de mí. Aunque 
sea una persona que no expresa sus sentimientos constantemente, quiero que sepáis que me 
acuerdo de vosotros cada día y que os llevaré en el corazón durante toda mi vida. 
 
  
 
  
 
 
 
Experiencia es esa cosa maravillosa que te permite reconocer un 
error cuando lo cometes de nuevo 
 
Franklin P. Jones 
 
 
Experience enables you to recognize a mistake when you make it 
again 
 
Franklin P. Jones 
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